Page last updated: 2024-12-05

pyrimethamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pyrimethamine is a medication used to treat and prevent malaria and toxoplasmosis. It is a type of medication called a dihydrofolate reductase inhibitor, which means it stops an enzyme in the body from working. This enzyme is needed for the production of DNA and RNA, which are essential for the growth and development of parasites. Pyrimethamine is often used in combination with other medications, such as sulfadoxine, to treat malaria. It is also used to prevent malaria in people who are traveling to areas where the disease is common. Pyrimethamine is effective in treating toxoplasmosis, a parasitic infection that can affect the brain and other organs. It is also used to treat certain types of cancer, such as lymphoma and leukemia. Pyrimethamine is typically taken by mouth. It can cause side effects, such as nausea, vomiting, diarrhea, and headache. More serious side effects can occur, such as bone marrow suppression and seizures. It is important to talk to a doctor before taking pyrimethamine, especially if you are pregnant, breastfeeding, or have any medical conditions.'

Maloprim: contains above 2 cpds [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4993
CHEMBL ID36
CHEBI ID8673
SCHEMBL ID25129
MeSH IDM0018253

Synonyms (245)

Synonym
BIDD:PXR0173
BIDD:GT0149
MLS001148621
AB00052084-21
BRD-K88429204-001-05-4
brd9204
brd-9204
BRD-K88429204-001-21-1
chloridin
bw 5063
darachlor
daraprime
pirimecidan
khloridin
daraclor
5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine
erbaprelina
2, 5-(p-chlorophenyl)-6-ethyl-
mls002701881 ,
nsc3061
pirimetamin
pyrimidine,4-diamino-5-(p-chlorophenyl)-6-ethyl-
rp 4753
malocid
malacid
daraprim
diaminopyritamin
nci-c01683
wln: t6n cnj bz dz er dg& f2
pyrimethamin
bw 50-63
primethamine
maloprim
2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine
ethylpyrimidine
chloridine
2, 5-(4-chlorophenyl)-6-ethyl-
tindurin
darapram
2,4-diamino-5-chlorophenyl-6-ethylpyrimidine
2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine
4753 r.p.
malocide
5-(4'-chlorophenyl)-2,4-diamino-6-ethylpyrimidine
pyremethamine
nsc-3061
crl-8142 & pyrimethamine
lactoferrin b & pyrimethamine
lactoferrin h & pyrimethamine
crl-8131 & pyrimethamine
smr000058714
MLS000028606 ,
DIVK1C_000652
KBIO1_000652
NCI60_002604
5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
SPECTRUM_000906
BSPBIO_003282
PRESTWICK_504
cas-58-14-0
NCGC00016256-01
PRESTWICK2_000037
PRESTWICK3_000037
5-(4-chlorophenyl)-6-ethyl-pyrimidine-2,4-diamine
2,4-pyrimidinediamine, 5-(4-chlorophenyl)-6-ethyl-
BSPBIO_000133
IDI1_000652
BPBIO1_000147
SPECTRUM5_001447
5-(4-chloro-phenyl)-6-ethyl-pyrimidine-2,4-diamine
cp6 ,
NCGC00023188-03
exr-101
AB00052084
pirimetamina
5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine
pirimetamina [spanish]
nsc 3061
ai3-25005
pyrimidine, 2,4-diamino-5-(p-chlorophenyl)-6-ethyl-
2,4-pyrimidinediamine, 5-(p-chlorophenyl)-6-ethyl-
5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine
ccris 546
einecs 200-364-2
wr 2978
pyrimethaminum [inn-latin]
pirimetamina [inn-spanish]
brn 0219864
58-14-0
C07391
PYRIMETHAMINE ,
5-(4-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine
DB00205
chloridyn
D00488
daraprim (tn)
pyrimethamine (jan/usp/inn)
NCGC00023188-06
NCGC00023188-05
NCGC00023188-04
KBIO3_002502
KBIO2_006522
KBIO2_001386
KBIOGR_001007
KBIOSS_001386
KBIO2_003954
SPBIO_000672
SPECTRUM4_000494
NCIOPEN2_008313
SPBIO_002054
NINDS_000652
PRESTWICK1_000037
SPECTRUM3_001701
PRESTWICK0_000037
SPECTRUM2_000886
SPECTRUM1500520
azt + pyrimethamine combination
NCGC00016256-02
NCGC00023188-07
pyrimethamine (pyr)
cid_4993
chembl36 ,
bdbm18512
HMS2092E13
AC-7879
TCMDC-123831 ,
TCMDC-125860 ,
L000713
MLS002454446
rp-4753
wr-2978
chebi:8673 ,
pyrimethaminum
gnf-pf-5586 ,
HMS502A14
HMS1920N12
HMS1568G15
NCGC00016256-08
cpd000058714
A831755
HMS3259C04
HMS2095G15
tox21_201834
NCGC00259383-01
tox21_300129
NCGC00254199-01
nsc757306
pharmakon1600-01500520
nsc-757306
tox21_110332
dtxcid601217
dtxsid9021217 ,
tinduring
HMS2235A17
MLS-0002822.0001
CCG-39626
NCGC00016256-05
NCGC00016256-07
NCGC00016256-03
NCGC00016256-12
NCGC00016256-10
NCGC00016256-06
NCGC00016256-11
NCGC00016256-09
NCGC00016256-14
NCGC00016256-04
NCGC00016256-13
unii-z3614qox8w
pyrimethamine [usp:inn:ban:jan]
hsdb 8042
z3614qox8w ,
FT-0631253
NCGC00016256-16
AB02313
pyrimethamine [green book]
pyrimethamine [vandf]
pyrimethamine [jan]
pyrimethamine [mart.]
pyrimethamine [who-dd]
pyrimethamine [usp-rs]
pyrimethamine [usp monograph]
pyrimethamine [ep monograph]
pyrimethamine [mi]
pyrimethaminum [who-ip latin]
pyrimethamine [inn]
pyrimethamine [who-ip]
fansidar component pyrimethamine
pyrimethamine [orange book]
pyrimethamine [iarc]
pyrimethamine component of fansidar
4KM0
AKOS015892534
gtpl4800
HMS3371L07
CS-1717
HY-18062
NC00528
BRD-K88429204-001-18-7
SCHEMBL25129
NCGC00016256-17
tox21_110332_1
KS-5223
2,4-diamino-6-ethyl-5-(4-chlorophenyl)pyrimidine
2,4,-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine
2,4-diamino-5-(4-chloro-phenyl)-6-ethylpyrimidine
Q-201648
daraclor (salt/mix)
P2037
OPERA_ID_1437
AB00052084_25
AB00052084_22
mfcd00057350
sr-01000003150
SR-01000003150-2
pyrimethamine, united states pharmacopeia (usp) reference standard
pyrimethamine, vetranal(tm), analytical standard
HMS3655D09
pyrimethamine, european pharmacopoeia (ep) reference standard
SR-01000003150-4
SBI-0051500.P003
HMS3712G15
BRD-K88429204-001-36-9
SW196698-3
pirimecidan;pirimetamin;rp 4753
Q421072
Z1515385085
S2006
HMS3675P11
HMS3871I03
HMS3743O05
2,4-diamino-5(4-chlorophenyl)-6-ethylpyrimidine
EN300-118717
2,4-diamono-5-(p-chlorophenyl)-6-ethylpyrimidine
p01bd01
pyrimethamine (iarc)
5-(p-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine
pyrimethaminum (inn-latin)
pyrimethamine (mart.)
pyrimethamine (usp-rs)
5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidine
2,4-diamino-5-p-chlorophenyl-6-ethylpyrimidine
pyrimethamine (usp:inn:ban:jan)
pirimetamina (inn-spanish)
pyrimethamine (ep monograph)
pyrimethamine (usp monograph)

Research Excerpts

Overview

Pyrimethamine is an effective drug in the cancer cell treatment and is a dihydrofolate reductase inhibitor. resistance is a major concern for the control of human haemoprotozoa, especially Plasmodium species.

ExcerptReferenceRelevance
"Pyrimethamine is an antiparasitic drug used for the treatment of malaria and toxoplasmosis with a well-documented excellent safety profile."( The multifaceted antineoplastic role of pyrimethamine against human malignancies.
Ahn, KS; Mistry, JR; Mohan, CD; Naz, I; Ramchandani, S; Rangappa, KS; Su, Q, 2022
)
1.71
"Pyrimethamine is an antiparasitic compound available only in tablet form for oral administration. "( Physicochemical and Microbiological Stability of Pyrimethamine in Paraben-free PCCA Base, SuspendIt.
Bostanian, LA; Graves, RA; Kader, C; Mandal, TK; Morris, TC; Pramar, YV,
)
1.83
"Pyrimethamine is an effective drug in the cancer cell treatment and is a dihydrofolate reductase inhibitor. "( CNT-based nanocarrier loaded with pyrimethamine for adipose mesenchymal stem cells differentiation and cancer treatment: The computational and experimental methods.
Hadipour, NL; Mollania, F; Mollania, N, 2020
)
2.28
"Pyrimethamine resistance is a major concern for the control of human haemoprotozoa, especially Plasmodium species. "( Selective sweep and phylogenetic models for the emergence and spread of pyrimethamine resistance mutations in Plasmodium vivax.
Ali, Q; Chaudhry, U; Connelley, T; Evans, M; Khan, MAU; Rashid, I; Saleem, MA; Sargison, ND; Shaukat, A, 2019
)
2.19
"Pyrimethamine (PYR) is a drug used in the treatment of newborn with congenital Toxoplasmosis. "( Effect of pyrimethamine treatment on male rat testicular cell population development.
Chavez-Saldaña, M; Durand-Montaño, C; Gutiérrez-Pérez, O; Rojas-Castañeda, JC; Vigueras-Villaseñor, RM, 2014
)
2.25
"Pyrimethamine is an antimalarial drug that has also been used successfully to treat autoimmune diseases such as lymphoproliferative syndrome. "( Pyrimethamine induces oxidative stress in Plasmodium yoelii 17XL-infected mice: a novel immunomodulatory mechanism of action for an old antimalarial drug?
Legorreta-Herrera, M; Narváez, V; Retana-Ugalde, R; Ventura-Gallegos, JL, 2010
)
3.25
"Pyrimethamine (PYR) is a potential pharmacological chaperone that works by stabilizing these mutant enzymes sufficiently to allow more β-hex to arrive in the lysosome, where it can carry out its function."( Crystal structure of β-hexosaminidase B in complex with pyrimethamine, a potential pharmacological chaperone.
Bateman, KS; Cherney, MM; James, MN; Mahuran, DJ; Tropak, M, 2011
)
1.34
"Pyrimethamine is a useful in vivo inhibitor of MATE proteins."( Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects.
Inoue, K; Ito, S; Jiang, M; Kumagai, Y; Kusuhara, H; Moriyama, Y; Shiroshita, T; Sugiyama, Y; Yuasa, H, 2011
)
1.36
"Pyrimethamine-sulfadoxine is an inhibitor of dihydrofolate reductase (DHFR) that has been widely used to treat chloroquine-resistant Plasmodium falciparum malaria."( Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax.
Hastings, MD; Sibley, CH, 2002
)
2.48
"Pyrimethamine is a folic acid antagonist used for the treatment of malaria and toxoplasmosis."( Inhibitory effects of ascorbic acid and folinic acid on chromosome aberrations induced by pyrimethamine in vitro.
Aydemir, N; Bilaloĝlu, R; Egel, C, 2002
)
1.26
"Pyrimethamine is an antimalarial agent widely used in clinical therapy. "( A comparative study on the genotoxic effect of pyrimethamine in bone marrow and spermatogonial mice cells.
Aydemir, N; Bilaloğlu, R; Celikler, S,
)
1.83
"Pyrimethamine is an antiparasitic agent currently used for therapy of central nervous system toxoplasmosis, a disease seen with increasing frequency in association with the AIDS epidemic. "( Pyrimethamine analysis by enzyme inhibition and HPLC assays.
Heimer, R; Jatlow, PI; Rainey, PM; Reynolds, KM; Roberts, WL, 1995
)
3.18
"Pyrimethamine is an inhibitor of dihydrofolate reductase and is used in the treatment of malaria and toxoplasmosis. "( The cytogenetic effects of pyrimethamine on male mouse germ cells.
Aydemir, N; Bilaloğlu, R, 1996
)
2.03
"Pyrimethamine is an antimalarial drug and a known teratogenic agent. "( Evaluation of the genotoxic effects of pyrimethamine, an antimalarial drug, in the in vivo mouse.
Vijayalaxmi, KK; Vishalakshi, M, 2000
)
2.02
"Pyrimethamine is a potent inhibitor of dihydrofolate reductase and is widely used in the treatment of opportunistic infections caused by the protozoan parasite Toxoplasma gondii. "( In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase.
Oh, J; Reynolds, MG; Roos, DS, 2001
)
2.04
"Pyrimethamine was found to be a low clearance compound (78.4 +/- 25.3 ml/hr identical to 8.6% of liver perfusate flow) with a large volume of distribution (267.5 +/- 55.3 ml) in the IPRL."( The disposition of pyrimethamine in the isolated perfused rat liver.
Breckenridge, AM; Coleman, MD; Edwards, G; Howells, RE; Mihaly, GW; Ward, SA, 1985
)
1.32

Effects

Pyrimethamine-sulfadoxine has been associated with severe and fatal cutaneous reactions as well as transient liver damage. PYR has been the treatment of choice for toxoplasmosis.

ExcerptReferenceRelevance
"Pyrimethamine has been used principally to treat infections from protozoan parasites. "( Pyrimethamine exerts significant antitumor effects on human ovarian cancer cells both in vitro and in vivo.
Liu, Y; Wang, H; Yi, T; Zhou, H, 2019
)
3.4
"Pyrimethamine (PYR) has been the treatment of choice for toxoplasmosis."( Effect of nitaxozanide and pyrimethamine on astrocytes infected by Toxoplasma gondii in vitro.
Dueñas Jiménez, JM; Galván-Ramírez, Mde L; García-Iglesias, T; Ramírez-Herrera, M; Rocío Rodríguez Pérez, L; Troyo-Sanroman, R, 2013
)
1.41
"Pyrimethamine alone has been shown to be teratogenic in rats, mice and hamsters, and others animals."( Effect of intramuscular sulfadoxine-pyrimethamine on pregnant Wistar rats.
Uche-Nwachi, EO, 1998
)
1.3
"Pyrimethamine-sulfadoxine has been associated with severe and fatal cutaneous reactions as well as transient liver damage. "( Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar).
Alexander, J; Howrie, DL; Kuritsky, JN; Miller, KD; Perez, TH; Taylor, S; Van Thiel, DH; Zitelli, BJ, 1987
)
2

Actions

Pyrimethamine was found to produce a significant increase in structural chromosomal aberrations after acute treatment in bone marrow cells of mice. The drug did not inhibit the assembly of microtubules, but produced aberrant forms.

ExcerptReferenceRelevance
"Pyrimethamine was found to produce a significant increase in structural chromosomal aberrations after acute treatment in bone marrow cells of mice (p < 0.001)."( A comparative study on the genotoxic effect of pyrimethamine in bone marrow and spermatogonial mice cells.
Aydemir, N; Bilaloğlu, R; Celikler, S,
)
1.11
"Pyrimethamine did not inhibit the assembly of microtubules, but produced aberrant forms."( Effects of potential aneuploidy inducing agents on microtubule assembly in vitro.
Hartley-Asp, B; Wallin, M, 1993
)
1.01

Treatment

Pyrimethamine is used for treatment of malaria and toxoplasmosis. Treatment did not result in a reduction in the size of the inducible reservoir.

ExcerptReferenceRelevance
"Pyrimethamine treatment did not result in a reduction in the size of the inducible reservoir."( The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy.
Bax, HI; Burger, D; Colbers, A; Crespo, R; de Mendonça Melo, M; de Vries-Sluijs, TEMS; Gruters, RA; Hossain, T; Kan, TW; Katsikis, PD; Koch, BCP; Li, L; Lungu, C; Mahmoudi, T; Mesplède, T; Mueller, YM; Nouwen, JL; Overmars, RJ; Palstra, RJ; Papageorgiou, G; Prins, HAB; Rao, S; Rijnders, BJA; Rokx, C; Schurink, CAM; Stoszko, M; van de Vijver, DAMC; van Gorp, ECM; van Kampen, JJA; van Nood, E; Verbon, A, 2023
)
1.93
"Pyrimethamine treatment of the infected monolayers inhibits the multiplicity of the parasite and reverses the relocalization of PABP aggregates."( Toxoplasma gondii infection induces the formation of host's nuclear granules containing poly(A)-binding proteins.
Ananvoranich, S; Avci, Y; Fischer, K; Roberts, M; Roscoe, S, 2018
)
1.2
"Oral pyrimethamine treatment was effective in two xenograft mouse models and specifically targeted leukemic cells in human AML cell lines and primary patient cells, while CD34+ cells from healthy donors were unaffected."( Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening.
Blanchard, JE; Brown, E; Chaturvedi, A; Gabdoulline, R; Ganser, A; Görlich, K; Hassell, JA; Heuser, M; Humphries, RK; Jyotsana, N; Lai, CK; Morgan, M; Murphy, C; Sharma, A, 2016
)
2.33
"Pyrimethamine-sulfonamides treatment was continued from birth to 1 year of age."( Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosis.
Brézin, AP; Couvreur, J; Mcleod, R; Mets, MB; Nobré, R; Thulliez, P, 2003
)
1.04
"Oral pyrimethamine treatment (10 mg/kg for 4 days) in infected mice (5-10%) returned the altered levels of the above enzymes to almost normal 1 week after the cessation of drug treatment."( Studies on ammonia-metabolizing enzymes during Plasmodium yoelii infection and pyrimethamine treatment in mice.
Agrawal, A; Pandey, VC; Puri, SK; Tripathi, LM, 1996
)
0.98
"Pyrimethamine (oral) treatment (10 mg/kg body weight) to infected mice (5-10%) for four days brought back the altered levels of the above cellular constituents in different tissues to normal, a week after cessation of drug treatment."( Status of ammonia, glutamate, lactate and pyruvate during Plasmodium yoelii infection and pyrimethamine treatment in mice.
Agarwal, A; Pandey, VC; Tripathi, LM, 1997
)
1.24
"Pyrimethamine treatment (10 mg/kg body weight for 4 days) brought back the altered parameters to normal a week after cessation of drug treatment."( Status of urea and related enzymes during Plasmodium yoelii infection and pyrimethamine treatment in mice.
Agrawal, A; Pandey, VC; Tripathi, LM, 1997
)
1.25
"Pyrimethamine is used for treatment of malaria and toxoplasmosis. "( In vivo dominant lethal effect of pyrimethamine in male mouse germ cells.
Akpinar, G; Aydemir, N; Bilaloğlu, R; Cimen, C; Egeli, U; Ergül, E; Tunca, B; Tutar, G, 1999
)
2.03
"The pyrimethamine-treated gametocytes were more infective to mosquitoes than were untreated controls."( A new model for testing gametocytocidal effects of some antimalarial drugs on Plasmodium falciparum in vitro.
Chutmongkonkul, M; Maier, WA; Seitz, HM, 1992
)
0.76
"Untreated and pyrimethamine-treated controls showed decreasing %Hct."( Protective effect of Thunbergia laurifolia extract on hemolysis during Plasmodium berghei infection.
Jaihan, U; Khobjai, W; Somsak, V; Watcharasamphankul, W, 2014
)
0.75
"Treatment with pyrimethamine plus sulfadoxine was successful but visual acuity and hip extension were partially recovered."( Disseminated toxoplasmosis in an immunocompetent patient from Peruvian Amazon.
Endo, S; Nunura, J; Pereyra, S; Rodriguez, A; Salazar, D; Solis, H; Vásquez, T,
)
0.47
"Treatment with pyrimethamine decreases cell proliferation in human ADPKD cells and blocks renal cyst formation in an adult and a neonatal PKD mouse model."( Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways.
Frank, DA; Haque, N; Humphreys, BD; Nelson, EA; Takakura, A; Zandi-Nejad, K; Zhou, J, 2011
)
2.15
"Treatment with pyrimethamine at 12.5 or 6.0 mg/kg protected 60 and 0% of mice, respectively."( Treatment of acute Toxoplasma gondii infections in mice with diclazuril or a combination of diclazuril and pyrimethamine.
Blagburn, BL; Lindsay, DS; Rippey, NS, 1995
)
0.84
"Treatment with pyrimethamine, clindamycin, and folinic acid decreased the diarrhea as well as the duodenal toxoplasma cyst load."( Duodenal and hepatic toxoplasmosis in a patient with HIV infection: review of the literature.
Alamy, M; Bonacini, M; Kanel, G, 1996
)
0.63
"Treatment with pyrimethamine plus sulfadiazine produced clinical cures in 100% of the infected mice 1 month after infection."( A clinical-parasitological monotherapy cure in the treatment of experimental infection by a highly virulent strain of Toxoplasma gondii.
Arribas, JR; de Diego, JA; Penin, P; Vázquez, E; Vázquez, JJ, 1996
)
0.63
"Treatment with pyrimethamine and sulfamethoxazolum combination administered via intragastric route, was started 2 hours after each mouse received an intraperitoneal injection of a lethal inoculum of 5 x 10(3) tachyzoites of RH strain toxoplasma gondii and the therapy was lasted for 52 days. "( [Preliminary application of PCR to curative effect assessment of chemotherapy against experimental acute infection of Toxoplasma gondii in mice].
Ke, OY; Xiang, X; Zhang, Z, 1997
)
0.65
"Oral treatment of pyrimethamine (10 mg/kg body weightx4 days) to P."( Studies on hepatic mitochondrial cytochrome P-450 during Plasmodium yoelii infection and pyrimethamine treatment in mice.
Pandey, VC; Srivastava, P, 2000
)
0.85
"Treatment of pyrimethamine with blood plasma in vitro yields a metabolite which is also produced when the drug is administered through intravenous injection in the rat. "( Studies on the determination and degradation of pyrimethamine in mammals.
Kaushik, P; Kumar, R; Sharma, CB, 1990
)
0.9

Toxicity

IPTi with sulfadoxine-pyrimethamine was safe and efficacious across a range of malaria transmission settings, suggesting that this intervention is a useful contribution to malaria control. A toxic solvatomorph of pyr-MeOH found to be the product from methanol recrystallization.

ExcerptReferenceRelevance
"2) times more likely to experience an adverse effect that necessitated withdrawal of the study drug than those who received placebo."( Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS.
Besch, CL; Child, C; Deyton, L; Hafner, R; Jacobson, MA; Matts, JP; Muth, K; Wentworth, DN, 1992
)
0.28
" The antimalarial effect of the triple combination on Plasmodium berghei ANKA-infected mice and the toxic effects in mice and rats were additive."( Antimalarial and toxic effect of triple combination of pyronaridine, sulfadoxine and pyrimethamine.
Ha, SH; Huang, J; Huang, ZS; Meng, F; Shao, BR; Shi, XH; Ye, XY; Zhan, CQ, 1989
)
0.5
" One adverse reaction of chloroquine that has an important bearing on its use is pruritus."( Toxicity and side-effects of antimalarials in Africa: a critical review.
Salako, LA, 1984
)
0.27
" Safe and effective drugs, capable of being administered as a single-dose or short-course treatment, are urgently needed to control the adaptable malaria parasite."( Falciparum malaria: the urgent need for safe and effective drugs.
Rieckmann, KH, 1983
)
0.27
" However, the toxic effects of piritrexim and trimetrexate suggest that dihydrofolate reductase (DHFR) activity is essential for the parasite, most probably because of the role of this enzyme in the synthesis of thymidine nucleotides via thymidylate synthase."( The toxicity of antifolates in Babesia bovis.
Bagnara, AS; Nott, SE, 1993
)
0.29
" If interim results provide convincing evidence of either excessive adverse effects or significant treatment benefit, the DSMB may recommend early termination of the trial to the NIAID and the study investigators."( The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
Childress, JF; DeMets, DL; Ellenberg, SS; Fleming, TR; Foulkes, M; Mayer, KH; O'Fallon, J; Pollard, RB; Rahal, JJ; Whitley, RJ, 1995
)
0.29
" Differences in rates of adverse outcomes between the three groups were not statistically significant."( Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy.
Edwards, R; Fuchs, E; Kerr, L; Phillips-Howard, PA; Schildknecht, J; Steffen, R; Vanhauwere, B, 1998
)
0.3
" Both regimens were safe and well tolerated and there were no adverse experiences attributed to the combination."( A randomized safety and tolerability trial of artesunate plus sulfadoxine--pyrimethamine versus sulfadoxine-pyrimethamine alone for the treatment of uncomplicated malaria in Gambian children.
Alloueche, A; Bayo, L; Doherty, JF; Milligan, P; Olliaro, P; Pinder, M; Sadiq, AD; von Seidlein, L,
)
0.36
" The pharmacokinetic data, however, showed that they are of similar profile, except in adverse features and contraindications, and values like their half-life (t1/2) where the long (t1/2) in drugs like sulphadoxine-pyrimethamine endows them with suppressive-cure feature, especially against recrudescent strains."( Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries.
Makonnen, E; Mengesha, T, 1999
)
0.49
" Pharmacokinetic profile demonstrates that all these drugs have similar therapeutic effects, but differ in their adverse reactions, contraindications, and half-life."( Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries.
Makonnen, E; Mengesha, T, 1999
)
0.3
" Toxic encephalopathy is a serious neurological manifestation which is slowly reversible depending on individual predisposition."( [Danger of malaria self-treatment. Acute neurologic toxicity of mefloquine and its combination with pyrimethamine-sulfadoxine].
Granier, H; Laborde, JP; Martin, J; Nicolas, X; Talarmin, F, 2001
)
0.53
" There were no adverse effects experienced by the patients."( A safety and efficacy trial of artesunate, sulphadoxine-pyrimethamine and primaquine in P falciparum malaria.
Faizal, HM; Fernando, WP; Galappaththy, G; Weerasinghe, KL; Wickremasinghe, AR; Wickremasinghe, DR, 2002
)
0.56
"The combination of artesunate, S + P and primaquine was found to be effective and safe in the treatment of uncomplicated P falciparum malaria."( A safety and efficacy trial of artesunate, sulphadoxine-pyrimethamine and primaquine in P falciparum malaria.
Faizal, HM; Fernando, WP; Galappaththy, G; Weerasinghe, KL; Wickremasinghe, AR; Wickremasinghe, DR, 2002
)
0.56
" Severe malaria in rural areas of Sudan, where facilities for the safe and effective use of parenteral quinine are lacking, is a frequent problem."( Descriptive study on the efficacy and safety of artesunate suppository in combination with other antimalarials in the treatment of severe malaria in Sudan.
Alkadru, AM; Awad, MI; Baraka, OZ; Behrens, RH; Eltayeb, IB, 2003
)
0.32
" Chemoprophylaxis or intermittent preventive treatment (IPT) with an effective antimalarial can ameliorate the adverse effects of malaria during pregnancy."( Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa.
Nahlen, B; Newman, RD; Parise, ME; Slutsker, L; Steketee, RW, 2003
)
0.32
"Hypersensitivity adverse drug reactions are much more common among patients with acquired immunodeficiency syndrome (AIDS) than in the general population."( Differential toxicity of reactive metabolites of clindamycin and sulfonamides in HIV-infected cells: influence of HIV infection on clindamycin toxicity in vitro.
Dekaban, GA; Rieder, MJ; Wijsman, JA, 2005
)
0.33
" Adverse events and clinical and parasitological outcomes were recorded."( A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda.
D'Alessandro, U; Fanello, CI; Karema, C; Ngamije, D; van Doren, W; Van Overmeir, C, 2007
)
0.34
" Additionally, reports of adverse effects were solicited and monitored during follow-up visits."( Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial.
Browne, E; Bruce, J; Chandramohan, D; Greenwood, B; Randal, A; Tagbor, H, 2006
)
0.57
" No serious liver toxic effects or white-blood-cell dyscrasias were noted."( Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial.
Browne, E; Bruce, J; Chandramohan, D; Greenwood, B; Randal, A; Tagbor, H, 2006
)
0.57
" This review evaluates the toxicity data of sulfadoxine/pyrimethamine, including severe cutaneous adverse reactions, teratogenicity and alterations in bilirubin metabolism."( Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment.
Newman, RD; Parise, ME; Peters, PJ; Thigpen, MC, 2007
)
0.86
" Secondary end-points were incidence of adverse events, mean haemoglobin concentration and prevalence of parasites carrying markers of resistance to SP."( A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children.
Bâ, el H; Boulanger, D; Cissé, B; Gaye, O; Greenwood, B; Hallett, R; Lines, J; Milligan, P; Simondon, F; Simondon, K; Sokhna, C; Sutherland, C; Targett, G; Trape, JF, 2008
)
0.35
" When used for prophylaxis, Amodiaquine (AQ) was associated with agranulocytosis but is considered safe for treatment and is increasingly being used in Africa."( Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi.
Bell, DJ; Molyneux, ME; Mukaka, M; Nyirongo, SK; Plowe, CV; Ward, SA; Winstanley, PA; Zijlstra, EE, 2008
)
0.72
" No significant adverse event attributable to any of the study drugs was found."( Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali.
Dama, S; Dembele, D; Dicko, A; Djimdé, AA; Doumbo, OK; Fofana, B; Ouologuem, D; Sagara, I; Sidibe, B; Toure, S, 2008
)
0.35
" Participants were actively monitored for adverse events for the first 14 days after each treatment, and then passively followed until their next study medication treatment, or withdrawal from study."( Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children.
Clark, TD; Dorsey, G; Jagannathan, P; Kamya, MR; Maiteki-Sebuguzi, C; Njama-Meya, D; Nzarubara, B; Rosenthal, PJ; Staedke, SG; Talisuna, AO; Yau, VM, 2008
)
0.35
" Most common drug-related adverse events were gastrointestinal symptoms (such as vomiting and diarrhea) which were slightly higher in the AS-SMP 24-hour group."( Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial.
Adam, I; Dara, N; Dicko, A; Dicko, YT; Djimdé, A; Doumbo, OK; Jansen, FH; Maiga, H; Mbacham, W; Rulisa, S; Sagara, I; Sissoko, K; Traore, OB, 2009
)
0.59
" The main outcome measures for safety were incidences of post-treatment clinical and laboratory adverse events."( Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy.
Geita, J; Hiawalyer, G; Hombhanje, FW; Jones, R; Kevau, I; Kuanch, C; Linge, D; Masta, A; Sapuri, M; Saweri, A; Toraso, S, 2009
)
0.35
" Both regimens were well tolerated with no serious adverse events."( Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy.
Geita, J; Hiawalyer, G; Hombhanje, FW; Jones, R; Kevau, I; Kuanch, C; Linge, D; Masta, A; Sapuri, M; Saweri, A; Toraso, S, 2009
)
0.35
" Data from the trials for incidence of clinical malaria, risk of anaemia (packed-cell volume <25% or haemoglobin <80 g/L), and incidence of hospital admissions and adverse events in infants up to 12 months of age were reanalysed by use of standard outcome definitions and time periods."( Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials.
Adjei, S; Alonso, P; Anemana, S; Aponte, JJ; Breckenridge, A; Carneiro, I; Chandramohan, D; Critchley, J; Danquah, I; Dodoo, A; Egan, A; Greenwood, B; Grobusch, MP; Issifou, S; Kobbe, R; Kremsner, PG; Lell, B; Macete, E; May, J; Menendez, C; Mockenhaupt, F; Mshinda, H; Newman, RD; Owusu-Agyei, S; Premji, Z; Sanz, S; Schellenberg, D; Sevene, E; Slutsker, L; Soulaymani-Becheikh, R; Tanner, M; Winstanley, P, 2009
)
0.58
" None of three serious dermatological adverse events in the IPTi group were judged related to study treatment compared with one of 13 in the placebo group."( Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials.
Adjei, S; Alonso, P; Anemana, S; Aponte, JJ; Breckenridge, A; Carneiro, I; Chandramohan, D; Critchley, J; Danquah, I; Dodoo, A; Egan, A; Greenwood, B; Grobusch, MP; Issifou, S; Kobbe, R; Kremsner, PG; Lell, B; Macete, E; May, J; Menendez, C; Mockenhaupt, F; Mshinda, H; Newman, RD; Owusu-Agyei, S; Premji, Z; Sanz, S; Schellenberg, D; Sevene, E; Slutsker, L; Soulaymani-Becheikh, R; Tanner, M; Winstanley, P, 2009
)
0.58
"IPTi with sulfadoxine-pyrimethamine was safe and efficacious across a range of malaria transmission settings, suggesting that this intervention is a useful contribution to malaria control."( Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials.
Adjei, S; Alonso, P; Anemana, S; Aponte, JJ; Breckenridge, A; Carneiro, I; Chandramohan, D; Critchley, J; Danquah, I; Dodoo, A; Egan, A; Greenwood, B; Grobusch, MP; Issifou, S; Kobbe, R; Kremsner, PG; Lell, B; Macete, E; May, J; Menendez, C; Mockenhaupt, F; Mshinda, H; Newman, RD; Owusu-Agyei, S; Premji, Z; Sanz, S; Schellenberg, D; Sevene, E; Slutsker, L; Soulaymani-Becheikh, R; Tanner, M; Winstanley, P, 2009
)
0.9
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"The conventional markers of toxicity in serum, oxidative stress parameters in tissue homogenates, histology of liver and alterations in global transcriptomic expression were evaluated to study the toxic effects of AQ and SP in isolation and in combination."( A study of toxicity and differential gene expression in murine liver following exposure to anti-malarial drugs: amodiaquine and sulphadoxine-pyrimethamine.
Mishra, SK; Rath, SK; Singh, P, 2011
)
0.57
" In the second and third trimesters, AL was not associated with increased adverse pregnancy outcomes as compared with quinine or sulphadoxine-pyrimethamine, showed improved tolerability relative to quinine, and its efficacy was non-inferior to quinine."( A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy.
D'Alessandro, U; Hamed, K; Juma, E; Kayentao, K; Manyando, C; Okafor, HU, 2012
)
0.58
"A toxic solvatomorph of pyrimethamine (Pyr-MeOH) was found to be the product from methanol recrystallization."( The risk of recrystallization: changes to the toxicity and morphology of pyrimethamine.
Brits, M; Caira, MR; Perold, Z, 2014
)
0.94
"We present a solvatomorph of pyrimethamine and provide several characteristic means to identify this unwanted toxic form and quantified the energy required to overcome its toxicity."( The risk of recrystallization: changes to the toxicity and morphology of pyrimethamine.
Brits, M; Caira, MR; Perold, Z, 2014
)
0.93
" There were no differences between the study arms in the incidence of serious adverse events during the intervention and the incidence of malaria during the 1-y period after the intervention was stopped."( Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial.
Achan, J; Aweeka, FT; Bigira, V; Clark, TD; Dorsey, G; Havlir, DV; Huang, L; Kamya, MR; Kapisi, J; Kinara, S; Muhindo, MK; Mwangwa, F; Osterbauer, B; Rosenthal, PJ, 2014
)
0.4
" The aim of this study was to evaluate the clinical and biological adverse effects of the combination of sulfadoxine-pyrimethamine."( Treatment of Congenital Toxoplasmosis: Safety of the Sulfadoxine-Pyrimethamine Combination in Children Based on a Method of Causality Assessment.
Charpiat, B; Corvaisier, S; Dupont, D; Leboucher, G; Peyron, F; Teil, J; Vial, T; Wallon, M, 2016
)
0.88
"Sixty-five children treated for 1 year with a combination of sulfadoxine-pyrimethamine (1 dose every 10 days) for congenital toxoplasmosis were followed up to evaluate abnormal hematological values and potential adverse events using a standardized method of causality assessment."( Treatment of Congenital Toxoplasmosis: Safety of the Sulfadoxine-Pyrimethamine Combination in Children Based on a Method of Causality Assessment.
Charpiat, B; Corvaisier, S; Dupont, D; Leboucher, G; Peyron, F; Teil, J; Vial, T; Wallon, M, 2016
)
0.9
"8%) presented at least 1 adverse clinical event that was nonspecific, such as diarrhea on the day of drug administration, vomiting and agitation."( Treatment of Congenital Toxoplasmosis: Safety of the Sulfadoxine-Pyrimethamine Combination in Children Based on a Method of Causality Assessment.
Charpiat, B; Corvaisier, S; Dupont, D; Leboucher, G; Peyron, F; Teil, J; Vial, T; Wallon, M, 2016
)
0.67
" Occurrences of congenital anomalies, deaths, and serious adverse events were comparable in neonates for both groups."( Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized Trial.
Ayoub, A; Duparc, S; Kamiza, S; Kimani, J; Orrico, R; Phiri, K; Robbins, J; Rojo, R; Vandenbroucke, P, 2016
)
0.67
"A surveillance system was established to record all deaths and all malaria cases diagnosed at health facilities and a pharmacovigilance system was established to detect adverse drug reactions."( Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial.
Ba, EH; Cairns, M; Cissé, B; Fall, FB; Faye, B; Gaye, O; Gomis, JF; Greenwood, BM; Kouevijdin, E; Milligan, PJ; Molez, JF; NDiaye, JL; Ndour, CT; Niane, FK; Rogier, C; Sokhna, C; Trape, JF, 2016
)
0.67
" No serious adverse events attributable to the intervention were detected, despite a high level of surveillance."( Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial.
Ba, EH; Cairns, M; Cissé, B; Fall, FB; Faye, B; Gaye, O; Gomis, JF; Greenwood, BM; Kouevijdin, E; Milligan, PJ; Molez, JF; NDiaye, JL; Ndour, CT; Niane, FK; Rogier, C; Sokhna, C; Trape, JF, 2016
)
0.67
" Monthly IPT-DP was associated with fewer serious adverse events than placebo, daily co-trimoxazole, or monthly SP."( Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis.
Dorsey, G; Gutman, J; Kovacs, S; Stergachis, A; Ter Kuile, FO, 2017
)
0.46
"In endemic areas, malaria and its adverse effects in schoolchildren may be prevented by intermittent preventive treatment (IPTsc)."( Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial.
da Luz, RI; Doua, JY; Lutumba, P; Matangila, JR; Mitashi, P; Van Geertruyden, JP, 2017
)
0.68
" Here we present the side effect profile of MQ for the treatment of uncomplicated malaria on the Thai-Myanmar/Cambodia borders."( Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients.
Lee, SJ; Luxemburger, C; Nosten, F; Price, RN; Ter Kuile, FO, 2017
)
0.46
" For quinine, clindamycin, and mefloquine and the combinations of sulfadoxine+pyrimethamine and artemether+lumefantrine, there are reports (including studies without internal comparison groups) that combined describe 304 to >1100 exposures of women in the first trimester for each drug with no conclusive evidence of adverse effects on pregnancy at therapeutic doses."( Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester.
Clark, RL, 2017
)
0.68
" Across manifestations, adverse event (AE)-related treatment discontinuation and/or change in therapy involved ≤37% of patients and occurred in >55% of studies: 100% for ocular toxoplasmosis, 57."( Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review.
Ben-Harari, RR; Casoy, J; Goodwin, E, 2017
)
0.76
" After exclusion of blue urine, adverse events were similar across all groups (59 [74%] of 80 participants had 162 adverse events overall, 145 [90%] of which were mild)."( Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial.
Bousema, T; Bradley, J; Brown, JM; Chen, I; Diarra, K; Diawara, H; Dicko, A; Drakeley, C; Gosling, R; Hwang, J; Issiaka, D; Keita, S; Kone, DT; Lanke, K; Mahamar, A; McCulloch, C; Müller, O; Roh, ME; Sanogo, K; Soumare, HM; Srinivasan, V; Stone, WJR; Traore, SF, 2018
)
0.48
"Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by the World Health Organization for the prevention of malaria in pregnancy (MIP)-associated adverse outcomes in high burden areas."( Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized
Champo, D; Chongwe, G; Ippolito, MM; Kabuya, JB; Manyando, C; Mulenga, M; Mwakazanga, D; Sikalima, J; Tende, C; Young, AMP, 2021
)
1.08
" Secondary endpoints include incident MIP at other time points, placental malaria, congenital malaria, hemoglobin trends, birth outcomes, and incidence of adverse events in infants up to the first birthday."( Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized
Champo, D; Chongwe, G; Ippolito, MM; Kabuya, JB; Manyando, C; Mulenga, M; Mwakazanga, D; Sikalima, J; Tende, C; Young, AMP, 2021
)
0.85
"In drug trials, adverse events (AEs) burden can induce treatment non-adherence or discontinuation."( Effect of adverse events on non-adherence and study non-completion in malaria chemoprevention during pregnancy trial: A nested case control study.
Chirwa, T; Divala, T; Kazembe, L; Laufer, MK; Mathanga, D; Mukaka, M; Patson, N; Peterson, I, 2022
)
0.72
" RCTs comparing IPTp DP versus recommended standard treatment for IPTp with these outcome measures were analyzed; change in QTc interval, serious adverse events (SAE), grade 3 or 4 adverse events possibly related to study drug and vomiting within 30 min after study drug administration."( Safety and tolerability of repeated doses of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a systematic review and an aggregated data meta-analysis of randomized controlled trials.
Abebe, A; Ahmedin, M; Atim, MG; Embaye, SM; Kahabuka, M; Kazembe, D; Manyazewal, T; Mesfin, T; Muthoka, EN; Namuganza, S; Usmael, K, 2023
)
0.91

Pharmacokinetics

Sulfadoxine (SDX) and pyrimethamine (PYM) were tested in children with uncomplicated malaria in Malawi. The study was intended to investigate the effect of concomitant administration of antimalarial drug on pharmacokinetic and post coitus contraceptive efficacy of female Sprague-Dawley rats.

ExcerptReferenceRelevance
"Single-dose pharmacokinetic variables of pyrimethamine were studied in horses."( Pharmacokinetics of intravenously and orally administered pyrimethamine in horses.
Burrows, GE; Clarke, CR; Ewing, P; Lauer, AK; MacAllister, CG; Spillers, DK, 1992
)
0.79
" Pyrimethamine concentration in plasma and CSF was quantified by gas chromatography, and plasma concentration-time data were analyzed, using a pharmacokinetic computer program."( Pharmacokinetics, penetration into cerebrospinal fluid, and hematologic effects after multiple oral administrations of pyrimethamine to horses.
Burrows, GE; Burrows, SL; Clarke, CR; Ewing, P; MacAllister, CG; Spillers, DK, 1992
)
1.4
" After the last maintenance dose of Maloprim, the following kinetic parameters (mean values) were determined for DDS and PYR, respectively: maximum plasma concentration (Cmax) = 1,134 and 116 ng ml-1; elimination half-life (t1/2) = 23 and 105 h; plasma clearance (CL) = 37."( Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man.
Edstein, MD; Rieckmann, KH; Veenendaal, JR, 1990
)
0.5
" Several assay methodologies have been developed, but high performance liquid chromatography has been the most used in recent pharmacokinetic studies."( Clinical pharmacokinetics of mefloquine.
Karbwang, J; White, NJ, 1990
)
0.28
" The pharmacokinetic parameters for group 1 and group 3 were not significantly different."( Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria.
Back, DJ; Breckenridge, AM; Bunnag, D; Karbwang, J, 1990
)
0.52
" The pharmacokinetic evaluation of each of the three components was based on the assumption of an open linear one-compartment model."( Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet.
Arnold, K; Fu, LC; Guo, XB; Li, GQ; Liu, QD; Wang, NS, 1990
)
0.55
" The mean values for intraperitoneal clearance and half-life were not significantly different between dose groups, indicating that the plasma pharmacokinetics of pyrimethamine were independent of dose."( Pyrimethamine pharmacokinetics and its tissue localization in mice: effect of dose size.
Breckenridge, AM; Coleman, MD; Edwards, G; Howells, RE; Mihaly, GW; Ward, SA, 1985
)
1.91
" The pharmacokinetic evaluation of each of the three components was based on the assumption of an open linear two-compartment model."( Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects.
Heizmann, P; Mimica, I; Portmann, R; Schwartz, DE; Weidekamm, E, 1987
)
0.51
" There was considerable interindividual variability in the pharmacokinetic parameters; for example in the male subjects receiving MQ alone peak concentrations ranged between 638 and 2494 ng X ml-1 with a mean concentration of 1442 ng X ml-1."( The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects.
Back, DJ; Breckenridge, AM; Bunnag, D; Karbwang, J, 1987
)
0.49
"For the past 300 years antimalarial dosage regimens have not been based on pharmacokinetic information."( Clinical pharmacokinetics of antimalarial drugs.
White, NJ,
)
0.13
" This assay was shown to be satisfactory for pharmacokinetic studies."( Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine.
Ahmad, RA; Rogers, HJ, 1980
)
0.5
" Similarly, evaluation of the pharmacokinetic properties of halofantrine has led to the demonstration that poor and erratic absorption could be just as likely to explain therapeutic failure as resistance of the parasite to effects of this drug."( Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.
Edwards, G; Ward, SA; Winstanley, PA, 1994
)
0.29
" The pharmacokinetics of dapsone and pyrimethamine were examined by using a population pharmacokinetic model."( Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.
Amantea, MA; Byrne, A; Davey, RT; Falloon, J; Graziani, A; Lavelle, J; Morgan, A; Ogata-Arakaki, D; Ownby, K; Polis, M, 1994
)
0.8
" Pyrimethamine was administered at 50 mg daily for 3 weeks to achieve steady state, and pharmacokinetic profiles were determined after administration of the last dose."( Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii.
Davidian, M; Hafner, R; Jacobson, JM; Luft, BJ; Raasch, RH; Rainey, PM, 1996
)
2.65
" Elimination of pyrimethamine was however, a relatively slow process compared with artemether, and thus resulted in a long terminal phase elimination half-life (50-106 hours)."( Pharmacokinetic interactions of artemether and pyrimethamine in healthy male Thais.
Karbwang, J; Na-Bangchang, K; Tan-ariya, P; Thanavibul, A; Thipawangkosol, P; Ubalee, R, 1998
)
0.9
"To develop a population pharmacokinetic model for pyrimethamine (PYR) and sulfadoxine (SDX) in children with congenital toxoplasmosis."( Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis.
Chemla, C; Dupouy, D; Jaussaud, R; Leroux, B; Millart, H; Pinon, JM; Quereux, C; Rémy, G; Simon, N; Trenque, T; Urien, S; Villena, I, 2004
)
0.86
" Population pharmacokinetic analysis was performed using a nonlinear mixed effects model."( Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis.
Chemla, C; Dupouy, D; Jaussaud, R; Leroux, B; Millart, H; Pinon, JM; Quereux, C; Rémy, G; Simon, N; Trenque, T; Urien, S; Villena, I, 2004
)
0.61
" A one-compartment model was used as the structural model, and individual pharmacokinetic parameters were estimated by Bayesian modeling."( Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.
Al Kurdi, M; Charpiat, B; Chaulet, JF; Corvaisier, S; Leboucher, G; Mounier, C; Peyron, F; Wallon, M, 2004
)
0.61
"To explore possible pharmacokinetic interactions between CQ and S/P during co-administration, and to determine their bioavailability in the locally made Homapak compared to the Good Manufacturing Practice (GMP) made formulations."( Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda.
Anokbonggo, WW; Gustafsson, LL; Hellgren, U; Lundblad, MS; Mahindi, M; Ntale, M; Obua, C; Ogwal-Okeng, JW, 2006
)
0.57
" Plasma samples were followed for 21 days, analysed by HPLC-UV methods, with pharmacokinetic modeling using the WinNonlin software."( Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda.
Anokbonggo, WW; Gustafsson, LL; Hellgren, U; Lundblad, MS; Mahindi, M; Ntale, M; Obua, C; Ogwal-Okeng, JW, 2006
)
0.57
" No significant differences were observed in the other pharmacokinetic parameters of S, P and CQ when given together or separately."( Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda.
Anokbonggo, WW; Gustafsson, LL; Hellgren, U; Lundblad, MS; Mahindi, M; Ntale, M; Obua, C; Ogwal-Okeng, JW, 2006
)
0.57
"There were no pharmacokinetic interactions between CQ, S and P when the compounds were given together, however, more investigations would be needed to explore this further."( Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda.
Anokbonggo, WW; Gustafsson, LL; Hellgren, U; Lundblad, MS; Mahindi, M; Ntale, M; Obua, C; Ogwal-Okeng, JW, 2006
)
0.57
"Our objective was to characterize the pharmacokinetic properties of sulfadoxine-pyrimethamine in African adults and children with acute falciparum malaria."( Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications.
Barnes, KI; Evans, A; Little, F; Smith, PJ; Watkins, WM; White, NJ, 2006
)
0.94
"In a prospective multicenter pharmacokinetic study in 307 patients with acute falciparum malaria, capillary blood concentrations of sulfadoxine and pyrimethamine were determined at 9 visits over a period of 42 days by mass spectrometry."( Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications.
Barnes, KI; Evans, A; Little, F; Smith, PJ; Watkins, WM; White, NJ, 2006
)
0.91
" Among prepartum women, the median half-life for sulfadoxine was significantly shorter than that observed in postpartum women (148 vs 256 h; P<."( Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya.
Ayisi, JG; Green, MD; Kager, PA; Nahlen, BL; Nettey, H; Parise, ME; Steketee, R; van Eijk, AM; van Ter Kuile, FO, 2007
)
0.62
"Pregnancy significantly modifies the disposition of SP, whereas HIV status has little influence on pharmacokinetic parameters in pregnant women."( Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya.
Ayisi, JG; Green, MD; Kager, PA; Nahlen, BL; Nettey, H; Parise, ME; Steketee, R; van Eijk, AM; van Ter Kuile, FO, 2007
)
0.62
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"To determine the pharmacokinetic disposition of sulfadoxine (SDOX) and pyrimethamine (PYR) when administered as intermittent presumptive treatment during pregnancy (IPTp) for malaria, 30 Papua New Guinean women in the second or third trimester of pregnancy and 30 age-matched nonpregnant women were given a single dose of 1,500 mg of SDOX plus 75 mg of pyrimethamine PYR."( Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women.
Baiwog, F; Davis, TM; Gomorrai, S; Ilett, KF; Karunajeewa, HA; Law, I; Mueller, I; Page-Sharp, M; Rogerson, S; Salman, S; Siba, P, 2009
)
0.85
" SP pharmacokinetic parameters differed significantly among the study sites."( Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy.
Adam, I; Barnes, KI; Cassam, Y; Doumbo, O; Guirou, E; Kayentao, K; Little, F; Mauff, K; Nyunt, MM; Smith, P; Sullivan, D; Thuma, P; Traore, B; van Dijk, J, 2010
)
0.64
" To assess its pharmacokinetic properties when administered as intermittent preventive treatment in pregnancy (IPTp), two 2-g doses were given 24 h apart to 31 pregnant and 29 age-matched nonpregnant Papua New Guinean women."( Pharmacokinetic properties of azithromycin in pregnancy.
Baiwog, F; Davis, TM; Gomorai, S; Griffin, S; Ilett, KF; Kandai, J; Karunajeewa, HA; Kose, K; Mueller, I; O'Halloran, SJ; Rogerson, SJ; Salman, S; Siba, P; Winmai, J, 2010
)
0.36
" However, information on pharmacokinetic disposition of SDX-pyrimethamine in children is limited."( Pharmacokinetic disposition of sulfadoxine in children with acute uncomplicated falciparum malaria treated with sulfadoxine-pyrimethamine in South West Nigeria.
Gbotosho, GO; Happi, CT; Oduola, A; Sijuade, A; Sowunmi, A, 2012
)
0.83
" We developed population pharmacokinetic (PK) models to describe the distribution of sulfadoxine (SDX) and pyrimethamine (PYM) in children with uncomplicated malaria in Malawi."( Population pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria.
Bell, DJ; Molyneux, ME; Mukaka, M; Nyirongo, SK; Ward, SA; Winstanley, PA, 2011
)
0.84
" Because of limited pharmacokinetic data and suggestions that higher milligram/kilogram pediatric doses than recommended should be considered, we assessed SDX/PYR disposition, randomized to conventional (25/1."( Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy.
Davis, TM; Griffin, S; Ilett, KF; Kose, K; Moore, B; Mueller, I; Pitus, N; Salman, S; Siba, P; Winmai, J, 2011
)
0.6
" Yet, limited data is available on pharmacokinetic interactions between these drugs."( Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali.
Barnes, KI; Beavogui, AH; Djimde, AA; Doumbo, OK; Evans, A; Fredericks, A; Maiga, H; Sangare, CP; Smith, P; Tekete, MM; Toure, S; Traore, ZI, 2011
)
0.62
" Exactly 100 μl of capillary blood was collected onto filter paper before drug administration at day 0 and at days 1, 3, 7, 14, 21 and 28 after drug administration for analysis of sulphadoxine and pyrimethamine pharmacokinetic parameters."( Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali.
Barnes, KI; Beavogui, AH; Djimde, AA; Doumbo, OK; Evans, A; Fredericks, A; Maiga, H; Sangare, CP; Smith, P; Tekete, MM; Toure, S; Traore, ZI, 2011
)
0.81
"001) and thus elimination half-life (3."( Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali.
Barnes, KI; Beavogui, AH; Djimde, AA; Doumbo, OK; Evans, A; Fredericks, A; Maiga, H; Sangare, CP; Smith, P; Tekete, MM; Toure, S; Traore, ZI, 2011
)
0.62
" Identified articles were included in the review if the study had at least one group that reported at least one pharmacokinetic parameter of interest in pregnant women."( Pharmacokinetics of antimalarials in pregnancy: a systematic review.
Ensom, MH; Wilby, KJ, 2011
)
0.37
"The aim of the present study was to compare the pharmacokinetic profiles between a new generic and the branded reference formulation of sulfadoxine/pyrimethamine FDC tablets, and to assess the bioequivalence of the 2 products in healthy Chinese volunteers."( Pharmacokinetic properties and bioequivalence of two sulfadoxine/pyrimethamine fixed-dose combination tablets: a parallel-design study in healthy Chinese male volunteers.
Jia, JY; Liu, GY; Liu, Y; Liu, YM; Lu, C; Pu, HH; Song, YX; Yu, C; Zhang, HC; Zhang, KE; Zheng, QS; Zhu, JM, 2012
)
0.82
" Pharmacokinetic properties (C(max), AUC(0-72), AUC(0-168), and T(max)) were calculated and analyzed statistically."( Pharmacokinetic properties and bioequivalence of two sulfadoxine/pyrimethamine fixed-dose combination tablets: a parallel-design study in healthy Chinese male volunteers.
Jia, JY; Liu, GY; Liu, Y; Liu, YM; Lu, C; Pu, HH; Song, YX; Yu, C; Zhang, HC; Zhang, KE; Zheng, QS; Zhu, JM, 2012
)
0.62
"The findings from this single-dose (1500/75-mg) study suggest that the test and reference formulations of sulfadoxine/pyrimethamine FDC 500/25-mg tablet have similar pharmacokinetic profiles both in terms of rate and extent of absorption."( Pharmacokinetic properties and bioequivalence of two sulfadoxine/pyrimethamine fixed-dose combination tablets: a parallel-design study in healthy Chinese male volunteers.
Jia, JY; Liu, GY; Liu, Y; Liu, YM; Lu, C; Pu, HH; Song, YX; Yu, C; Zhang, HC; Zhang, KE; Zheng, QS; Zhu, JM, 2012
)
0.83
" Compartmental pharmacokinetic models were developed using a population-based approach."( Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.
Batty, KT; Benjamin, JM; Davis, TM; Lorry, L; Moore, BR; Mueller, I; Page-Sharp, M; Robinson, LJ; Salman, S; Siba, PM; Tawat, S; Yadi, G, 2015
)
0.63
"The ongoing development of new antimalarial drugs and the increasing use of controlled human malaria infection (CHMI) studies to investigate their activity in early-stage clinical trials require the development of methods to analyze their pharmacodynamic effect."( Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR.
Baker, M; Marquart, L; McCarthy, JS; O'Rourke, P, 2015
)
0.42
" However, pharmacokinetic studies in pregnancy show variable and often contradictory findings."( Trimester-Specific Population Pharmacokinetics and Other Correlates of Variability in Sulphadoxine-Pyrimethamine Disposition Among Ugandan Pregnant Women.
Bisaso, KR; Byamugisha, J; Mukonzo, JK; Ntale, M; Obua, C; Odia, G; Odongo, CO; Ojara, FW, 2015
)
0.63
" Population pharmacokinetic analysis was done using NONMEM software."( Trimester-Specific Population Pharmacokinetics and Other Correlates of Variability in Sulphadoxine-Pyrimethamine Disposition Among Ugandan Pregnant Women.
Bisaso, KR; Byamugisha, J; Mukonzo, JK; Ntale, M; Obua, C; Odia, G; Odongo, CO; Ojara, FW, 2015
)
0.63
" Between trimesters, statistically significant differences in central volumes of distribution (V(2)) were observed for both drugs, while differences in the distribution half-life and the terminal elimination half-life were observed for pyrimethamine and sulphadoxine, respectively."( Trimester-Specific Population Pharmacokinetics and Other Correlates of Variability in Sulphadoxine-Pyrimethamine Disposition Among Ugandan Pregnant Women.
Bisaso, KR; Byamugisha, J; Mukonzo, JK; Ntale, M; Obua, C; Odia, G; Odongo, CO; Ojara, FW, 2015
)
0.82
" Data from 98 women during pregnancy and 77 after delivery in four African countries were analyzed using nonlinear mixed-effects modeling to characterize the effects of pregnancy, postpartum duration, and other covariates such as body weight and hematocrit on sulfadoxine/pyrimethamine pharmacokinetic properties."( Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive Treatment of Malaria During Pregnancy and After Delivery.
Adam, I; Barnes, KI; de Kock, M; Denti, P; Nyunt, MM; Tarning, J; Workman, L, 2017
)
0.91
"Despite extensive use and accumulated evidence of safety, there have been few pharmacokinetic studies from which appropriate chloroquine (CQ) dosing regimens could be developed specifically for pregnant women."( Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling.
Baiwog, F; Davis, TME; Ilett, KF; Karunajeewa, HA; Kose, K; Mueller, I; Page-Sharp, M; Rogerson, SJ; Salman, S; Siba, PM, 2017
)
0.46
"The study was intended to investigate the effect of concomitant administration of antimalarial drug (pyrimethamine or arteether) on pharmacokinetic and post coitus contraceptive efficacy of ormeloxifene in female Sprague-Dawley rats."( Effect of arteether and pyrimethamine coadministration on the pharmacokinetic and pharmacodynamic profile of ormeloxifene.
Jaiswal, S; Lal, J; Sharma, A; Shukla, M, 2017
)
0.98
" This study determined the pharmacokinetic characteristics of the mefloquine stereoisomers and the metabolite carboxymefloquine (CMQ) when given as IPTp in pregnant women."( Population Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon.
Akerey-Diop, D; Basra, A; Geditz, M; Gonzalez, R; Hofmann, U; Kerb, R; Kremsner, PG; Lehr, T; Mackanga, JR; Matsiegui, PB; Menendez, C; Mombo-Ngoma, G; Ramharter, M; Schwab, M; Wojtyniak, JG; Würbel, H; Zoleko Manego, R, 2019
)
0.51
" Understanding the safety, pharmacokinetic and pharmacodynamic properties of antimalarial combination therapies is crucial in optimising dosing."( Pharmacokinetic considerations in seasonal malaria chemoprevention.
Chotsiri, P; Tarning, J; White, NJ, 2022
)
0.72
" Pharmacokinetic and anti-toxoplasma activity profiles of the printlets and compressed tablets were superimposable with no statistical difference (p > 0."( Pyrimethamine 3D printlets for pediatric toxoplasmosis: design, pharmacokinetics, and anti-toxoplasma activity.
Dharani, S; Kayalar, C; Khan, MA; Khuroo, T; Kuttolamadom, MA; Mohamed, EM; Rahman, Z; Sangaré, LO, 2023
)
2.35

Compound-Compound Interactions

Randomised and quasi-randomised trials of chloroquine or amodiaquine given with sulfadoxine-pyrimethamine compared with either drug alone in adults or children with confirmed uncomplicated falciparum malaria.

ExcerptReferenceRelevance
"The activity of the macrolide antibiotic clarithromycin was examined alone or in combination with other drugs for the treatment of acute or chronic infections with Toxoplasma gondii in mice."( Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis.
Araujo, FG; Lin, T; Prokocimer, P; Remington, JS, 1992
)
0.28
"The efficacy of dapsone alone or combined with pyrimethamine against Toxoplasma gondii was investigated experimentally."( Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine.
Chastang, C; Chau, F; Derouin, F; Piketty, C; Pocidalo, JJ; Rouveix, B, 1991
)
0.78
"The activity of recombinant gamma interferon (rIFN-gamma) in combination with either pyrimethamine or clindamycin was examined in a murine model of acute toxoplasmosis."( Activity of gamma interferon in combination with pyrimethamine or clindamycin in treatment of murine toxoplasmosis.
Israelski, D; Remington, J, 1990
)
0.76
" Mefloquine was administered alone (750 mg orally; group 1), or with primaquine (PQ, 45 mg; group 2), or in combination with sulfadoxine (1."( Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria.
Back, DJ; Breckenridge, AM; Bunnag, D; Karbwang, J, 1990
)
0.52
" 175 Europeans travelling to different malaria endemic areas received either mefloquine alone (250 mg/week) or its combination with sulfadoxine (500 mg/week) plus pyrimethamine (25 mg/week)."( Tolerance of mefloquine alone and in combination with sulfadoxine-pyrimethamine in the prophylaxis of malaria.
Dietrich, M; Horstmann, RD; Reisinger, EC,
)
0.56
"The presence of low concentrations of the lipophilic dihydrofolate reductase inhibitors metoprine or trimetrexate, which cause little inhibition in the growth of cultured hepatoma cells in combination with weakly inhibiting concentrations of 5,10-dideazatetrahydrofolate, exhibit greater activity than would be predicted by the activity of the individual components."( Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
Boschelli, D; Galivan, J; Kerwar, SS; Nimec, Z; Oronsky, AL; Rhee, M, 1988
)
0.27
"The efficacy of roxithromycin alone or in combination with pyrimethamine or sulphadiazine was examined in vitro and in a murine model of acute toxoplasmosis."( In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.
Bryskier, A; Derouin, F; Moutot, M; Romand, S, 1995
)
0.77
"Sulfadiazine and the metabolites N4-acetyl-sulfadiazine, 4-OH-sulfadiazine, 5-OH-sulfadiazine, 5-OH-glucuronide-sulfadiazine, and 5-OH-sulfate-sulfadiazine were tested separately and in combination with pyrimethamine for the inhibitory activity on Toxoplasma gondii growth in vitro."( In vitro effects of sulfadiazine and its metabolites alone and in combination with pyrimethamine on Toxoplasma gondii.
Camps, W; Galama, J; Melchers, W; Schoondermark-van de Ven, E; Vree, T, 1995
)
0.7
"In The Gambia, insecticide impregnation of bed nets, used alone or combined with Maloprim, reduced morbidity and mortality from malaria amongst children between one and 4 years of age."( A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, west Africa. 8. Cost-effectiveness of bed net impregnation alone or combined with chemoprophylaxis in preventing mortality and morbidit
Aikins, M; Alonso, PL; Armstrong Schellenberg, JR; Greenwood, BM; Mills, A; Picard, J, 1993
)
0.29
"The efficacy of atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, and minocycline was examined in vitro and in a murine model of acute toxoplasmosis."( In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Derouin, F; Pudney, M; Romand, S, 1993
)
0.76
"The activity of atovaquone in the treatment of murine toxoplasmosis was greatly enhanced when administered in combination with pyrimethamine or sulfadiazine."( The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Araujo, FG; Lin, T; Remington, JS, 1993
)
0.7
" Doses of each drug that were not effective in reducing inflammation in the brain of mice with toxoplasmic encephalitis when used alone were used in combination with a dose of rifabutin which was minimally effective."( Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Araujo, FG; Remington, JS; Suzuki, Y, 1996
)
0.53
"The anticryptosporidial activity of four macrolides alone and in combination with other antimicrobial agents was investigated against ten clinical isolates of Cryptosporidium parvum recovered from stools of AIDS patients."( In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum.
Cirioni, O; Giacometti, A; Scalise, G, 1996
)
0.51
"We report one case of successful treatment of cerebral toxoplasmosis in acquired immunodeficiency syndrome (AIDS) with azithromycin combined with pyrimethamine."( [Azithromycin combined with pyrimethamine in the treatment of neurotoxoplasmosis, in an AIDS patient].
Dionisio, D; Leoncini, F; Milo, D; Sterrantino, G; Trotta, M, 1997
)
0.79
"To assess the effectiveness of chloroquine or amodiaquine given with sulfadoxine-pyrimethamine to treat uncomplicated falciparum malaria."( Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
McIntosh, HM, 2000
)
0.78
"Randomised and quasi-randomised trials of chloroquine or amodiaquine given with sulfadoxine-pyrimethamine compared with either drug alone in adults or children with confirmed uncomplicated falciparum malaria."( Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
McIntosh, HM, 2000
)
0.78
"In areas where chloroquine or amodiaquine are still effective, despite some degree of resistance, using these drugs in combination with sulfadoxine-pyrimethamine, rather than sulfadoxine-pyrimethamine alone, may make people feel better faster and improve sustained parasites clearance."( Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
McIntosh, HM, 2000
)
0.76
"The in vitro activity of lactoferrins alone and in combination with clarithromycin, minocycline and pyrimethamine was investigated against three clinical isolates of Pneumocystis carinii."( Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline.
Barchiesi, F; Cirioni, O; Giacometti, A; Scalise, G, 2000
)
0.74
"The activity of gatifloxacin against Toxoplasma gondii, either alone or in combination with pyrimethamine or gamma interferon (IFN-gamma), was examined in vitro and in vivo."( Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii.
Araujo, FG; Khan, AA; Remington, JS; Slifer, TR, 2001
)
0.78
" From September to December 1998, 598 children with uncomplicated malaria were treated; 135 received chloroquine (CQ) alone, 276 received pyrimethamine/sulfadoxine (Fansidar, PSD) alone, 113 received PSD with a single dose of artesunate (PSD + 1ART) and 74 received PSD combined with three doses of artesunate (PSD + 3ART)."( Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria.
Coleman, R; Doherty, T; Jawara, M; Targett, G; von Seidlein, L; Walraven, G, 2001
)
0.75
"To assess the effectiveness of chloroquine or amodiaquine given with sulfadoxine-pyrimethamine to treat uncomplicated falciparum malaria."( Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
McIntosh, HM, 2001
)
0.79
"Randomised and quasi-randomised trials of chloroquine or amodiaquine given with sulfadoxine-pyrimethamine compared with either drug alone in adults or children with confirmed uncomplicated falciparum malaria."( Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
McIntosh, HM, 2001
)
0.78
"In areas where chloroquine or amodiaquine are still effective, despite some degree of resistance, using these drugs in combination with sulfadoxine-pyrimethamine, rather than sulfadoxine-pyrimethamine alone, may make people feel better faster and improve sustained parasites clearance."( Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
McIntosh, HM, 2001
)
0.76
" Three doses of 200, 300 and 400 mg/kg DFO were used either alone or in combination with pyrimethamine."( Effect of deferoxamine alone and combined with pyrimethamine on acute toxoplasmosis in mice.
Mahmoud, MS, 1999
)
0.78
" Overall 14,017 (85%) individuals living in the study area were treated with either placebo or sulfadoxine-pyrimethamine (SP) combined with a single dose of artesunate (AS)."( The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia.
Alexander, N; Bennett, S; Coleman, R; De Martin, S; Deen, JL; Doherty, JF; Drakeley, C; Greenwood, BM; Jawara, M; Lindsay, SW; Manneh, F; McAdam, KP; Milligan, PJ; Okunoye, K; Olliaro, P; Pinder, M; Schim van der Loeff, M; Targett, GA; von Seidlein, L; Walraven, G,
)
0.6
"The effectiveness of chloroquine or sulfadoxine-pyrimethamine administered with artesunate for treating uncomplicated falciparum malaria was assessed in 2 Vietnamese provinces where the sensitivity of parasites in vitro to conventional therapies had increased with the removal of drug pressure."( Treatment of uncomplicated falciparum malaria in southern Vietnam: can chloroquine or sulfadoxine-pyrimethamine be reintroduced in combination with artesunate?
Cox-Singh, J; Davis, TM; Doan, HN; Hewitt, S; Le, DC; Nguyen, MH; Nguyen, TH; Tran, BK; Tran, QT; Vo, NP, 2003
)
0.79
" In 2002, we assessed the efficacy of SP alone and combined with amodiaquine (AQ/SP) or chloroquine (CQ/SP) in Ugandan children with uncomplicated falciparum malaria."( Efficacy of sulphadoxine-pyrimethamine alone or combined with amodiaquine or chloroquine for the treatment of uncomplicated falciparum malaria in Ugandan children.
Bakyaita, N; D'Alessandro, U; Egwang, TG; Langi, P; Mutabingwa, TK; Nalunkuma-Kazibwe, A; Talisuna, AO; Van Marck, E; Watkins, WW, 2004
)
0.63
"The efficacy of pyrimethamine or sulfadoxine administered in combination with azithromycin was examined in a rodent malaria model."( Plasmodium yoelii: activity of azithromycin in combination with pyrimethamine or sulfadoxine against blood and sporozoite induced infections in Swiss mice.
Neerja, J; Puri, SK,
)
0.72
" At a meeting in Port Moresby in October 1997, it was decided to explore a possible change of the current first-line treatment of uncomplicated malaria with chloroquine alone (amodiaquine for children under five years) to chloroquine or amodiaquine in combination with sulfadoxine-pyrimethamine (S-P)."( Therapeutic efficacy of chloroquine or amodiaquine in combination with sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Papua New Guinea.
Bulungol, P; Hwaihwanje, I; Jayatilaka, KD; Kemiki, A; Taviri, J,
)
0.53
"To overcome the declining efficacy of the 4-aminoquinolines in Papua New Guinea, sulfadoxine/pyrimethamine (SP) was combined with the 4-aminoquinolines as the first line treatment for falciparum malaria since 2000."( Rapid selection of dhfr mutant allele in Plasmodium falciparum isolates after the introduction of sulfadoxine/pyrimethamine in combination with 4-aminoquinolines in Papua New Guinea.
Björkman, A; Hwaihwanje, I; Kaneko, A; Kobayakawa, T; Mita, T; Osawa, H; Takahashi, N; Tanabe, K; Tsukahara, T, 2006
)
0.77
" A few potent chalcones were selected for their antimalarial interaction in combination with artemisinin in vitro."( Antimalarial pharmacodynamics of chalcone derivatives in combination with artemisinin against Plasmodium falciparum in vitro.
Awasthi, SK; Bhasin, VK; Bhattacharya, A; Mishra, LC; Sharma, M, 2009
)
0.35
"The effectiveness of methylene blue (MB) combined with pyrimethamine (PYR), chloroquine (CQ) or quinine (Q) was examined in a classical four-day suppressive test against a causative agent of rodent malaria, Plasmodium berghei."( The in vivo antimalarial activity of methylene blue combined with pyrimethamine, chloroquine and quinine.
Aldana, I; Bertani, S; Deharo, E; Garavito, G; Quiliano, M; Valentin, A, 2012
)
0.86
"Artesunate (AS) in combination with sulfadoxine/pyrimethamine (SP) is the first-line therapy for management of uncomplicated Plasmodium falciparum malaria in Sudan."( Pharmacokinetics of artesunate alone and in combination with sulfadoxine/pyrimethamine in healthy Sudanese volunteers.
Awad, AI; Elamin, SB; Matar, KM, 2014
)
0.89
"The aim of this study is to evaluate the effects of pyrimethamine (PYR) and sulfadiazine (SDZ) combined with levamisole and echinacea on the survival of mice infected with Toxoplasma gondii."( In Vivo Efficacy of Drugs against Toxoplasma gondii Combined with Immunomodulators.
Bilgin, K; Hokelek, M; Köksal, ZŞ; Yanik, K; Yılmaz, EM, 2016
)
0.68
" Furthermore, doxycycline has anti-malarial properties and is already recommended as prophylaxis for travellers and for treatment of falciparum malaria in combination with other anti-malarial drugs."( Has doxycycline, in combination with anti-malarial drugs, a role to play in intermittent preventive treatment of Plasmodium falciparum malaria infection in pregnant women in Africa?
Boxberger, M; Gaillard, T; Madamet, M; Pradines, B, 2018
)
0.48
"In this study, the effects of the treatment with different doses of fluconazole (FLZ) in combination with the current treatment of acute toxoplasmosis on reducing the mortality rate and the parasitic load in the murine model in vivo were studied."( Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine.
Anita, M; Hadi, M; Mohammad, JM; Reza, S; Sina, S; Soudabeh, E, 2021
)
0.82

Bioavailability

The use of most of the antimalarials is restricted owing to their poor solubility and low bioavailability problems. The developed analytical approach was successfully validated and was applied in the pharmacokinetic evaluation of the bioavailability between two sulfadoxine/pyrimethamine formulations available on the Eastern African market.

ExcerptReferenceRelevance
" Bioavailability after oral administration was 56%."( Pharmacokinetics of intravenously and orally administered pyrimethamine in horses.
Burrows, GE; Clarke, CR; Ewing, P; Lauer, AK; MacAllister, CG; Spillers, DK, 1992
)
0.53
"The oral single-dose pharmacokinetics and bioavailability of mefloquine (M) in combination with pyrimethamine (P) and sulfadoxine (S) from a single non-lacquered tablet (NL; M 250 mg, P 25 mg, S 500 mg) and two lacquered tablets (L; M 125 mg, P 12."( Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet.
Arnold, K; Fu, LC; Guo, XB; Li, GQ; Liu, QD; Wang, NS, 1990
)
0.77
"001) serum concentrations of PYR were found in Papua New Guineans than in Caucasians at both sampling times, an observation which may reflect differences in the bioavailability of PYR between the two racial groups."( Race-linked differences in serum concentrations of dapsone, monoacetyldapsone and pyrimethamine during malaria prophylaxis.
Cochrane, JP; Cook, IF; Edstein, MD, 1986
)
0.5
" The results indicate that concomitant therapy of these antimalarials with the implicated antacid and antidiarrhoeal agents will result in poor bioavailability of the antimalarials."( In vitro experiments on chloroquine and pyrimethamine absorption in the presence of antacid constituents or kaolin.
D'Arcy, PF; McElnay, JC; Mukhtar, HA; Temple, DJ, 1982
)
0.53
"The bioavailability of two oral preparations of pyrimethamine-sulfadoxine are compared in a randomised cross-over study."( A study of the comparative bioavailability of pyrimethamine-sulfadoxine obtained from two oral preparations.
Mberu, E; Murphy, SA, 1994
)
0.8
" The developed analytical approach was successfully validated and was applied in the pharmacokinetic evaluation of the bioavailability between two sulfadoxine/pyrimethamine formulations available on the Eastern African market, using a cross-over design."( Liquid chromatographic-mass spectrometric assay for simultaneous pyrimethamine and sulfadoxine determination in human plasma samples.
Decaestecker, TN; Remon, JP; Risha, PG; Sinnaeve, BA; Van Bocxlaer, JF; Vervaet, C, 2005
)
0.76
"The main objective of this work was to assess the relative bioavailability of two tablet formulations containing sulfadoxine/pyrimethamine (SP) and marketed in Tanzania."( Existence of antimalarial formulations with low bioavailability in Tanzania.
Ericsson, O; Gustafsson, LL; Justin-Temu, M; Massele, A; Minzi, OM, 2006
)
0.54
"To explore possible pharmacokinetic interactions between CQ and S/P during co-administration, and to determine their bioavailability in the locally made Homapak compared to the Good Manufacturing Practice (GMP) made formulations."( Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda.
Anokbonggo, WW; Gustafsson, LL; Hellgren, U; Lundblad, MS; Mahindi, M; Ntale, M; Obua, C; Ogwal-Okeng, JW, 2006
)
0.57
" The relative bioavailability of CQ and S in Homapak showed bioequivalence to reference formulations."( Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda.
Anokbonggo, WW; Gustafsson, LL; Hellgren, U; Lundblad, MS; Mahindi, M; Ntale, M; Obua, C; Ogwal-Okeng, JW, 2006
)
0.57
" We summarized the data under the following themes: content and dissolution; relative bioavailability of antimalarial products; antimalarial stability and shelf life; general tests on pharmaceutical dosage forms; and the presence of degradation or unidentifiable impurities in formulations."( Antimalarial drug quality in Africa.
Amin, AA; Kokwaro, GO, 2007
)
0.34
" The literature was varied in the quality and breadth of data presented, with most bioavailability studies poorly designed and executed."( Antimalarial drug quality in Africa.
Amin, AA; Kokwaro, GO, 2007
)
0.34
" The results indicate the suitability of this technique in antimalarial drug quality and bioavailability studies."( A simple technique for the detection of anti-malarial drug formulations and their presence in human urine.
Akida, JA; Lemnge, MM; Lugimbana, L; Malebo, HM; Malle, LN; Segeja, MD, 2006
)
0.33
" The only significant relationship for a range of potential covariates, including malarial parasitemia, was with pregnancy, which accounted for an 86% increase in the volume of distribution of the central compartment relative to bioavailability without a significant change in the AUC(0-infinity)."( Pharmacokinetic properties of azithromycin in pregnancy.
Baiwog, F; Davis, TM; Gomorai, S; Griffin, S; Ilett, KF; Kandai, J; Karunajeewa, HA; Kose, K; Mueller, I; O'Halloran, SJ; Rogerson, SJ; Salman, S; Siba, P; Winmai, J, 2010
)
0.36
" The greatest bioavailability was observed in the 4-week-old rats: for the animals fed the low-protein diet, the area under the concentration-time curve (AUC) amounted to 593."( Kinetics of pyrimethamine in young and adult rats on a standard diet and on a low-protein diet.
Florek, E; Mouankie, JB; Senczuk, W,
)
0.51
" There was a 32% reduction in SDX relative bioavailability with the double dose but no evidence of dose-dependent metabolism."( Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy.
Davis, TM; Griffin, S; Ilett, KF; Kose, K; Moore, B; Mueller, I; Pitus, N; Salman, S; Siba, P; Winmai, J, 2011
)
0.6
"The use of most of the antimalarials like pyrimethamine is restricted owing to their poor solubility and low bioavailability problems."( Polyelectrolyte stabilized antimalarial nanosuspension using factorial design approach.
Dhapte, V; Pokharkar, V, 2011
)
0.63
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
"001) in association with a greater clearance relative to bioavailability (73."( Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.
Batty, KT; Benjamin, JM; Davis, TM; Lorry, L; Moore, BR; Mueller, I; Page-Sharp, M; Robinson, LJ; Salman, S; Siba, PM; Tawat, S; Yadi, G, 2015
)
0.63
" CF fortified with highly bioavailable iron improved iron status but not Hb concentration, despite three-monthly IPT of malaria."( The effect of iron-fortified complementary food and intermittent preventive treatment of malaria on anaemia in 12- to 36-month-old children: a cluster-randomised controlled trial.
Adiossan, LG; Brittenham, GM; Diakité, VG; Glinz, D; Hurrell, RF; N'Goran, EK; Ouattara, M; Righetti, AA; Seifert, B; Utzinger, J; Wegmüller, R; Zimmermann, MB, 2015
)
0.42
" The ADME properties of these active molecules were also predicted to enhance the knowhow of the oral bioavailability, indicating good bioavailability of the active entities."( Ionic liquid mediated stereoselective synthesis of alanine linked hybrid quinazoline-4(3H)-one derivatives perturbing the malarial reductase activity in folate pathway.
Bhatt, JD; Chudasama, CJ; Dixit, BC; Dixit, RB; Patel, BD; Patel, TS; Patel, UH; Vanparia, SF, 2017
)
0.46
" In the split-dose group, mefloquine bioavailability was significantly increased by 5%."( Population Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon.
Akerey-Diop, D; Basra, A; Geditz, M; Gonzalez, R; Hofmann, U; Kerb, R; Kremsner, PG; Lehr, T; Mackanga, JR; Matsiegui, PB; Menendez, C; Mombo-Ngoma, G; Ramharter, M; Schwab, M; Wojtyniak, JG; Würbel, H; Zoleko Manego, R, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Sulphadoxine-pyrimethamine (SP) was adopted when proof of its superiority to weekly prophylactic dosing with either chloroquine or pyrmethamine became evident. A study was carried out to assess the efficacy of a modified 7 day course of quinine in children with falciparum malaria.

ExcerptRelevanceReference
"A high-performance liquid chromatographic method was developed to enable dapsone, monoacetyl dapsone and pyrimethamine to be measured simultaneously in plasma samples from volunteers in England and Malaysia who had been dosed with Maloprim."( Determination of plasma concentrations of dapsone, monoacetyl dapsone and pyrimethamine in human subjects dosed with maloprim.
Jones, CR; Ovenell, SM, 1979
)
0.7
" The usefulness of high dosage heparin in the treatment of the subacute form of disseminated intravascualr coagulation is illustrated in the first admission."( A case of recurrent subacute disseminated intravascular coagulation associated with malarial prophylaxis.
Gon, F; Reid, FP, 1975
)
0.25
"18 for the 50-mg/day and 25-mg/day dosage of pyrimethamine, respectively."( Ocular toxoplasmosis in human immunodeficiency virus-infected patients.
Cochereau-Massin, I; Girard, B; Katlama, C; Lautier-Frau, M; LeHoang, P; Leport, C; Marcel, P; Robinet, M; Zazoun, L; Zerdoun, E, 1992
)
0.54
" Repeated daily dosing resulted in accumulation of pyrimethamine in plasma, with steady state being achieved within 5 days, when the mean peak plasma concentration was more than twice that measured after the first dose."( Pharmacokinetics, penetration into cerebrospinal fluid, and hematologic effects after multiple oral administrations of pyrimethamine to horses.
Burrows, GE; Burrows, SL; Clarke, CR; Ewing, P; MacAllister, CG; Spillers, DK, 1992
)
0.74
" Dosage must be adjusted to the results of blood counts."( [Usefulness of folinic acid in cytopenia induced by antiparasitic drugs in AIDS patients].
Leport, C; Niyongabo, T; Vildé, JL, 1991
)
0.28
" Dosage data indicated that fatalities had taken higher doses and continued prophylaxis after onset of symptoms."( Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain.
Phillips-Howard, PA; West, LJ, 1990
)
0.56
" Male infertility was dose-dependent, with no pregnancies occurring among the partners of mice who received the maximum dosage of pyrimethamine."( Pyrimethamine: an approach to the development of a male contraceptive.
Cosentino, MJ; Fried, J; Pakyz, RE, 1990
)
1.93
"The plasma pharmacokinetics and mass fate of [14C]pyrimethamine were investigated in the mouse, following dosage with 12."( Pyrimethamine pharmacokinetics and its tissue localization in mice: effect of dose size.
Breckenridge, AM; Coleman, MD; Edwards, G; Howells, RE; Mihaly, GW; Ward, SA, 1985
)
1.97
" 25% of animals dosed with BASE died; among the survivors plasma drug levels fell rapidly below the minimum inhibitory concentration (MIC) for Plasmodium berghei (100-200 ng ml-1) by 5 weeks."( The sustained release of pyrimethamine base or pyrimethamine pamoate from a biodegradable injectable depot preparation in mice.
Breckenridge, AM; Coleman, MD; Edwards, G; Howells, RE; Mihaly, GW; Ward, SA, 1985
)
0.57
" The drugs were given as a combined dosage and separately to different groups via stomach gavage tube."( Pigmentary changes in rat oral mucosa following antimalarial therapy.
Adkins, KF; Barber, MT; Savage, NW, 1986
)
0.27
" The dosage of mefloquine is 250 mg weekly (1 tablet Lariam) for 4 weeks, followed by 1 tablet every fortnight."( [Malaria in Switzerland].
Fernex, M, 1988
)
0.27
" Six Brazilian volunteers received a loading dose of 2 tablets followed by 20 maintenance doses of 1 tablet at a dosage interval of 7 days."( Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects.
Heizmann, P; Mimica, I; Portmann, R; Schwartz, DE; Weidekamm, E, 1987
)
0.51
" The dosage and the duration of the therapy must be adapted to each case."( [Efficacy of specific chemotherapy in the prevention of recurrences of toxoplasmic chorioretinitis during the 4 years following the treatment].
Bloch-Michel, E; Timsit, JC, 1987
)
0.27
" dosage of pyrimethamine pamoate, drug absorption was significantly delayed, maximum plasma levels being reached after 4 h, these levels being approximately one-third of those in the other three groups."( The disposition of pyrimethamine base and pyrimethamine pamoate in the mouse: effect of route of administration.
Breckenridge, AM; Coleman, MD; Edwards, G; Howells, RE; Mihaly, GW,
)
0.85
"Twenty-one cases of agranulocytosis following dosage with one tablet of Maloprim given once or twice weekly are reviewed."( Agranulocytosis associated with maloprim: review of cases.
Farquhar, JA; Hutchinson, DB; Whiteman, PD, 1986
)
0.27
"For the past 300 years antimalarial dosage regimens have not been based on pharmacokinetic information."( Clinical pharmacokinetics of antimalarial drugs.
White, NJ,
)
0.13
" In groups 1, 2, and 3 the dosages of chloroquine base administered alone were adjusted to body weight, surface area of subject, and age; in group 4 a combination of chloroquine diphosphate and pyrimethamine was given at a standard dosage related to age."( Effect of four different types of single-dose treatment with chloroquine and with chloroquine and pyrimethamine on Plasmodium falciparum infections in a semi-immune population in northern Nigeria.
Kusnecov, R; Lietaert, P; Storey, J, 1972
)
0.66
"Two different diets for the host and three drug dosage regimens were used to select lines resistant to sulfadoxine and pyrimethamine from the parent strain of the rodent malaria parasite Plasmodium berghei [the N (K173) strain]."( Plasmodium berghei: diet and drug dosage regimens influencing selection of drug-resistant parasites in mice.
Merkli, B; Richle, R, 1983
)
0.47
"A study was carried out to assess the efficacy of a modified 7 day course of quinine in children with falciparum malaria, in comparison with those of a 7 day course of quinine at standard dosage and a combination of a 7 day course of quinine and sulfadoxine-pyrimethamine, and in relation to the MIC, and to the serum levels of quinine during the course of treatment."( Treatment of quinine resistant falciparum malaria in Thai children.
Attanath, P; Chongsuphajaisiddhi, T; Sabchareon, A, 1983
)
0.45
" The KZ1 isolate from East Africa had an intermediate level of chloroquine resistance and a flat dose-response curve and each of its clones had a similar dose-response curve, indicating that the intermediate level of chloroquine resistance did not result from the KZ1 isolate's being a mixture of clones with high and low sensitivity."( Drug sensitivity and isoenzyme type in cloned lines of Plasmodium falciparum.
Carter, R; Graves, PM; Keystone, JS; Seeley, DC, 1984
)
0.27
" Reappraisal of quinine therapy has led to important modifications in dosage recommendations and recognition of a major complication of severe malaria associated with its use--hypoglycaemia."( Management of Plasmodium falciparum malaria.
Phillips, RE, 1984
)
0.27
"Pharmacokinetic data were evaluated for 14 volunteers after administration of 1 tablet of Fansidar, and a computer simulation of multiple dosing (1 tablet per week) was performed."( Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting.
Dubach, UC; Forgo, I; Plozza-Nottebrock, H; Weidekamm, E, 1982
)
0.57
"A sensitive, rapid and selective high-performance liquid chromatographic (HPLC) method has been developed to measure plasma levels of pyrimethamine in human subjects dosed with the antimalarials Fansidar or Fansidar and mefloquine."( Determination of pyrimethamine in human plasma after administration of fansidar of fansidar-mefloquine by means of high-performance liquid chromatography with fluorescence detection.
Timm, U; Weidekamm, E, 1982
)
0.81
" The dosage regimen for pyrimethamine and sulfadiazine was established by pharmacokinetic studies in two monkeys."( Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine.
Baars, I; Camps, W; Eskes, T; Galama, J; Melchers, W; Meuwissen, J; Schoondermark-van de Ven, E; Vree, T, 1995
)
0.82
"In recent years major advances have been made in the clinical pharmacology of many drugs used for the treatment of tropical diseases, particularly in the design and development of dosage regimens for the treatment of severe malaria."( Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.
Edwards, G; Ward, SA; Winstanley, PA, 1994
)
0.29
" This pilot study suggests that the combination of pyrimethamine and azithromycin may be further investigated and that the optimal dosage of azithromycin has yet to be determined."( Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS.
Hazebroucq, V; Joly, V; Leport, C; Morlat, P; Raffi, F; Saba, J; Vildé, JL, 1993
)
1.98
"The increased embryotoxicity of pyrimethamine (PYM) with concomitant oral dosing of folic acid (FA) was examined in rats."( Synergistic embryotoxicity of combination pyrimethamine and folic acid in rats.
Chung, MK; Han, SS; Roh, JK,
)
0.68
"In a randomized trial, a high dosage chloroquine monotherapy (45 mg/kg over 3 days) was compared with combination regimens of sulfadoxine/pyrimethamine and chloroquine/clindamycin for treating Gabonese school children with Plasmodium falciparum malaria."( Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria.
Bienzle, U; Graninger, W; Kremsner, PG; Metzger, W; Mordmüller, B, 1995
)
0.87
" These results suggest that combining rifabutin with certain drugs that are active against Toxoplasma gondii may be useful for the treatment of toxoplasmic encephalitis in humans and may allow for a reduction in dosage of either or both drugs with a resulting reduction in untoward side effects."( Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Araujo, FG; Remington, JS; Suzuki, Y, 1996
)
0.53
" The weekly dosage of pyrimethamine ranged from 25 to 1,400 mg; one patient with severe diarrhea received 2,100 mg/week."( Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS.
Klinker, H; Langmann, P; Richter, E, 1996
)
1.06
" There is potential advantage of this combination therapy in reducing the dosage and treatment period of artemisinin derivative, which is therefore likely to improve complaince in clinical practice."( Artemether-pyrimethamine in the treatment of pyrimethamine-resistant falciparum malaria.
Kanda, T; Karbwang, J; Na-Bangchang, K; Suprakob, K; Tan-ariya, P; Thanavibul, A; Tipwangso, P, 1996
)
0.68
" This malaria parasite was sensitive to standard dosage of either chloroquine or sulphadoxine-pyrimethamine."( Malaria in Mvumi, central Tanzania and the in vivo response of Plasmodium falciparum to chloroquine and sulphadoxine pyrimethamine.
Mboera, LE; Ndawi, BT; Wakibara, JV, 1997
)
0.73
" gondii pneumonia should use the synergistic combination of pyrimethamine and a sulfa-based antibiotic, optimal prophylactic antibiotic combinations and dosing schedules for recurrent infection are still being investigated."( Pulmonary toxoplasmosis.
Campagna, AC, 1997
)
0.54
"The stability of pyrimethamine in a liquid dosage formulation stored for up to three months was studies."( Stability of pyrimethamine in a liquid dosage formulation stored for three months.
Hipple, TF; Morosco, RS; Nahata, MC, 1997
)
1.01
" Chemoprophylaxis was given to both the groups at weekly intervals using age adjusted dosage of Pyrixine tablet (sulfadoxine-pyrimethamine)."( The use of personal protective measures in control of malaria in a defined community.
Kyaw, MP; Lin, H; Linn, N; Lwin, M; Maung, NS; Ohn, M; Oo, T; Soe, K, 1997
)
0.5
" In a pilot study carried out in Gabon, a reduced dosage of the triple combination with a mean of 1 mg/kg of mefloquine/2 mg/kg of sulfadoxine/0."( Malaria chemotherapy trial at a minimal effective dose of mefloquine/sulfadoxine/pyrimethamine compared with equivalent doses of sulfadoxine/pyrimethamine or mefloquine alone.
Handschin, J; Kremsner, PG; Lehman, LG; Lell, B; Schmidt-Ott, JR; Sturchler, D, 1998
)
0.53
" All sanctioned providers limited their first choices of antimalarial drug to those recommended by the national malaria control program and reported using correct dosing regimens."( Use of antimalarial drugs in Mali: policy versus reality.
Dicko, A; Diop, S; Djimde, A; Doumbo, O; Plowe, CV; Wellems, TE, 1998
)
0.3
" From the results obtained, it is concluded that 2-weeks repeated dosing with PYR is sufficient to detect toxicity on male reproductive organs in rats using histopathological examination."( Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 21). Comparison of the effects of 2- and 4-weeks pyrimethamine treatment in rats.
Fujii, H; Masuda, T; Murakami, Y; Ogasawara, H; Suzuki, Y; Takeda, M, 2000
)
0.51
" In conclusion, CTX at the dosage employed for primary PCP/TE prophylaxis does not seem to protect against bacterial infections more than second-line DP."( Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial.
Ammassari, A; Antinori, A; Cingolani, A; De Luca, A; Grillo, R; Murri, R; Pallavicini, F; Pezzotti, P, 2001
)
0.31
"We report the case of a patient who did not follow the prescribed dosage and who developed acute neurological disorders after overdosing."( [Danger of malaria self-treatment. Acute neurologic toxicity of mefloquine and its combination with pyrimethamine-sulfadoxine].
Granier, H; Laborde, JP; Martin, J; Nicolas, X; Talarmin, F, 2001
)
0.53
"), showed an anxiogenic-like effect that reached a maximum with the dosage of 5 mg/kg."( Mouse light/dark box test reveals anxiogenic-like effects by activation of histamine H1 receptors.
Bartolini, A; Ipponi, A; Malmberg-Aiello, P; Schunack, W,
)
0.13
" In areas where levels of drug resistance and complexity of infections are high, drug dosage and parasite genotyping may be of limited interest in improving the precision of drug efficacy measurement."( Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children.
Aubouy, A; Bakary, M; Cot, M; Deloron, P; Keundjian, A; Le Bras, J; Makita, JR; Mbomat, B; Migot-Nabias, F, 2003
)
0.53
" The dosage schedule led to a rapid clinical response and reduced parasite clearance and fever subsidence times of (31."( Descriptive study on the efficacy and safety of artesunate suppository in combination with other antimalarials in the treatment of severe malaria in Sudan.
Alkadru, AM; Awad, MI; Baraka, OZ; Behrens, RH; Eltayeb, IB, 2003
)
0.32
" Evidence of systemic toxicity was observed in animals dosed chronically with pyrimethamine or amiloride, but no skin papillomas were observed in mice treated with amiloride, dipyridamole, or pyrimethamine for 26 weeks."( Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent components.
Lin, KK; Rosenzweig, BA; Sistare, FD; Thompson, KL; Weaver, JL; Zhang, J, 2003
)
0.55
" Within a short time of dosing such animals, there is little or none of the uncombined drug in the blood."( The treatment of experimental toxoplasmosis in rabbits.
BEVERLEY, JK; FRY, BA, 1957
)
0.24
" The weekly dosage of the drugs (300 mg of chloroquine base or 25 mg of pyrimethamine per 50 g of salt) had in each case been adjusted to the average salt consumption."( Chloroquine or pyrimethamine in salt as a supressive against sporozoite-induced vivax malaria (Chesson strain).
BURGESS, RW; COATNEY, GR; MICKELSEN, O; PIRKLE, CI; YOUNG, MD, 1958
)
0.82
" Increasing the drug dosage does not overcome the resistance."( The development of pyrimethamine resistance by Plasmodium falciparum.
BURGESS, RW; YOUNG, MD, 1959
)
0.57
"The mean pyrimethamine concentration was 1,108+/-459 ng/ml with a dosage of 37."( Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART.
Klinker, H; Langmann, P; Schirmer, D; Zilly, M, 2004
)
1.07
" To optimize PYR/SDX combination treatment in congenital toxoplasmosis, short dosing intervals in very young low-wight children are probably appropriate."( Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis.
Chemla, C; Dupouy, D; Jaussaud, R; Leroux, B; Millart, H; Pinon, JM; Quereux, C; Rémy, G; Simon, N; Trenque, T; Urien, S; Villena, I, 2004
)
0.61
"36), there was a significant reduction in hospital admissions for anemia during the month after dosing for both the first and second dose."( Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial.
Aide, P; Alonso, P; Aponte, JJ; DgeDge, M; Dobaño, C; Espasa, M; Mabunda, S; Macete, E; Mandomando, I; Menendez, C; Sanz, S; Sigauque, B, 2006
)
0.33
"The dose-response curves and effective concentration that resulted in a 50% inhibitory of parasitemia (IC50) of chloroquine, artemisinin, artemether and pyronaridine phosphate against Plasmodium falciparum strain FCC1/HN cultured in vitro were tested by microfluorimetric assay (MFA) and compared with those determined by microscopy-based assay."( [The microfluorimetric assay (MFA) in in vitro testing the sensitivity of Plasmodium falciparum to antimalarial drugs].
Hi, YC; Huang, F; Tang, LH; Wang, QM, 2006
)
0.33
" Among HIV-negative women, there was no conclusive additional effect of monthly dosing (2 trials; 24% and 39% resistance)."( Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review.
Filler, SJ; ter Kuile, FO; van Eijk, AM, 2007
)
0.65
" However, more frequent dosing is required in HIV-positive women not using cotrimoxazole prophylaxis for opportunistic infections."( Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review.
Filler, SJ; ter Kuile, FO; van Eijk, AM, 2007
)
0.65
" We summarized the data under the following themes: content and dissolution; relative bioavailability of antimalarial products; antimalarial stability and shelf life; general tests on pharmaceutical dosage forms; and the presence of degradation or unidentifiable impurities in formulations."( Antimalarial drug quality in Africa.
Amin, AA; Kokwaro, GO, 2007
)
0.34
" The review highlights the common finding in drug quality studies that (i) most antimalarial products pass the basic tests for pharmaceutical dosage forms, such as the uniformity of weight for tablets, (ii) most antimalarial drugs pass the content test and (iii) in vitro product dissolution is the main problem area where most drugs fail to meet required pharmacopoeial specifications, especially with regard to sulfadoxine-pyrimethamine products."( Antimalarial drug quality in Africa.
Amin, AA; Kokwaro, GO, 2007
)
0.5
"5% improvement in the accumulated proportion of patients (1) treated, (2) treated within 24h of illness onset, (3) treated with the recommended antimalarials, (4) treated at an adequate dosage and (5) treated for the correct duration."( Home-based management of fever and malaria treatment practices in Uganda.
Nsungwa-Sabiiti, J; Ogwal-Okeng, J; Pariyo, G; Peterson, S; Petzold, MG; Tomson, G, 2007
)
0.34
"Single-dose SP was a common result of trying to implement the standard 2-dose regimen and was inferior to all other dosing regimens."( Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women.
Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mukwamataba, D; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007
)
0.61
" However, the optimal dosing regimen in settings in which human immunodeficiency virus (HIV) is highly prevalent among pregnant women remains controversial."( Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women.
Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mubikayi, L; Mukwamataba, D; Mulele, CK; Mulenga, M; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007
)
0.56
" falciparum malaria were randomly assigned to either one of the two dosing schemes."( Single-day, three-dose treatment with fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine to cure Plasmodium falciparum malaria.
Jansen, FH; Penali, LK, 2008
)
0.57
"1%) were the three main molecules which account for antimalarial self-treatment However the use of these molecules was inappropriate regarding the dosage (41."( [Self-medication in the treatment of acute malaria: study based on users of private health drug stores in Ouagadougou, Burkina Faso].
Diarra, M; Guissou, IP; Ouédraogo, LT; Somé, IT, 2008
)
0.35
"4%) respondents knew the correct drug, dosage and timing of IPT."( Perception and practice of malaria prophylaxis in pregnancy among primary health care providers in Ibadan, Nigeria.
Fawole, AO; Onyeaso, NC, 2008
)
0.35
"7% respectively for AQ and SP received a dosage higher than the theoretical dosage."( Child age or weight: difficulties related to the prescription of the right dosage of antimalarial combinations to treat children in Senegal.
Lalou, R; Le Hesran, JY; Senghor, P; Souares, A, 2010
)
0.36
"7% agreement between self-reported data and blood drug dosage for amodiaquine treatment."( Self-reported data: a major tool to assess compliance with anti-malarial combination therapy among children in Senegal.
Carlotti, MP; Lalou, R; Le Hesran, JY; Moulin, P; Sarrassat, S; Souares, A, 2009
)
0.35
" We determined the association between amodiaquine dosage by body weight and mild adverse events (AEs) and investigated whether alternative age-based regimens could improve dosing accuracy and tolerability, using data from two trials of IPTc in Senegal, one in which AQ dose was determined by age and the other in which it was determined by weight category."( Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children.
Ba, EH; Cairns, M; Cames, C; Cisse, B; Gaye, O; Greenwood, BM; Milligan, PJ; Simondon, K; Sokhna, C; Trape, JF, 2010
)
0.36
" The use of sulphadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria during pregnancy was adopted when proof of its superiority to weekly prophylactic dosing with either chloroquine or pyrimethamine became evident from studies in different malaria endemic countries."( Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges.
Agomo, CO; Oyibo, WA, 2011
)
0.89
" Test compounds were administered in a dosage of 50 mg/kg every other day till 60 days."( The synthesis and antifertility evaluation of 3 analogs of pyrimethamine on male rat reproductive indices.
Noori, MH; Sadeghipour, HR; Sattarian, M; Vosooghi, M; Zahmatkesh, M, 2010
)
0.6
" The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model."( Spiroindolones, a potent compound class for the treatment of malaria.
Beck, HP; Brun, R; Cohen, SB; Dartois, V; Dharia, NV; Diagana, TT; Fidock, DA; Goh, A; González-Páez, GE; Jegla, T; Keller, TH; Lakshminarayana, SB; Lee, MC; McNamara, C; Nosten, F; Plouffe, DM; Renia, L; Rottmann, M; Russell, B; Schmitt, EK; Seitz, P; Spencer, KR; Suwanarusk, R; Tan, J; Winzeler, EA; Yeung, BK; Zou, B, 2010
)
0.36
" We discuss optimal dosing for ABCs and their likely protection against several sexually transmitted and reproductive tract infections."( Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy.
Chandramohan, D; Chico, RM, 2011
)
0.37
" Because of concerns about the complex dosing schedule, we assessed patient adherence to AL 2 years after routine implementation."( Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi.
Ali, D; Filler, SJ; Jafali, J; Kachur, SP; Luka, M; Mace, KE; Mathanga, DP; Mwandama, D; Sande, J; Skarbinski, J, 2011
)
0.37
" There was significant association between gravidity and SP dosage taken (Pearson χ2 = 18."( The effectiveness and perception of the use of sulphadoxine-pyrimethamine in intermittent preventive treatment of malaria in pregnancy programme in Offinso district of Ashanti region, Ghana.
Browne, E; Lawson, B; Tutu, EO, 2011
)
0.61
" The treatment of malaria in young children and the relative benefits of age- and weight-based dosing need further exploration."( Monitoring antimalarial drug resistance in India via sentinel sites: outcomes and risk factors for treatment failure, 2009-2010.
Anvikar, AR; Arora, U; Bhatt, RM; Das, MK; Dhariwal, AC; Ghosh, SK; Gupta, R; Kaitholia, K; Kumar, A; Mishra, N; Shah, NK; Sharma, SK; Singh, JP; Sonal, GS; Srivastava, B; Valecha, N, 2012
)
0.38
" Many controversies were identified, including pharmacokinetic equivalence of novel dosage forms, altered pharmacokinetic parameters in children versus adults, effect of drug interactions, and association of pharmacokinetic changes with clinical outcomes."( Pharmacokinetic profile of artemisinin derivatives and companion drugs used in artemisinin-based combination therapies for the treatment of Plasmodium falciparum malaria in children.
Ensom, MH; Pawluk, SA; Wilby, KJ, 2013
)
0.39
" While SP was well known and attitudes towards IPTp were positive, health workers were often not informed of up-to-date dosing schedules, limiting coverage."( Systemic constraints continue to limit coverage of intermittent preventive treatment for malaria in pregnancy in southeast Tanzania.
Ba-Break, MM; Graham, KJ, 2013
)
0.39
"To maximize IPTp coverage, sufficient and consistent supplies of SP to both public and private health facilities are a necessity, combined with effective communication of revised dosing schedules."( Systemic constraints continue to limit coverage of intermittent preventive treatment for malaria in pregnancy in southeast Tanzania.
Ba-Break, MM; Graham, KJ, 2013
)
0.39
" However, the optimal chemoprevention drug and dosing strategy is unclear in areas of year-round transmission and resistance to many antimalarial drugs."( Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial.
Achan, J; Aweeka, FT; Bigira, V; Clark, TD; Dorsey, G; Havlir, DV; Huang, L; Kamya, MR; Kapisi, J; Kinara, S; Muhindo, MK; Mwangwa, F; Osterbauer, B; Rosenthal, PJ, 2014
)
0.4
" With this, one of the focuses of the pharmaceutical research scientist involves investigating possible metastable forms of a given drug to be incorporated into solid dosage forms."( Amorphous Sulfadoxine: A Physical Stability and Crystallization Kinetics Study.
Aucamp, M; Liebenberg, W; Milne, M, 2016
)
0.43
"While clinically relevant differences in SP disposition between trimesters were not seen, increased clearance with pregnancy and the increasing volume of distribution in the central compartment with gestational age lend support to the revised World Health Organization guidelines advocating more frequent dosing of SP for IPTp."( Trimester-Specific Population Pharmacokinetics and Other Correlates of Variability in Sulphadoxine-Pyrimethamine Disposition Among Ugandan Pregnant Women.
Bisaso, KR; Byamugisha, J; Mukonzo, JK; Ntale, M; Obua, C; Odia, G; Odongo, CO; Ojara, FW, 2015
)
0.63
"IPTp-SP usage among pregnant women in Sekondi-Takoradi reduces malaria and its use for malaria prevention should be strengthened with proper dosage completion and coverage."( Prevalence of intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP) use during pregnancy and other associated factors in Sekondi-Takoradi, Ghana.
Acquah, S; Afoakwah, R; Boampong, JN; Iriemenam, NC; Nwaefuna, E; Onyeabor, OS; Orish, VN; Sanyaolu, AO, 2015
)
0.65
" We sought to determine whether increased dosage of SP is still associated with a reduced risk of low birth weight (LBW) in an area where malaria transmission is low."( Dosage of Sulfadoxine-Pyrimethamine and Risk of Low Birth Weight in a Cohort of Zambian Pregnant Women in a Low Malaria Prevalence Region.
Chi, BH; Kumwenda, A; Smid, M; Stoner, MC; Stringer, E; Stringer, JS; Vwalika, B, 2017
)
0.77
" In most cases, it was not severe and reversed after increase in folinic acid dosage (25."( High Frequency of Bone Marrow Depression During Congenital Toxoplasmosis Therapy in a Cohort of Children Identified by Neonatal Screening in Minas Gerais, Brazil.
Carellos, EVM; de Andrade, GMQ; de Andrade, JQ; Figueiredo, RM; Januário, JN; Romanelli, RMC; Tibúrcio, JD; Vasconcelos-Santos, DV, 2017
)
0.46
" falciparum found in pregnant women and the general population (GP) from Nanoro, Burkina Faso and the association of IPTp-SP dosing and other variables with mutations was studied."( Increase in the prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates collected from early to late pregnancy in Nanoro, Burkina Faso.
d'Alessandro, U; de Jong, MD; Derra, K; Geskus, RB; Lompo, P; Mens, PF; Ruizendaal, E; Schallig, HDFH; Scott, S; Tahita, MC; Tinto, H; Traore-Coulibaly, M; Versteeg, I, 2017
)
0.69
" An increase in mutation prevalence due to IPTp-SP dosing could not be confirmed."( Increase in the prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates collected from early to late pregnancy in Nanoro, Burkina Faso.
d'Alessandro, U; de Jong, MD; Derra, K; Geskus, RB; Lompo, P; Mens, PF; Ruizendaal, E; Schallig, HDFH; Scott, S; Tahita, MC; Tinto, H; Traore-Coulibaly, M; Versteeg, I, 2017
)
0.69
" It was nongenotoxic in an Ames assay, an in vitro micronucleus assay, and an in vivo rat micronucleus assay when dosed orally up to 2000 mg/kg."( Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
Berry, P; Campo, B; Cao, J; Ciaravino, V; Easom, EE; Erve, JCL; Freund, YR; Gamo, FJ; Guo, D; Jacobs, RT; Plattner, JJ; Rosenthal, PJ; Sanz, LM; Zhang, YK, 2017
)
0.46
" This may soon change to recommending artemisinin-based combination therapies (standard duration of dosing = 3 days)."( Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester.
Clark, RL, 2017
)
0.46
"Despite extensive use and accumulated evidence of safety, there have been few pharmacokinetic studies from which appropriate chloroquine (CQ) dosing regimens could be developed specifically for pregnant women."( Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling.
Baiwog, F; Davis, TME; Ilett, KF; Karunajeewa, HA; Kose, K; Mueller, I; Page-Sharp, M; Rogerson, SJ; Salman, S; Siba, PM, 2017
)
0.46
" Suboptimal dosing in children may lead to treatment failure and increased resistance."( Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria.
Allen, EN; Barnes, KI; Bell, DJ; de Kock, M; Denti, P; Djimde, AA; Tarning, J; Tekete, MM; Ward, SA; Workman, L, 2018
)
0.73
" Future studies are needed to better understand the biological mechanisms of in utero drug exposure on drug metabolism and how this may affect the dosing of antimalarial drugs for treatment and prevention during infancy."( Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial.
Aweeka, F; Beeson, J; Charlebois, ED; Clark, TD; Dorsey, G; Drakeley, C; Feeney, ME; Greenhouse, B; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muhindo, MK; Nakalembe, M; Nankya, F; Natureeba, P; Okiring, J; Olwoch, P; Opira, B; Prahl, M; Reiling, L; Rodriguez-Barraquer, I; Ssewanyana, I; Tetteh, K; Wallender, E, 2018
)
0.48
" The adjusted dosing history for each individual was identified as the one with the lowest difference between observed and individual predicted concentrations estimated by the two PK models for all the possible adherence schemes."( Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial.
Csajka, C; Décosterd, L; Genton, B; Guidi, M; Mueller, I; Schneider, M; Senn, N; Sottas, O; Thieffry, B, 2019
)
0.51
" We did a random-effects meta-analysis (clinical studies) or multivariate log-binomial regression (surveys) to obtain summarised dose-response data (relative risk reduction [RRR]) and multivariate meta-regression to explore the modifying effects of sulfadoxine-pyrimethamine resistance (as indicated by Ala437Gly, Lys540Glu, and Ala581Gly substitutions in the dhps gene)."( Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis.
Desai, M; Gutman, J; Hopkins Sibley, C; Kayentao, K; Khairallah, C; Koshy, G; Larsen, DA; Meshnick, SR; Okell, LC; Rogerson, SJ; Roper, C; Slaughter, DEC; Taylor, SM; Ter Kuile, FO; van Eijk, AM, 2019
)
0.95
" Interviews focused on perception of purpose of ANC pharmaceuticals (particularly iron supplements, sulfadoxine-pyrimethamine as intermittent prevention of malaria and antiretroviral therapy for HIV), beliefs regarding efficacy and risk, and understanding of dosage and regimen."( "They Merely Prescribe and I Merely Swallow": Perceptions of Antenatal Pharmaceuticals and Nutritional Supplements Among Pregnant Women in Bamako, Mali.
Doumbia, SO; Hurley, EA; Searle, AR; Winch, PJ, 2020
)
0.77
" Communication that positions pharmaceuticals as beneficial to mother and child, while presenting understandable information about purpose, dosing and potential side effects can promote uptake of multi-drug regimens and ANC services in general."( "They Merely Prescribe and I Merely Swallow": Perceptions of Antenatal Pharmaceuticals and Nutritional Supplements Among Pregnant Women in Bamako, Mali.
Doumbia, SO; Hurley, EA; Searle, AR; Winch, PJ, 2020
)
0.56
" Also, three or more dosing was associated (p < 0."( Coverage and effectiveness of intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) on adverse pregnancy outcomes in the Mount Cameroon area, South West Cameroon.
Achidi, EA; Anchang-Kimbi, JK; Apinjoh, TO; Dionne-Odom, J; Kalaji, LN; Mbacham, HF; Ngole Sumbele, IU; Tita, ATN; Wepnje, GB, 2020
)
0.78
" Mediation analyses showed sulfadoxine-pyrimethamine conferred a greater non-malarial effect than did dihydroartemisinin-piperaquine (mean difference 87 g, 95% CI 43 to 131), whereas dihydroartemisinin-piperaquine conferred a slightly larger antimalarial effect than did sulfadoxine-pyrimethamine (8 g, -9 to 26), although more frequent dosing increased the antimalarial effect (31 g, 3 to 60)."( Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on birthweight: a mediation analysis.
Chico, RM; Desai, M; Dorsey, G; Glymour, MM; Gosling, R; Gutman, J; Kajubi, R; Kakuru, A; Kamya, MR; Kuile, FOT; L'Ianziva, A; Rerolle, F; Roh, ME; Shiboski, S, 2020
)
1.04
"015) despite an identical SA dosing scheme."( Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a case-control study.
Enders, M; Garweg, JG; Gruetzmacher, B; Hlobil, H; Hoerauf, A; Klarmann-Schulz, U; Reiter-Owona, I; Rilling, V, 2020
)
0.77
" Additionally, these models are able to identify patient characteristics that cause alterations in the expected PK/PD profiles and through simulations can recommend changes to dosing which compensate for the differences."( Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations.
Hughes, E; Jagannathan, P; Mohamed Ali, A; Savic, RM; Wallender, E, 2021
)
0.62
" We assessed the different SP dosage regimen available under the new policy to determine the dose at which women obtained optimal protection against anaemia during pregnancy."( Intermittent preventive treatment comparing two versus three doses of sulphadoxine pyrimethamine (IPTp-SP) in the prevention of anaemia in pregnancy in Ghana: A cross-sectional study.
Agyeman, YN; Annor, RB; Newton, S; Owusu-Dabo, E, 2021
)
0.85
" This study shows that a successful implementation of the IPTp strategy can be achieved by improving access to prenatal care at community health facilities, and strengthening patient-provider communication to ensure adequate knowledge on dosing of IPTp-SP and the benefits to mother and child."( Determinants of intermittent preventive treatment with sulfadoxine-pyrimethamine in pregnant women (IPTp-SP) in Mali, a household survey.
Beebe, M; Doumbia, S; Sangho, O; Tounkara, M; Whiting-Collins, LJ; Winch, PJ, 2021
)
0.86
" A dose-response association was observed with increasing doses of SP from the second trimester linked to increasing protection against LBW deliveries."( Impact of Intermittent Presumptive Treatment for Malaria in Pregnancy on Hospital Birth Outcomes on the Kenyan Coast.
Amadi, D; Bejon, P; Berkley, JA; Kamau, A; Musau, M; Mwakio, S; Nyaguara, A; Seale, AC; Snow, RW, 2023
)
0.91
" Infected mice were dosed with MQ solution or MQ-niosomes at 50 mg/kg/day, starting from the second day post-infection (PI) (acute model) or the fifth week PI (chronic model), and this was continued for six consecutive days."( Mefloquine loaded niosomes as a promising approach for the treatment of acute and chronic toxoplasmosis.
Aboul Asaad, IA; Amer, BS; Carter, WG; El Maghraby, GM; El Sharazly, BM; Ismail, HIH; Mohamed, DA; Yassen, NA, 2023
)
0.91
" This flexibility is readily achieved using an oral liquid dosage form."( Physicochemical and Microbiological Stability of Pyrimethamine in Paraben-free PCCA Base, SuspendIt.
Bostanian, LA; Graves, RA; Kader, C; Mandal, TK; Morris, TC; Pramar, YV,
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antimalarialA drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
EC 1.5.1.3 (dihydrofolate reductase) inhibitorAn EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor that interferes with the action of dihydrofolate reductase (EC 1.5.1.3).
antiprotozoal drugAny antimicrobial drug which is used to treat or prevent protozoal infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (105)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency79.43280.004023.8416100.0000AID485290
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
pregnane X receptorRattus norvegicus (Norway rat)Potency50.11870.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency35.14750.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency22.20470.173734.304761.8120AID1346924
Fumarate hydrataseHomo sapiens (human)Potency22.41540.00308.794948.0869AID1347053
GALC proteinHomo sapiens (human)Potency0.707928.183828.183828.1838AID1159614
SMAD family member 3Homo sapiens (human)Potency22.20470.173734.304761.8120AID1346924
TDP1 proteinHomo sapiens (human)Potency0.92270.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency20.58670.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency34.07720.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency43.93810.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency3.69250.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency23.46620.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency13.80290.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency5.35220.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency22.20470.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency33.49150.003041.611522,387.1992AID1159553
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency8.87660.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency39.81070.375827.485161.6524AID588526
pregnane X nuclear receptorHomo sapiens (human)Potency53.56600.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency38.94160.000229.305416,493.5996AID1259244; AID1259248; AID588513; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency12.30180.00108.379861.1304AID1645840
polyproteinZika virusPotency22.41540.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency23.49730.00018.4406100.0000AID720579; AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency53.62480.001024.504861.6448AID588534; AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency36.61230.001019.414170.9645AID588536; AID743191
IDH1Homo sapiens (human)Potency1.99110.005210.865235.4813AID686970
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency55.31480.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency25.14060.001628.015177.1139AID1224843; AID1224895
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency54.941019.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency40.78290.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency25.67290.039147.5451146.8240AID1224845; AID1224896
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency7.94330.00207.533739.8107AID891
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency10.26630.316212.443531.6228AID902; AID924
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency11.58210.00419.984825.9290AID504444
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency39.81070.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency8.40930.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency12.25870.000627.21521,122.0200AID651741; AID743202; AID743219
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency0.70790.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency0.70790.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency0.70790.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency5.61910.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency9.99240.005612.367736.1254AID624044
survival motor neuron protein isoform dHomo sapiens (human)Potency21.81450.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency7.50590.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency31.62280.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency35.42220.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency33.29400.00339.158239.8107AID1347407
Cellular tumor antigen p53Homo sapiens (human)Potency37.18940.002319.595674.0614AID651631; AID651743
Integrin beta-3Homo sapiens (human)Potency12.58930.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency12.58930.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency35.42220.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency29.84930.026622.448266.8242AID651802
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency41.59800.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency41.59800.011912.222168.7989AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency7.50591.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
dual specificity protein phosphatase 3Homo sapiens (human)IC50 (µMol)80.00000.40009.361090.0000AID686961; AID743310
low molecular weight phosphotyrosine protein phosphatase isoform cHomo sapiens (human)IC50 (µMol)28.25004.970011.256719.6000AID652005; AID686963
tyrosine-protein phosphatase non-receptor type 22 isoform 1Homo sapiens (human)IC50 (µMol)80.00000.48002.64498.3270AID652006; AID743309
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)73.50000.00001.77679.2000AID158542
Bifunctional dihydrofolate reductase-thymidylate synthasePlasmodium vivax (malaria parasite P. vivax)Ki0.00160.00020.00520.0225AID1797767
Solute carrier family 22 member 1Mus musculus (house mouse)Ki3.60003.60005.45007.3000AID1058956
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)13.57000.21005.553710.0000AID1442001
Bile salt export pumpHomo sapiens (human)IC50 (µMol)200.10000.11007.190310.0000AID1449628
Dihydrofolate reductaseHomo sapiens (human)IC50 (µMol)3.10570.00060.87267.3000AID1327821; AID1623967; AID1624004; AID341462; AID56807; AID671160; AID747614
Dihydrofolate reductaseHomo sapiens (human)Ki0.11600.00000.37564.9000AID1485221; AID1533249; AID1611287; AID518563; AID56350; AID56459; AID57135; AID57141; AID57948
Dihydrofolate reductase Bos taurus (cattle)IC50 (µMol)0.10070.00170.04350.1007AID1462733; AID1486840
Beta-hexosaminidase subunit alphaHomo sapiens (human)IC50 (µMol)11.08333.10006.83338.9000AID1227098; AID1227099; AID1227101; AID1227102; AID1227112; AID1227113
Beta-hexosaminidase subunit betaHomo sapiens (human)IC50 (µMol)10.22863.10006.40009.1000AID1227098; AID1227099; AID1227100; AID1227101; AID1227102; AID1227112; AID1227114
Dihydrofolate reductaseEscherichia coli K-12IC50 (µMol)4.30000.00150.55126.8000AID341469; AID671161
Dihydrofolate reductaseEscherichia coli K-12Ki0.06360.00000.37904.0200AID57405; AID57406; AID57407; AID57408; AID57588
Cytochrome P450 2C9 Homo sapiens (human)Ki51.50000.00031.684210.0000AID54410
Bifunctional dihydrofolate reductase-thymidylate synthasePlasmodium falciparum K1IC50 (µMol)30.79290.00151.11635.8000AID1367779; AID1367782; AID157842; AID158540; AID158541; AID158542; AID158543; AID268783
Bifunctional dihydrofolate reductase-thymidylate synthasePlasmodium falciparum K1Ki0.10810.00000.43696.6645AID1797769; AID211987; AID211988; AID219249; AID238767; AID58121; AID58122; AID58128; AID58250; AID58251; AID58252; AID58253; AID58254; AID58255; AID58282; AID58283; AID58284; AID58285; AID58286
Dihydrofolate reductasePneumocystis cariniiIC50 (µMol)3.25000.00060.54766.2000AID55698; AID55702; AID55704; AID55705; AID55832; AID55833; AID55836; AID747610
Dihydrofolate reductasePneumocystis cariniiKi0.00970.00000.04680.1520AID55851
Substance-K receptorRattus norvegicus (Norway rat)Ki0.07170.00050.06870.1340AID211987
Dihydrofolate reductaseCandida albicansIC50 (µMol)5.00000.00220.91875.0000AID57074
Low molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)IC50 (µMol)15.61502.86009.633617.2000AID651700; AID686962
Dipeptidyl peptidase 4Homo sapiens (human)IC50 (µMol)0.39000.00010.444410.0000AID56182
Pteridine reductase 1Leishmania majorIC50 (µMol)13.60002.95002.95002.9500AID1589588
Bifunctional dihydrofolate reductase-thymidylate synthaseToxoplasma gondiiIC50 (µMol)0.32170.00061.042810.0000AID1623966; AID341470; AID56164; AID56174; AID56179; AID56182; AID56189; AID56317; AID56318; AID56349; AID671162
Bifunctional dihydrofolate reductase-thymidylate synthasePlasmodium falciparum 3D7IC50 (µMol)2.48000.09001.28502.4800AID373640
Bifunctional dihydrofolate reductase-thymidylate synthasePlasmodium falciparum 3D7Ki0.00090.00090.14660.2923AID373625
Multidrug and toxin extrusion protein 1Mus musculus (house mouse)Ki0.14500.14500.14500.1450AID1058957
Dihydrofolate reductaseRattus norvegicus (Norway rat)IC50 (µMol)2.07270.00060.35076.2000AID57645; AID57797; AID57813; AID57817; AID57819; AID57826; AID57968; AID57972; AID57975; AID747611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)76.99600.06008.9128130.5170AID1902; AID1914
Estrogen receptorRattus norvegicus (Norway rat)EC50 (µMol)150.00000.006022.3670130.5170AID1914
Dihydrofolate reductaseEscherichia coli K-12Kd0.00800.00001.24596.6000AID57266; AID57267; AID57268; AID57269
Estrogen receptor betaRattus norvegicus (Norway rat)EC50 (µMol)150.00000.006022.3670130.5170AID1914
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductaseEscherichia coli K-12Ratio0.00090.00030.00090.0013AID57598; AID57599; AID57600; AID57601
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (390)

Processvia Protein(s)Taxonomy
heart valve developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
ventricular septum developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
aorta developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of inflammatory responsecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
establishment of endothelial barriercGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to mechanical stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to cAMPcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to cGMPcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to transforming growth factor beta stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to 2,3,7,8-tetrachlorodibenzodioxinecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of gene expressioncGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of mitochondrion organizationcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductase Bos taurus (cattle)
response to methotrexateDihydrofolate reductase Bos taurus (cattle)
tetrahydrofolate metabolic processDihydrofolate reductase Bos taurus (cattle)
tetrahydrofolate biosynthetic processDihydrofolate reductase Bos taurus (cattle)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
skeletal system developmentBeta-hexosaminidase subunit alphaHomo sapiens (human)
carbohydrate metabolic processBeta-hexosaminidase subunit alphaHomo sapiens (human)
glycosaminoglycan biosynthetic processBeta-hexosaminidase subunit alphaHomo sapiens (human)
ganglioside catabolic processBeta-hexosaminidase subunit alphaHomo sapiens (human)
lysosome organizationBeta-hexosaminidase subunit alphaHomo sapiens (human)
sensory perception of soundBeta-hexosaminidase subunit alphaHomo sapiens (human)
adult walking behaviorBeta-hexosaminidase subunit alphaHomo sapiens (human)
lipid storageBeta-hexosaminidase subunit alphaHomo sapiens (human)
sexual reproductionBeta-hexosaminidase subunit alphaHomo sapiens (human)
glycosaminoglycan metabolic processBeta-hexosaminidase subunit alphaHomo sapiens (human)
dermatan sulfate catabolic processBeta-hexosaminidase subunit alphaHomo sapiens (human)
hyaluronan catabolic processBeta-hexosaminidase subunit alphaHomo sapiens (human)
myelinationBeta-hexosaminidase subunit alphaHomo sapiens (human)
cell morphogenesis involved in neuron differentiationBeta-hexosaminidase subunit alphaHomo sapiens (human)
neuromuscular process controlling postureBeta-hexosaminidase subunit alphaHomo sapiens (human)
neuromuscular process controlling balanceBeta-hexosaminidase subunit alphaHomo sapiens (human)
maintenance of location in cellBeta-hexosaminidase subunit alphaHomo sapiens (human)
skeletal system developmentBeta-hexosaminidase subunit betaHomo sapiens (human)
ganglioside catabolic processBeta-hexosaminidase subunit betaHomo sapiens (human)
intracellular calcium ion homeostasisBeta-hexosaminidase subunit betaHomo sapiens (human)
lysosome organizationBeta-hexosaminidase subunit betaHomo sapiens (human)
single fertilizationBeta-hexosaminidase subunit betaHomo sapiens (human)
penetration of zona pellucidaBeta-hexosaminidase subunit betaHomo sapiens (human)
sensory perception of soundBeta-hexosaminidase subunit betaHomo sapiens (human)
locomotory behaviorBeta-hexosaminidase subunit betaHomo sapiens (human)
male courtship behaviorBeta-hexosaminidase subunit betaHomo sapiens (human)
regulation of cell shapeBeta-hexosaminidase subunit betaHomo sapiens (human)
phospholipid biosynthetic processBeta-hexosaminidase subunit betaHomo sapiens (human)
oligosaccharide catabolic processBeta-hexosaminidase subunit betaHomo sapiens (human)
lipid storageBeta-hexosaminidase subunit betaHomo sapiens (human)
glycosaminoglycan metabolic processBeta-hexosaminidase subunit betaHomo sapiens (human)
chondroitin sulfate catabolic processBeta-hexosaminidase subunit betaHomo sapiens (human)
dermatan sulfate catabolic processBeta-hexosaminidase subunit betaHomo sapiens (human)
hyaluronan catabolic processBeta-hexosaminidase subunit betaHomo sapiens (human)
myelinationBeta-hexosaminidase subunit betaHomo sapiens (human)
astrocyte cell migrationBeta-hexosaminidase subunit betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-hexosaminidase subunit betaHomo sapiens (human)
oogenesisBeta-hexosaminidase subunit betaHomo sapiens (human)
neuromuscular process controlling balanceBeta-hexosaminidase subunit betaHomo sapiens (human)
maintenance of location in cellBeta-hexosaminidase subunit betaHomo sapiens (human)
neuron cellular homeostasisBeta-hexosaminidase subunit betaHomo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
10-formyltetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to xenobiotic stimulusDihydrofolate reductaseEscherichia coli K-12
folic acid biosynthetic processDihydrofolate reductaseEscherichia coli K-12
one-carbon metabolic processDihydrofolate reductaseEscherichia coli K-12
response to methotrexateDihydrofolate reductaseEscherichia coli K-12
tetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to antibioticDihydrofolate reductaseEscherichia coli K-12
dihydrofolate metabolic processDihydrofolate reductaseEscherichia coli K-12
folic acid metabolic processDihydrofolate reductaseEscherichia coli K-12
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
behavioral fear responseDipeptidyl peptidase 4Homo sapiens (human)
response to hypoxiaDipeptidyl peptidase 4Homo sapiens (human)
proteolysisDipeptidyl peptidase 4Homo sapiens (human)
cell adhesionDipeptidyl peptidase 4Homo sapiens (human)
positive regulation of cell population proliferationDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of extracellular matrix disassemblyDipeptidyl peptidase 4Homo sapiens (human)
peptide hormone processingDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellDipeptidyl peptidase 4Homo sapiens (human)
T cell costimulationDipeptidyl peptidase 4Homo sapiens (human)
regulation of cell-cell adhesion mediated by integrinDipeptidyl peptidase 4Homo sapiens (human)
locomotory exploration behaviorDipeptidyl peptidase 4Homo sapiens (human)
psychomotor behaviorDipeptidyl peptidase 4Homo sapiens (human)
T cell activationDipeptidyl peptidase 4Homo sapiens (human)
endothelial cell migrationDipeptidyl peptidase 4Homo sapiens (human)
symbiont entry into host cellDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated virion attachment to host cellDipeptidyl peptidase 4Homo sapiens (human)
negative chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
membrane fusionDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of neutrophil chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
glucagon processingDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (131)

Processvia Protein(s)Taxonomy
magnesium ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP-stimulated cyclic-nucleotide phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
zinc ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
TPR domain bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
phosphate ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein homodimerization activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductase Bos taurus (cattle)
dihydrofolate reductase activityDihydrofolate reductase Bos taurus (cattle)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
beta-N-acetylhexosaminidase activityBeta-hexosaminidase subunit alphaHomo sapiens (human)
protein bindingBeta-hexosaminidase subunit alphaHomo sapiens (human)
acetylglucosaminyltransferase activityBeta-hexosaminidase subunit alphaHomo sapiens (human)
protein heterodimerization activityBeta-hexosaminidase subunit alphaHomo sapiens (human)
N-acetyl-beta-D-galactosaminidase activityBeta-hexosaminidase subunit alphaHomo sapiens (human)
beta-N-acetylhexosaminidase activityBeta-hexosaminidase subunit betaHomo sapiens (human)
protein bindingBeta-hexosaminidase subunit betaHomo sapiens (human)
acetylglucosaminyltransferase activityBeta-hexosaminidase subunit betaHomo sapiens (human)
identical protein bindingBeta-hexosaminidase subunit betaHomo sapiens (human)
N-acetyl-beta-D-galactosaminidase activityBeta-hexosaminidase subunit betaHomo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseEscherichia coli K-12
protein bindingDihydrofolate reductaseEscherichia coli K-12
folic acid bindingDihydrofolate reductaseEscherichia coli K-12
oxidoreductase activityDihydrofolate reductaseEscherichia coli K-12
NADP bindingDihydrofolate reductaseEscherichia coli K-12
methotrexate bindingDihydrofolate reductaseEscherichia coli K-12
dihydrofolic acid bindingDihydrofolate reductaseEscherichia coli K-12
NADP+ bindingDihydrofolate reductaseEscherichia coli K-12
NADPH bindingDihydrofolate reductaseEscherichia coli K-12
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
acid phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
protein tyrosine phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
protein bindingLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
virus receptor activityDipeptidyl peptidase 4Homo sapiens (human)
protease bindingDipeptidyl peptidase 4Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
serine-type endopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
signaling receptor bindingDipeptidyl peptidase 4Homo sapiens (human)
protein bindingDipeptidyl peptidase 4Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 4Homo sapiens (human)
protein homodimerization activityDipeptidyl peptidase 4Homo sapiens (human)
chemorepellent activityDipeptidyl peptidase 4Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (85)

Processvia Protein(s)Taxonomy
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial outer membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial inner membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
endoplasmic reticulumcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
Golgi apparatuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
presynaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial inner membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial outer membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
synaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial matrixcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytoplasmDihydrofolate reductase Bos taurus (cattle)
mitochondrionDihydrofolate reductase Bos taurus (cattle)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
cytosolBeta-hexosaminidase subunit alphaHomo sapiens (human)
membraneBeta-hexosaminidase subunit alphaHomo sapiens (human)
azurophil granuleBeta-hexosaminidase subunit alphaHomo sapiens (human)
lysosomal lumenBeta-hexosaminidase subunit alphaHomo sapiens (human)
intracellular membrane-bounded organelleBeta-hexosaminidase subunit alphaHomo sapiens (human)
extracellular exosomeBeta-hexosaminidase subunit alphaHomo sapiens (human)
beta-N-acetylhexosaminidase complexBeta-hexosaminidase subunit alphaHomo sapiens (human)
lysosomeBeta-hexosaminidase subunit alphaHomo sapiens (human)
membraneBeta-hexosaminidase subunit alphaHomo sapiens (human)
acrosomal vesicleBeta-hexosaminidase subunit betaHomo sapiens (human)
extracellular regionBeta-hexosaminidase subunit betaHomo sapiens (human)
membraneBeta-hexosaminidase subunit betaHomo sapiens (human)
azurophil granule lumenBeta-hexosaminidase subunit betaHomo sapiens (human)
azurophil granuleBeta-hexosaminidase subunit betaHomo sapiens (human)
lysosomal lumenBeta-hexosaminidase subunit betaHomo sapiens (human)
cortical granuleBeta-hexosaminidase subunit betaHomo sapiens (human)
extracellular exosomeBeta-hexosaminidase subunit betaHomo sapiens (human)
beta-N-acetylhexosaminidase complexBeta-hexosaminidase subunit betaHomo sapiens (human)
lysosomeBeta-hexosaminidase subunit betaHomo sapiens (human)
membraneBeta-hexosaminidase subunit betaHomo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
cytosolDihydrofolate reductaseEscherichia coli K-12
cytosolDihydrofolate reductaseEscherichia coli K-12
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytoplasmLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
cytosolLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
cytoplasmic side of plasma membraneLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
sarcolemmaLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
extracellular exosomeLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
extracellular regionDipeptidyl peptidase 4Homo sapiens (human)
lysosomal membraneDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
focal adhesionDipeptidyl peptidase 4Homo sapiens (human)
cell surfaceDipeptidyl peptidase 4Homo sapiens (human)
membraneDipeptidyl peptidase 4Homo sapiens (human)
apical plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
lamellipodiumDipeptidyl peptidase 4Homo sapiens (human)
endocytic vesicleDipeptidyl peptidase 4Homo sapiens (human)
lamellipodium membraneDipeptidyl peptidase 4Homo sapiens (human)
membrane raftDipeptidyl peptidase 4Homo sapiens (human)
intercellular canaliculusDipeptidyl peptidase 4Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1019)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347155Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347150Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1797769Antimalarial Testing In Vitro (IC50) and Measurement of Inhibition Constant (Ki) from Article 10.1038/nsb921: \\Insights into antifolate resistance from malarial DHFR-TS structures.\\2003Nature structural biology, May, Volume: 10, Issue:5
Insights into antifolate resistance from malarial DHFR-TS structures.
AID1797737In Vitro Inhibition Assay from Article 10.1128/AAC.00386-06: \\Structure-activity relationships of Bacillus cereus and Bacillus anthracis dihydrofolate reductase: toward the identification of new potent drug leads.\\2006Antimicrobial agents and chemotherapy, Oct, Volume: 50, Issue:10
Structure-activity relationships of Bacillus cereus and Bacillus anthracis dihydrofolate reductase: toward the identification of new potent drug leads.
AID1797767Inhibitor Screening Using Bacterial System (IC50) and Measurement of Inhibition Constant (Ki) from Article 10.1128/AAC.00448-06: \\Evaluation of the activities of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reduct2006Antimicrobial agents and chemotherapy, Nov, Volume: 50, Issue:11
Evaluation of the activities of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial complementation assays.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1611287Inhibition of human dihydrofolate reductase using dihydrofolate as substrate in presence of NADPH by UV-vis spectrophotometry analysis2019Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24
6-Hydrophobic aromatic substituent pyrimethamine analogues as potential antimalarials for pyrimethamine-resistant Plasmodium falciparum.
AID1667078Inhibition of HDAC6 in human MDA-MB-231 cells assessed as accumulation of acetylated tubulin at 50 to 100 uM by western blot analysis2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1667069Antiproliferative activity in human A549 cells assessed as inhibition of cell viability after 72 hrs by MTS assay2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1367787Antimalarial activity against mid-ring stage of chloroquine-resistant Plasmodium falciparum Dd2 infected in human O-positive erythrocytes after 72 hrs by SYBR Green I dye-based fluorescence assay2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely.
AID394670Antimalarial activity as inhibition of schizont maturation against Plasmodium malariae Thai after 40 - 70 hrs2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Genetic analysis of the dihydrofolate reductase-thymidylate synthase gene from geographically diverse isolates of Plasmodium malariae.
AID356813Pharmacological chaperone effect on beta Hex A alpha IVS9 + 1G>A/IVS8-7G>A mutant in fibroblasts from Tay-Sachs disease patient assessed as increase in HEX A activity relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1143993Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 80 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID157842Antiplasmodial activity IC50 against Plasmodium falciparum K1CB1 DHFR double-mutant (C59R/S10)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1415882Selectivity ratio of IC50 for human HepG2 cells to IC50 for Plasmodium falciparum 3D72017MedChemComm, May-01, Volume: 8, Issue:5
Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-
AID1143954Ratio of quinine hydrochloride SD90 to compound SD90 for trophozoite-induced Plasmodium berghei infected in mouse assessed as daily dose required to suppression of 90% parasite infection administered with diet for 6 days1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1833126Induction of stage conversion in Toxoplasma gondii ESG reporter strain at 2 uM2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID1574650Selectivity index, ratio of CC50 for HEK293 cells to IC50 for Plasmodium falciparum 3D72019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1059659Inhibition of Toxoplasma gondii DHFR
AID519626Antimicrobial activity against Toxoplasma gondii RH harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID733061Antitubercular activity against Mycobacterium tuberculosis H37Rv by BacTiter-Gl Microbial Cell Viability assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines acting as antimycobacterial agents.
AID1667091Inhibition of STAT3 in human MDA-MB-231 cells assessed as downregulation of cyclinD1 expression at 100 to 200 uM after 24 hrs by western blot analysis2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID356789Pharmacological chaperone effect on beta Hex A beta-T150P/P417L mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity at 3 ug/ml by immunoselection assay relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1188166Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by microdilution AlamarBlue broth assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Sequential synthesis of amino-1,4-naphthoquinone-appended triazoles and triazole-chromene hybrids and their antimycobacterial evaluation.
AID1485238Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID519611Antimicrobial activity against Toxoplasma gondii B1 harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID519624Antimicrobial activity against Toxoplasma gondii isolate RMS-2001-MAU infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1485231Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1533257Antiplasmodial activity against Plasmodium falciparum W2 harboring DHFR IRNI haplotype N51I/C59R/S108N triple mutant2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
AID1196723Antiparasitic activity against promastigote form of Leishmania mexicana MHOM/BZ/61/M379 after 24 hrs by haemocytometer2015European journal of medicinal chemistry, Mar-06, Volume: 92Antileishmanial activity of quinazoline derivatives: synthesis, docking screens, molecular dynamic simulations and electrochemical studies.
AID1667072Cytotoxicity against African Green monkey Vero cells assessed as inhibition of cell viability after 72 hrs by MTS assay2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1143947Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 40 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID57408Inhibitor constant of compound for wild type Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID596017Antiparasitic activity against clindamycin-resistant Toxoplasma gondii 4 infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 1 uM treated for 48 hrs immediately after infection followed by reinoculated into fresh HFF monolayers 2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Chemistry and biology of macrolide antiparasitic agents.
AID478212Antimicrobial activity against Toxoplasma gondii infected in human CRL1634 cells assessed as intracellular parasite survival at 50 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID1439514Inhibition of bovine liver DHFR using FH2 as substrate preincubated for 2 mins followed by substrate addition in presence of NADPH2017European journal of medicinal chemistry, Mar-31, Volume: 129Novel 2,3-disubstituted quinazoline-4(3H)-one molecules derived from amino acid linked sulphonamide as a potent malarial antifolates for DHFR inhibition.
AID1261837Antiparasitic activity against Toxoplasma gondii RH tachyzoite expressing beta-galactosidase assessed as inhibition of tachyzoite invasion into human foreskin fibroblast host cells after 96 hrs by colorimetric microtitre assay2015European journal of medicinal chemistry, Nov-13, Volume: 105Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1.
AID158715Inhibition against Plasmodium falciparum Dd2 in erythrocytes in semiautomated micro dilution assay2003Bioorganic & medicinal chemistry letters, Jul-07, Volume: 13, Issue:13
Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties.
AID1355304Plasmodicidal activity against Plasmodium falciparum 3D7A infected in erythrocytes assessed as parasite survival at 10 times IC50 pre-incubated for 48 hrs followed by compound washout and measured after 24 hrs by 1H-hypoxanthine incorporation assay (Rvb =2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Discovery of Marinoquinolines as Potent and Fast-Acting Plasmodium falciparum Inhibitors with in Vivo Activity.
AID1227107Inhibition of STAT3 phosphorylation in ATSD patient fibroblasts at 100 uM2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID1533245Inhibition of Plasmodium falciparum K1CB1 DHFR NRNI haplotype C59R/S108N double mutant2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
AID122498Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 40 mg/kg; 1 cured at 60 days postinjection.1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Folate antagonists. 21. Synthesis and antimalarial properties of 2,4-diamino-6-(benzylamino)pyrido[3,2-d]pyrimidines.
AID229767Ratio of Inhibition of the C59R+S108N mutant of dihydrofolate reductase (DHFR) to inhibition of wild type dihydrofolate reductase.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1426081Agonist activity at mouse TAAR5 expressed in HEK293 cells assessed as cAMP accumulation after 20 mins by BRET assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID1723480Antimalarial activity against Plasmodium falciparum isolate GB0087 assessed as reduction in parasitemia at 1 to 10 times EC50 supplemented with fresh medium containing compounds every 24 hrs for 72 hrs relative to control2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Development of Potent
AID1441247Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as time duration for parasite cure at 10 mg/kg, sc administered QD for 4 days starting at 96 hrs post infection by Giemsa-staining based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID159736Compound was tested in vivo for antimalarial activity against Plasmodium berghei in mice (Mus musculus) after 6 days of administration (ED90 is the dose necessary to reduce the percentage of infected cells to 10% of the level found in the infected untreat2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials.
AID372373Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-1 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis.
AID1853165Selectivity index, ratio of IC50 for Antimalarial activity against chloroquine sensitive Plasmodium falciparum 3D7 infected in human RBC to IC50 for Cytotoxicity against human HepG2 cells2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Preparation, biological evaluation and QSAR analysis of urea substituted 2,4-diamino-pyrimidine anti-malarials.
AID356807Activation of on beta Hex A beta C137Y/C137Y mutant in postnuclear supernatant of fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity per mg of protein at 3 mg/ml by relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID90953The ability to inhibit [3H]- uracil incorporation by Toxoplasma gondii in cultures of HEL cells was tested1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
AID1467546Antimicrobial activity against Mycobacterium tuberculosis H37Rv by Alamar blue assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
One-pot microwave assisted stereoselective synthesis of novel dihydro-2'H-spiro[indene-2,1'-pyrrolo-[3,4-c]pyrrole]-tetraones and evaluation of their antimycobacterial activity and inhibition of AChE.
AID211987Binding affinity was evaluated as inhibition of mutant (C59R + S108N) Plasmodium falciparum DHFR-TS.1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria.
AID616032Antiparasitic activity against Toxoplasma gondii PRU tachyzoites harboring beta-Gal gene infected in human HFF cells after 72 hrs by microtiter plate based assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.
AID322127In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID1485236Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1639283Antiplasmodial activity against drug-sensitive Plasmodium falciparum 3D7 ring stage forms assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID576705Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S117N mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID58121Inhibitor constant of compound for mutant S108 N Plasmodium falciparum in dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID158557In vitro inhibition of Plasmodium falciparum K1 (S108N + C59R) culture1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria.
AID510927Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone1 bearing P-type ATPase4 I398F and P990R mutations after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID1227126Induction of wild type HexA activity in non-GM2 gangliosidosis patient fibroblasts at 33 ug/ml incubated for 5 days2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID56164Inhibition of Toxoplasma gondii Dihydrofolate Reductase1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID57797Compound was tested for inhibition activity against rat liver lipophilic Dihydrofolate reductase (DHFR).1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID1145672Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1587110Anti-plasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in erythrocytes after 72 hrs by SYBR green dye based fluorescence assay2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Synthesis, Profiling, and in Vivo Evaluation of Cyclopeptides Containing
AID1436319Antimalarial activity against intraerythrocytic stage of Plasmodium falciparum 3D7A assessed as log (viable parasites +1) at 10 times IC50 after 48 hrs by [3H]-hypoxanthine incorporation assay (Rvb = 5 No_unit)2017European journal of medicinal chemistry, Jan-27, Volume: 126Novel inhibitors of Plasmodium falciparum based on 2,5-disubstituted furans.
AID233652Selectivity ratio of IC50(rat liver)/IC50(Pneumocystis carinii)2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase.
AID1143944Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 320 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1485239Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1457212Antimalarial activity against Plasmodium falciparum V1/S infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID229040Cytotoxicity by the selective inhibition against African green monkey kidney fibroblast (vero cells).2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID57266Thermodynamic dissociation constant of compound for mutant T46A Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID1143983Toxicity in sporozoite-induced Plasmodium gallinaceum infected white leghorn chicken assessed as mortality at 320 mg/kg, sc administered 72 hrs after infection measured up to 6 days1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1182793Resistance index, ratio of IC50 for Plasmodium falciparum K1 to IC50 for Plasmodium falciparum NF542014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID576701Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR F57L and S117N mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID683347Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for chloroquine-sensitive Plasmodium falciparum D62012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
Novel 4-aminoquinoline-pyrimidine based hybrids with improved in vitro and in vivo antimalarial activity.
AID1833151Anti-bradyzoite activity against Toxoplasma gondii ESG reporter stain infected in NHDF cells assessed as parasite proliferation at 4 uM measured after 30 days by optical microscopic analysis2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID1648003Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as reduction in parasite rowth incubated for 72 hrs by DAPI staining based fluorescence assay2020Journal of natural products, 02-28, Volume: 83, Issue:2
A Meroisoprenoid, Heptenolides, and
AID728296Antiparasitic activity against tachyzoites of Toxoplasma gondii RH type 1 infected in HFF cells incubated for 24 hrs followed by compound washout measured after 72 hrs by beta-galactoside reporter assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii.
AID1723484Antimalarial activity against Plasmodium falciparum isolate GB0020 assessed as reduction in parasitemia at 10 times EC50 measured after 72 hrs2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Development of Potent
AID1274588Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis2015Journal of natural products, Dec-24, Volume: 78, Issue:12
Rotenoids, Flavonoids, and Chalcones from the Root Bark of Millettia usaramensis.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1485248Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1623969Kinetic solubility of the compound at pH 7 after 24 hrs by shake flask method2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID58123Ratio of Kd to Ki for mutant S108 N Plasmodium falciparum dihydrofolate reductase; ND=no data1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID57826Inhibitory activity against dihydrofolate reductase DHFR in rat liver2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase.
AID56182Inhibition of Dihydrofolate reductase of Toxoplasma gondii1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID1071659Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition by Alamar Blue staining-based broth microdilution assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Antimycobacterial evaluation of novel hybrid arylidene thiazolidine-2,4-diones.
AID356803Pharmacological chaperone effect on beta Hex A beta-P504S/delta16kb mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity at 3 ug/ml by immunoselection assay relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID341471Selectivity for Escherichia coli dihydrofolate reductase over human dihydrofolate reductase2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID607059Antimalarial activity against mefloquine-resistant Plasmodium falciparum W2 after 48 hrs by LDH assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Antimalarial pyrido[1,2-a]benzimidazoles.
AID1329799Antiplasmodial activity against pyrimethamine-sensitive Plasmodium falciparum 3D7 infected in human erythrocytes incubated for 50 hrs by SYBR green 1 dye based fluorescence assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and evaluation of naphthyl bearing 1,2,3-triazole analogs as antiplasmodial agents, cytotoxicity and docking studies.
AID58124Ratio of Kd to Ki for Plasmodium falciparum dihydrofolate reductase; ND=no data1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID1485243Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1058955Plasma concentration in ddY mouse at 5 mg/kg2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
The synthesis and biodistribution of [(11)C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo.
AID1145671Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1457213Antimalarial activity against Plasmodium falciparum 7G8 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting 2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID232861Safety ratio is cytotoxicity to KB cells/IC50 TM4.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID57141Inhibition of recombinant Dihydrofolate reductase from humans.1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Design, synthesis, and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolate reductase.
AID605733Antimalarial activity against Plasmodium falciparum W2 infected in human erythrocytes assessed as decrease in parasitemia after 72 hrs2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Imidazolopiperazines: hit to lead optimization of new antimalarial agents.
AID1467547Cytotoxicity against monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
One-pot microwave assisted stereoselective synthesis of novel dihydro-2'H-spiro[indene-2,1'-pyrrolo-[3,4-c]pyrrole]-tetraones and evaluation of their antimycobacterial activity and inhibition of AChE.
AID1134959Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as change in mean survival time at 10 mg/kg, sc single dose after 72 hrs of infection1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1623973Parasiticidal activity against bacterial beta-galactosidase expressing Toxoplasma gondii I RH 2F clone infected in HFF cells after 72 hrs2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID116251Antimalarial effect against trophozoite induced Plasmodium berghei in mice (Mus musculus) at dosage of 40 mg/kg after subcutaneous administration; no data1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID519625Antimicrobial activity against Toxoplasma gondii isolate GUY-2003-MEL harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex2, 145 sil Val mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1533247Inhibition of Plasmodium falciparum CSL-2 DHFR NRNL haplotype C59R/S108N/I164L triple mutant2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
AID1623974Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID1624004Inhibition of human DHFR2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID602119NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID57598Ratio of Kd to Ki of compound for mutant T46A Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID394669Antiplasmodial activity against Plasmodium vivax2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Genetic analysis of the dihydrofolate reductase-thymidylate synthase gene from geographically diverse isolates of Plasmodium malariae.
AID1182795Resistance index, ratio of IC50 for Plasmodium falciparum W2 to IC50 for Plasmodium falciparum NF542014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1182796Resistance index, ratio of IC50 for Plasmodium falciparum Dd2 to IC50 for Plasmodium falciparum NF542014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID356809Activation of on beta Hex A beta C137Y/C137Y mutant in enriched lysosomal fraction of fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity per mg of protein at 3 mg/ml by relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID125020Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 20 mg/kg.1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Folate antagonists. 21. Synthesis and antimalarial properties of 2,4-diamino-6-(benzylamino)pyrido[3,2-d]pyrimidines.
AID58250Binding affinity towards mutant dihydrofolate reductase (N51I+C59R+S108N DHFR) of Plasmodium falciparum2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID158038Inhibitory concentration against multidrug-resistant Plasmodium falciparum Dd2.2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Structure-activity relationships of novel anti-malarial agents. Part 4: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides.
AID510926Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID1444620Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in red blood cells after 72 hrs by Malstat reagent based LDH assay2017European journal of medicinal chemistry, May-05, Volume: 131N-Piperonyl substitution on aminoquinoline-pyrimidine hybrids: Effect on the antiplasmodial potency.
AID576707Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S58R and S117N mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID478211Antimicrobial activity against Toxoplasma gondii infected in human CRL1634 cells assessed as intracellular parasite survival at 25 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID56174Compound was tested for inhibition activity against Toxoplasma gondii (Toxoplasma gondii) Dihydrofolate reductase1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID1202553Antiplasmodial activity against Plasmodium berghei infected in CD1 mouse assessed as reduction in parasitemia at 50 mg/kg, po administered for 4 days measured on day 4 relative to vehicle-treated control2015European journal of medicinal chemistry, , Volume: 96Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents.
AID560257Antimalarial activity against Plasmodium falciparum Kenyan isolates expressing DHFR Ser108Asn, Asn51Ile and Cys59Arg triple mutant by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.
AID1623970Intrinsic clearance in human liver microsomes at 10 uM preincubated for 10 mins followed by NADPH addition and measured up to 60 mins by LC/MS/MS analysis2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID1538878Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter 96 Non-radioactive Cell Proliferation Assay2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Green synthesis, biological evaluation, molecular docking studies and 3D-QSAR analysis of novel phenylalanine linked quinazoline-4(3H)-one-sulphonamide hybrid entities distorting the malarial reductase activity in folate pathway.
AID596083Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 1 uM treated for 48 hrs after 6 hrs infection followed by reinoculated2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Chemistry and biology of macrolide antiparasitic agents.
AID1305448Antimalarial activity against Plasmodium falciparum 3D7 incubated for 72 hours by DAPI-staining based confocal imaging analysis2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Selective anti-malarial minor groove binders.
AID1368006Antimalarial activity against Plasmodium falciparum in infected in human RBC2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Ionic liquid mediated stereoselective synthesis of alanine linked hybrid quinazoline-4(3H)-one derivatives perturbing the malarial reductase activity in folate pathway.
AID95845In vitro cytotoxicity against Plasmodium falciparum infected KB cell line2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID1450035Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 at 40 uM measured after 72 hrs by DAPI staining based high throughput screening assay relative to control2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Antiplasmodial β-triketones from the flowers of the Australian tree Angophora woodsiana.
AID356782Increase in thermostability of beta Hex A betaR505Q mutant isolated from Sandhoff disease patient assessed as residual enzyme activity at 3 ug/ml at 37 degC after 30 mins relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1833133Anti-bradyzoite activity against Toxoplasma gondii ESG reporter strain infected in NHDF cells assessed as cell lysis at 2 uM measured after 21 days2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID519613Antimicrobial activity against Toxoplasma gondii ME49 infected in human MRC-5 cells infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID576709Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR F57L, S58R, T61M, S117T mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID1148778Antimalarial activity against Plasmodium berghei KBG13 infected in mouse assessed as minimum dose required for disease cures1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Antimalarial activity of some novel derivatives of 2,4-diamino-5(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine).
AID1155470Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR I method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
AID361331Effect on beta-galactosidase in fibroblasts with Hex A alpha-G269S/ins1278TACT mutation isolated from Tay-Sachs disease patient2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID234270Ratio of IC50 rat liver DHFR vs IC50 of Toxoplasma gondii DHFR1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID1442001Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
AID341470Inhibition of Toxoplasma gondii dihydrofolate reductase2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID26811Partition coefficient (logP)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability.
AID57817Inhibition of rat liver Dihydrofolate Reductase1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID322131In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID559548Antimalarial activity against pyrimethamine-sensitive Plasmodium falciparum 3D7 expressing wild type DHFR by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.
AID607065Antimalarial activity against Plasmodium falciparum K12011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Antimalarial pyrido[1,2-a]benzimidazoles.
AID1145679Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 to IC50 for sensitive Pediococcus cerevisiae ATCC 8081977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID549612Antimalarial activity against mefloquine-resistant, chloroquine-sensitive Plasmodium falciparum D6 assessed as inhibition of [3H]hypoxanthine uptake in presence of 1 mM folinic acid2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
In vitro efficacy of 7-benzylamino-1-isoquinolinamines against Plasmodium falciparum related to the efficacy of chalcones.
AID1574648Growth inhibition of HEK293 cells at 10 uM after 72 hrs by resazurin dye based assay relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID232760Selectivity index measured as the ratio of IC50 for rat liver DHFR to IC50 for Toxoplasma gondii DHFR.1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase.
AID1574649Growth inhibition of HEK293 cells at 40 uM after 72 hrs by resazurin dye based assay relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID56317Inhibitory activity against Toxoplasma gondii Dihydrofolate reductase1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID124688Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 320 mg/kg subcutaneous dose1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediamines.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID55704Inhibition of Pneumocystis carinii Dihydrofolate Reductase1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID57968Inhibitory activity against rat liver dihydrofolate reductase1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID543839Antimalarial activity against chloroquine-sensitive Plasmodium berghei ATCC 50175 infected in ICR mouse assessed as chemosuppression of parasitemia at 1.2 mg/kg/day, po pretreated for 4 days before infection and measured after 72 hrs2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Antimalarial activity of a new stilbene glycoside from Parthenocissus tricuspidata in mice.
AID1145681Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth in presence of 0.002 ug/ml folic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID234269Ratio of IC50 rat liver DHFR vs IC50 of Pneumocystis carinii DHFR1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID1227099Inhibition of human placental HexA using MUGS substrate incubated for 1 to 2 hrs at pH 4.5 by spectrofluorometry2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID57599Ratio of Kd to Ki of compound for mutant T46N Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID361328Inhibition of beta-hexosaminidase A at pH 4.5 by competitive binding assay2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1444622Cytotoxicity against African green monkey Vero cells2017European journal of medicinal chemistry, May-05, Volume: 131N-Piperonyl substitution on aminoquinoline-pyrimidine hybrids: Effect on the antiplasmodial potency.
AID1457210Antimalarial activity against Plasmodium falciparum TM90C2B infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation count2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID157697Anti-malarial activity against Plasmodium falciparum Dd22003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
AID157697Anti-malarial activity against Plasmodium falciparum Dd22003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
AID747611Inhibition of rat liver DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID1227110Toxicity against ATSD patient fibroblasts assessed as reduction in beta-galactosidase activity at2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID747607Selectivity ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID322134Antimalarial activity against Plasmodium falciparum D6 as reduced [3H]hypoxanthine uptake after 72 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID1071104Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate Alamar blue assay2014European journal of medicinal chemistry, Mar-03, Volume: 74Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.
AID1442006Ratio of Kii for human OCT1-ASP+-inhibitor complex to Kis for human OCT1-inhibitor complex by Lineweaver-Burk plot analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
AID343765Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival at 50 uM after 18 hrs by [5,6-13H]uracil incorporation assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID543853Antimalarial activity against chloroquine-sensitive Plasmodium berghei ATCC 50175 infected in ICR mouse assessed as parasitemia at 1.2 mg/kg/day, po administered 24 hrs post-treatment measured after 4 days (Rvb = 56.3+/-0.16 %)2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Antimalarial activity of a new stilbene glycoside from Parthenocissus tricuspidata in mice.
AID159184In vitro relative antiplasmodial activity (IC50) compared to Pyr against Plasmodium falciparum TM4/8.2 wild-type2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID1485233Cytotoxicity against human Calu3 cells assessed as alterations in cell morphology measured after 5 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID356791Pharmacological chaperone effect on beta Hex A beta-G353R/IVS12-26G>A mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity at 3 ug/ml by immunoselection assay relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1485241Antiviral activity against coxsackie B4 virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID373632Inhibition of Plasmodium falciparum DHFR-TS QM template N51I, C59R, S108N, I164L mutant expressed in Escherichia coli BL21(DE3)2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID1457222Antimalarial activity against intraerythrocytic stage of Plasmodium falciparum assessed as time required to clear 99.9% of initial parasite population at 10 times IC50 preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID56189Inhibitory activity against dihydrofolate reductase DHFR in Toxoplasma gondii.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID55833Inhibitory activity against Pneumocystis carinii dihydrofolate reductase1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID229684Relative affinity for dihydrofolate reductase of rat liver and Pneumocystis carinii1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID1611281Competitive inhibition of wild type Plasmodium falciparum dihydrofolate reductase expressed in Escherichia coli BL21(DE3)pLysS using dihydrofolate as substrate in presence of NADPH by UV-vis spectrophotometry analysis2019Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24
6-Hydrophobic aromatic substituent pyrimethamine analogues as potential antimalarials for pyrimethamine-resistant Plasmodium falciparum.
AID1327820Inhibition of Toxoplasma gondii TS-DHFR expressed in Escherichia coli BL21 preincubated for 15 mins followed by addition of DHF as substrate and NADPH measured after 60 mins by resazurin/diaphorase coupled assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Discovery of Potent and Selective Leads against
AID1143943Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 640 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1723476Antimalarial activity against Plasmodium falciparum isolate GB0004 assessed as reduction in parasitemia at 1 to 10 times EC50 supplemented with fresh medium containing compounds every 24 hrs for 72 hrs relative to control2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Development of Potent
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID48922Minimum inhibitory concentration required to inhibit Candida albicans (in vitro)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines.
AID119229Antimalarial activity against trophozoite-induced Plasmodium berghei in mice (Mus musculus)1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID576702Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S58R and S117N mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID1623995Antiparasitic activity against Toxoplasma gondii RH in naive mouse receiving brain/lung tissue homogenate of 54 mg/kg, po qd for 7 days dosed CD1 mouse assessed as infection cure rate measured after 15 days post homogenate injection relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID57268Thermodynamic dissociation constant of compound for mutant T46S Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID562110Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1145675Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1202554Antiplasmodial activity against Plasmodium berghei infected in CD1 mouse assessed as survival time at 50 mg/kg, po administered for 4 days measured on day 4 relative to vehicle-treated control2015European journal of medicinal chemistry, , Volume: 96Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents.
AID373646Ratio of IC50 for pyrimethamine-resistant form-2 Plasmodium falciparum N51I, C59R, S108N, I164L, K96N mutant to IC50 for Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID1077196Cytotoxicity against CHO cells after 48 hrs by MTT assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID1485246Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1155422Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 after 72 hrs by SYBR I method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
AID373643Ratio of IC50 for WR99210-resistant form-2 Plasmodium falciparum N51I, C59R, N108S, I164L mutant to IC50 for Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID700779Selectivity ratio of IC50 for Plasmodium falciparum Dd2 to IC50 for Plasmodium falciparum 3D7A2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.
AID1441244Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as time duration for parasite cure at 5 mg/kg, sc administered QD for 4 days starting at 2 hrs post infection by Giemsa-staining based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1623966Inhibition of Toxoplasma gondii DHFR-TS expressed in Escherichia coli BL21 competent cells using DHF as substrate preincubated for 15 mins followed by substrate and NADPH addition and measured after 60 mins by resazurin dye based diaphorase-coupled assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID344038Toxicity against human foreskin fibroblasts at 10 uM after 48 hrs by MTT method2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID1415880Selectivity ratio of IC50 for human G9a to IC50 for Plasmodium falciparum 3D72017MedChemComm, May-01, Volume: 8, Issue:5
Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-
AID1441259Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as time duration for parasite cure at 90 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysi2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID215506Inhibition of Trypanosoma brucei rhodesiense growth1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Design, synthesis, and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolate reductase.
AID1457216Antimalarial activity against intraerythrocytic stage of Plasmodium falciparum assessed as time required for maximal killing effect at 10 times IC50 preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation coun2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1134961Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as change in mean survival time at 2.5 mg/kg, sc single dose after 72 hrs of infection1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1574646Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by DAPI staining-based confocal imaging analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID560258Antimalarial activity against Plasmodium falciparum isolate Kil-164 expressing DHFR Ser108Asn, Asn51Ile, Cys59Arg and Ile164Leu quadruple mutant by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.
AID733062Antitubercular activity against Mycobacterium tuberculosis H37Rv by microdilution alamar Blue broth assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines acting as antimycobacterial agents.
AID210628Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 25 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID571510Antiparasitic activity against Babesia gibsoni infected in dog erythrocytes assessed as growth inhibition at 20 uM by Giemsa staining based microscopy2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Cloning, expression, and characterization of Babesia gibsoni dihydrofolate reductase-thymidylate synthase: inhibitory effect of antifolates on its catalytic activity and parasite proliferation.
AID1779234Antimalarial activity against synchronous ring stage of Plasmodium falciparum Dd2 assessed as parasite growth inhibition incubated for 72 hrs by Griffith assay based fluorescence analysis2021European journal of medicinal chemistry, Oct-05, Volume: 221Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID1143952Toxicity in Plasmodium berghei infected mouse assessed as mortality at 640 mg/kg, sc administered 72 hrs after infection measured after 2 to 5 days1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID124678Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after subcutaneous administration dose of 2.5 mg/kg1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediamines.
AID373637Inhibition of WR99210-resistant form-2 Plasmodium falciparum N51I, C59R, N108S, I164L mutant expressed in Escherichia coli BL21(DE3)2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID559549Antimalarial activity against Plasmodium falciparum Kenyan isolates by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.
AID1616630Antiplasmodial activity against asexual form of Plasmodium falciparum NF54 assessed as reduction in female gametocytes activation preincubated for 48 hrs followed by gametocytes activation and measured after 24 hrs by fluorescence based automated inverted2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Development of Chemical Entities Endowed with Potent Fast-Killing Properties against
AID607063Antimalarial activity against Plasmodium falciparum FCR32011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Antimalarial pyrido[1,2-a]benzimidazoles.
AID1077198Antiplasmodial activity against asexual erythrocytic stage of chloroquine-resistant Plasmodium falciparum Dd2 assessed as parasite growth inhibition after 48 hrs by lactate dehydrogenase assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID1401966Antimycobacterial activity against Mycobacterium tuberculosis H37Rv2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and antimycobacterial activity of triterpeni≿ A-ring azepanes.
AID1667185Antimalarial activity against drug-resistant Plasmodium falciparum Dd22020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Synthesis and efficacy of pyrvinium-inspired analogs against tuberculosis and malaria pathogens.
AID1486833Antimalarial activity against Plasmodium falciparum ring stage forms after 48 hrs2017Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15
1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.
AID1639289Cytotoxicity against HEK293 cells assessed as growth inhibition after 72 hrs by resazurin dye-based fluorescence assay relative to control2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID1143939Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 10 mg/kg, sc administered 72 hrs after infection relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID747608Inhibition of Mycobacterium avium DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID774658Antimalarial activity against asexual stage of Plasmodium falciparum 3D7 after 72 hrs by image-based HTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID229685Relative affinity for dihydrofolate reductase of rat liver and Toxoplasma gondii1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID1227098Inhibition of human placental HexA using MUGS substrate incubated for 1 to 2 hrs at pH 7.0 by spectrofluorometry2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID119309Number of mice cured at a dose of 640 mg/kg sc1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID1623967Inhibition of human DHFR expressed in Escherichia coli BL21 competent cells using DHF as substrate preincubated for 15 mins followed by substrate and NADPH addition and measured after 60 mins by resazurin dye based diaphorase-coupled assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID159183Antiplasmodial activity (IC50) compared to Pyr against Plasmodium falciparum K1CB1 DHFR double-mutant (C59R/S108N)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID1611295Selectivity ratio of IC50 for African green monkey Vero cells to IC50 for Plasmodium falciparum TM4/8.2 infected in human erythrocytes2019Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24
6-Hydrophobic aromatic substituent pyrimethamine analogues as potential antimalarials for pyrimethamine-resistant Plasmodium falciparum.
AID125005Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 160 mg/kg; 5 cured at 60 days postinjection.1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Folate antagonists. 21. Synthesis and antimalarial properties of 2,4-diamino-6-(benzylamino)pyrido[3,2-d]pyrimidines.
AID56350Inhibition of recombinant Dihydrofolate reductase from humans.1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Design, synthesis, and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolate reductase.
AID373631Inhibition of Plasmodium falciparum DHFR-TS QM template N51I, C59R, S108N, I164L mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID683338Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in red blood cells after 72 hrs by parasitic LDH assay2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
Novel 4-aminoquinoline-pyrimidine based hybrids with improved in vitro and in vivo antimalarial activity.
AID235844Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum V1/S infected BC cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID356783Pharmacological chaperone effect on beta Hex A beta-C137Y/C137Y mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity at 3 ug/ml by immunoselection assay relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1625413Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 infected in human RBC incubated for 18 to 20 hrs by microdilution radioisotope method2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Antimalarial Oxoprotoberberine Alkaloids from the Leaves of Miliusa cuneata.
AID159855Dose required by the animals(mouse) to survive after 31 days2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials.
AID58276Inhibition of the wild-type dihydrofolate reductase (DHFR)relative to Pyr.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID279388Growth inhibition of Plasmodium falciparum Dd2 ring stage infected erythrocytes after 72 hrs by DAPI fluorimetry2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
AID596084Antiparasitic activity against clindamycin-resistant Toxoplasma gondii 4 infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 1 uM treated for 48 hrs after 6 hrs infection followed by reinoculated into fresh HFF monolayers measur2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Chemistry and biology of macrolide antiparasitic agents.
AID1457207Antimalarial activity against Plasmodium falciparum T9/94 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation countin2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID373647Ratio of IC50 for pyrimethamine-resistant form-3 Plasmodium falciparum N51I, C59R, S108N, I164L, I150V, N182I, N201D mutant to IC50 for Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID373634Inhibition of Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant expressed in Escherichia coli BL21(DE3)2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID772517Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1611288Selectivity ratio of Ki for human dihydrofolate reductase to Ki for wild type Plasmodium falciparum TM4/8.2 dihydrofolate reductase2019Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24
6-Hydrophobic aromatic substituent pyrimethamine analogues as potential antimalarials for pyrimethamine-resistant Plasmodium falciparum.
AID519622Antimicrobial activity against Toxoplasma gondii isolate RMS-1994-LEF harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 204 sil Ala mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID607061Antimalarial activity against Plasmodium falciparum NF542011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Antimalarial pyrido[1,2-a]benzimidazoles.
AID722363Aqueous solubility in pH 7.4 PBS buffer at 37 degC incubated for 24 hrs by HPLC method2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Synthesis, characterization and antimalarial activity of quinoline-pyrimidine hybrids.
AID248852In vitro antimalarial activity for DHFR wild-type, chloroquine and pyrimethamine-resistant Plasmodium falciparum W22005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
In vitro metabolism of phenoxypropoxybiguanide analogues in human liver microsomes to potent antimalarial dihydrotriazines.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID159707Antimalarial activity as toxic deaths 2-5 days post infection for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 640 mg/kg subcutaneous dose over 72 hr1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides.
AID1623991Antiparasitic activity against Toxoplasma gondii RH infected in CD1 mouse assessed as improvement in mouse survival at 18 mg/kg, po qd bid administered starting on day 1 post infection through day 7 and measured after 30 days relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID576700Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S117N mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID1174521Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 assessed as inhibition of parasite growth after 72 hrs by parasite LDH release assay2015European journal of medicinal chemistry, Jan-07, Volume: 894-Aminoquinoline-pyrimidine hybrids: synthesis, antimalarial activity, heme binding and docking studies.
AID356795Pharmacological chaperone effect on beta Hex A beta-P417L/delta16kb mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity at 3 ug/ml by immunoselection assay relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1329800Antiplasmodial activity against pyrimethamine-resistant Plasmodium falciparum Dd2 infected in human erythrocytes incubated for 50 hrs by SYBR green 1 dye based fluorescence assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and evaluation of naphthyl bearing 1,2,3-triazole analogs as antiplasmodial agents, cytotoxicity and docking studies.
AID373642Ratio of IC50 for WR99210-resistant form-1 Plasmodium falciparum I51N, C59R, N108S, I164L mutant to IC50 for Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID249023Inhibitory concentration against cycloguanil sensitive Plasmodium falciparum FJB-D4 2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
1-Aryl-4,6-diamino-1,2-dihydrotriazine as antimalarial agent: a new synthetic route.
AID1182743Antiplasmodial activity against Plasmodium falciparum K1 by SYBR-green based assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID1145677Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID373635Ratio of IC50 for WR99210-resistant form-A Plasmodium falciparum DHFR-TS I51N, C59R, N108S, L164I, D54N mutant to IC50 for Plasmodium falciparum DHFR-TS QM template N51I, C59R, S108N, I164L mutant2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID1058956Inhibition of mouse Oct1 transfected in HEK293 cells assessed as uptake of [14C]-TEA preincubated for 15 mins by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
The synthesis and biodistribution of [(11)C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo.
AID57406Inhibitor constant of compound for mutant T46N Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID1155473Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR I method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
AID1833127Induction of stage conversion in Toxoplasma gondii ESG reporter strain at 4 uM2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID1182791Antiplasmodial activity against Plasmodium falciparum SB1-A6 harboring mutations conferring drug-resistance by SYBR-green based assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1485250Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1486840Inhibition of bovine liver DHFR pre-incubated 2 mins before dihydrofolic acid substrate addition and measured over 10 mins in presence of NADPH2017Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15
1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.
AID1274585Cytotoxicity against HEK293 cells assessed as cell viability after 72 hrs by resazurin-based plate reader analysis2015Journal of natural products, Dec-24, Volume: 78, Issue:12
Rotenoids, Flavonoids, and Chalcones from the Root Bark of Millettia usaramensis.
AID565415Antimalarial activity against Plasmodium falciparum Pf3D70087/N9 infected in immunodeficient HM-beta2 m null mouse after 7 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes.
AID1145688Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as active dose required to increase of 100% in mean survival time1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1441255Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as parasite growth inhibition at 30 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID518563Binding affinity to human recombinant DHFR expressed in Escherichia coli BL21(DE3) by competitive binding assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID1623992Antiparasitic activity against Toxoplasma gondii RH infected in CD1 mouse assessed as improvement in mouse survival at 54 mg/kg, po qd administered starting on day 1 post infection through day 7 and measured after 30 days relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID235843Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum TM4/8.2 infected Vero cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1145689Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as dose required to survivors for period of 60 days1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1145682Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth in presence of 0.002 ug/ml folic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1574645Antimalarial activity against Plasmodium falciparum 3D7 after 72 hrs by DAPI staining-based confocal imaging analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1533246Inhibition of Plasmodium falciparum W2 DHFR IRNI haplotype N51I/C59R/S108N triple mutant2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
AID322126In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID1143946Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 80 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID565416Antimalarial activity against Plasmodium falciparum PfV1S0176/N10 infected in immunodeficient HM-IL2Rgamma null mouse after 7 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes.
AID1533248Inhibition of Plasmodium falciparum V1/S DHFR IRNL haplotype N51I/C59R/S108N/I164L quadruple mutant2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
AID232423Ratio of inhibition of Human DHFR to inhibition of wild type DHFR.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID1134960Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as change in mean survival time at 5 mg/kg, sc single dose after 72 hrs of infection1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1145683Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction in growth in presence of 0.001 ug/ml folic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID232440Ratio of inhibitions against mutant and wild type (WT) Plasmodium falciparum DHFR-TS.1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria.
AID300109Antiparasitemia activity against Plasmodium berghei infected mice (Mus musculus) at 30 mg/kg subcutaneous dose for 4 days2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID1812458Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as time to kill initial parasite load at 10 times IC50 concentration2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID373624Inhibition of pyrimethamine-resistant form-3 Plasmodium falciparum N51I, C59R, S108N, I164L, I150V, N182I, N201D mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID268782Inhibition of Cryptosporidium hominis DHFR2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Analysis of complexes of inhibitors with Cryptosporidium hominis DHFR leads to a new trimethoprim derivative.
AID229768Ratio of Inhibition of the S108N mutant of dihydrofolate reductase (DHFR) to inhibition of wild type dihydrofolate reductase.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID1305451Cytotoxicity against HEK293 cells by alamar blue assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Selective anti-malarial minor groove binders.
AID356797Pharmacological chaperone effect on beta Hex A beta-P417L/delta16kb mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity at 3 ug/ml by immunoselection assay relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1069174Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 7 days by BacTiter-Glo assay2014European journal of medicinal chemistry, Feb-12, Volume: 73Design, synthesis and evaluation of acridine and fused-quinoline derivatives as potential anti-tuberculosis agents.
AID518314Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum clinical isolate harboring S108N, N51I, C59R mutation in DHFR assessed as decrease in parasitaemia2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID343764Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival at 25 uM after 18 hrs by [5,6-13H]uracil incorporation assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID356816Pharmacological chaperone effect on beta Hex A beta-C137Y/C137Y mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1227106Inhibition of human DHFR2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID1713722Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth by microdilution alamar blue broth assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
A facile stereoselective synthesis of dispiro-indeno pyrrolidine/pyrrolothiazole-thiochroman hybrids and evaluation of their antimycobacterial, anticancer and AchE inhibitory activities.
AID1457215Antimalarial activity against Plasmodium falciparum FCB infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting 2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID571511Antiparasitic activity against Babesia gibsoni infected in dog erythrocytes assessed as growth inhibition at 80 uM by Giemsa staining based microscopy2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Cloning, expression, and characterization of Babesia gibsoni dihydrofolate reductase-thymidylate synthase: inhibitory effect of antifolates on its catalytic activity and parasite proliferation.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1305450Antimalarial activity against Plasmodium falciparum Dd2 incubated for 72 hours by DAPI-staining based confocal imaging analysis2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Selective anti-malarial minor groove binders.
AID159001In vitro antimalarial activity against Plasmodium falciparum K12001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials.
AID1182742Antiplasmodial activity against Plasmodium falciparum NF54 by SYBR-green based assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID1441261Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as parasite cure level at 10 to 90 mg/kg, ip administered on days 1 post infection by Giemsa-stained microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID124700Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after subcutaneous administration dose of 40 mg/kg; 1 survived after 60 days of postinfection1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediamines.
AID356819Pharmacological chaperone effect on beta Hex A beta delta16kb/P417L mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID55832Inhibitory activity against Pneumocystis carinii Dihydrofolate reductase1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID605732Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as decrease in parasitemia after 72 hrs2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Imidazolopiperazines: hit to lead optimization of new antimalarial agents.
AID247036Effective dose against chloroquine-sensitive, pyrimethamine-sensitive, mefloquine-sensitive Plasmodium falciparum HB32005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
AID1653496Inhibition of Mycobacterium smegmatis ATCC 607 dihydrofolic reductase2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID576699Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID1450033Growth inhibition of HEK293 cells at 40 uM relative to control2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Antiplasmodial β-triketones from the flowers of the Australian tree Angophora woodsiana.
AID518315Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum V1/S harboring S108N, N51I, C59R, I164L mutation in DHFR assessed as decrease in parasitaemia2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID1227112Inhibition of HexA in normal human fibroblasts using MUGS substrate incubated for 1 to 2 hrs at pH 4.5 by spectrofluorometry2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID1589589Inhibition of N-terminal His-tagged Trypanosoma brucei pteridine reductase 1 using di-hydrobiopterine as substrate measured at 1 min interval for 50 mins in presence of NADPH2019Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8
Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.
AID747610Inhibition of Pneumocystis carinii DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID1355871Antiplasmodial activity against 4-aminoquinoline/antifolates-resistant Plasmodium falciparum Dd2 ring stage infected in human erythrocytes at 40 uM after 72 hrs by DAPI staining based method2018Journal of natural products, 07-27, Volume: 81, Issue:7
Antiplasmodial β-Triketone-Flavanone Hybrids from the Flowers of the Australian Tree Corymbia torelliana.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID361327Inhibition of beta-hexosaminidase B at pH 4.3 assessed as residual enzyme activity2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID41220In vitro cytotoxicity against Plasmodium falciparum infected BC cell line.2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID571507Inhibition of Babesia gibsoni Dihydrofolate reductase-thymidylate synthase expressed in Escherichia coli BL212008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Cloning, expression, and characterization of Babesia gibsoni dihydrofolate reductase-thymidylate synthase: inhibitory effect of antifolates on its catalytic activity and parasite proliferation.
AID1294351Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 incubated for 7 days by BacTiter-Glo cell viability assay2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis.
AID372375Antiparasitic activity against artemisinin-resistant Toxoplasma gondii STL500-10A infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis.
AID57407Inhibitor constant of compound for mutant T46S Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID478204Antimicrobial activity against wild-type Toxoplasma gondii RH infected in human CRL1634 cells assessed as intracellular parasite survival at 50 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID57267Thermodynamic dissociation constant of compound for mutant T46N Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID519615Antimicrobial activity against Toxoplasma gondii isolate TOU-1998-TRI infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1143941Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 2.5 mg/kg, sc administered 72 hrs after infection relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID356777Activation of beta Hex A alpha IVS9 + 1G>A/IVS8-7G>A mutant isolated from Tay-Sachs disease patient assessed as increase in HEX A activity relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID774662Antimalarial activity against early (1 to 3) gametocytic stage of Plasmodium falciparum at 120 uM after 72 hrs by image-based HTS assay relative to control2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID428940Antiprotozoal activity against 100Toxoplasma gondii RH tachyzoites infected in CBA/J mouse survival at 5 mg/kg, po administered 2 hrs postinfection for 7 consecutive days2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection.
AID1415879Inhibition of human G9a using biotinylated peptide H3( 1 to 25 residues) as substrate measured after 15 mins in presence of [3H]-SAM by scintillation proximity assay2017MedChemComm, May-01, Volume: 8, Issue:5
Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-
AID356820Pharmacological chaperone effect on beta Hex A beta P504S/delta16kb mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID57600Ratio of Kd to Ki of compound for mutant T46S Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID300110Antiparasitemia activity against Plasmodium berghei infected mice (Mus musculus) at 30 mg/kg peroral dose for 4 days2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID1667087Inhibition of STAT3 in human MDA-MB-231 cells assessed as effect on pSTAT3 expression at 50 to 100 uM after 24 hrs by western blot analysis2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1779235Selectivity index, ratio of IC50 for antimalarial activity against Plasmodium falciparum Dd2 to IC50 of antimalarial activity against Plasmodium falciparum 3D72021European journal of medicinal chemistry, Oct-05, Volume: 221Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID58282Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with double (A16V + S108T) mutations2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.
AID322132In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID1723479Antimalarial activity against Plasmodium falciparum isolate GB0071 assessed as reduction in parasitemia at 1 to 10 times EC50 supplemented with fresh medium containing compounds every 24 hrs for 72 hrs relative to control2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Development of Potent
AID322129In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID57948Inhibition of recombinant Dihydrofolate reductase from Leishmania major.1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Design, synthesis, and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolate reductase.
AID518562Binding affinity to recombinant Plasmodium falciparum V1/S DHFR S108N, N51I, C59R, I164L mutant by competitive binding assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID1144004Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 20 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1227123Induction of HexA alpha G269S mutant activity in ATSD patient fibroblasts assessed as GlcCer level at 11 ug/ml incubated for 10 days by TLC method2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID1441260Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as mouse survival at 90 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID279386Growth inhibition of Plasmodium falciparum 3D7 ring stage in infected erythrocytes after 72 hrs in DAPI fluorimetry2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
AID1485240Cytotoxicity against human HeLa cells assessed as alterations in cell morphology measured after 5 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID478203Antimicrobial activity against wild-type Toxoplasma gondii RH infected in human CRL1634 cells assessed as intracellular parasite survival at 25 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID57819Inhibition of Dihydrofolate reductase (DHFR) of in rat liver1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID124999Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 10 mg/kg.1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Folate antagonists. 21. Synthesis and antimalarial properties of 2,4-diamino-6-(benzylamino)pyrido[3,2-d]pyrimidines.
AID344037Toxicity against human foreskin fibroblasts at 5 uM after 48 hrs by MTT method2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID159590Antimalarial activity as survivor number at day 60 for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 640 mg/kg subcutaneous dose over 72 hr1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides.
AID373629Inhibition of Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID1192799Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by SYBR green-based assay2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Synthesis and in vitro evaluation of novel 8-aminoquinoline-pyrazolopyrimidine hybrids as potent antimalarial agents.
AID235845Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum V1/S infected KB cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID322133In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID700784Antiplasmodial activity against Plasmodium falciparum 3D7A assessed as inhibition of [3H]hypoxanthine incorporation incubated for 24 hrs prior to [3H]hypoxanthine addition measured after 24 hrs by beta scintillation counting2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.
AID1143951Toxicity in Plasmodium berghei infected mouse assessed as mortality at 320 mg/kg, sc administered 72 hrs after infection measured after 2 to 5 days1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID519621Antimicrobial activity against Toxoplasma gondii NED infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID343766Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival after 18 hrs by [5,6-13H]uracil incorporation assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID231313Ratio of binding affinity for mutant (N51I+C59R+S108N) to that of wild type dihydrofolate reductase2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID247035Effective dose against chloroquine-resistant, pyrimethamine-resistant, mefloquine-resistant Plasmodium falciparum Dd22005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
AID1429844Ratio of IC50 for chloroquine-sensitive Plasmodium falciparum NF54 after 24 hrs to IC50 for chloroquine-sensitive Plasmodium falciparum NF54 after 72 hrs2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.
AID1437501Growth inhibition of HEK293 cells after 72 hrs by PrestoBlue staining based fluorescence assay
AID159711Antimalarial activity as survivor numbers at day 60 for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 80 mg/kg subcutaneous dose over 72 hr1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides.
AID1227122Induction of HexA alpha G269S mutant activity in ATSD patient fibroblasts assessed as LacCer level at 11 ug/ml incubated for 10 days by TLC method2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID616030Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.
AID1653497Inhibition of Mycobacterium smegmatis ATCC 607 dihydrofolic reductase assessed as ratio of Km to Ki2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID722365Partition coefficient, log D of the compound using n-octanol/PBS buffer system at pH 5.5 by HPLC method2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Synthesis, characterization and antimalarial activity of quinoline-pyrimidine hybrids.
AID1624003Selectivity ratio of IC50 for human DHFR to IC50 for Toxoplasma gondii DHFR2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID1190841Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 by SYBR Green-based method2015Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
Synthesis and biological evaluation of adamantane-based aminophenols as a novel class of antiplasmodial agents.
AID519610Antimicrobial activity against Toxoplasma gondii ENT harboring DHPS Ex2, E474D/Ex3, 156 sil Leu/Ex4, R560K/Ex5, 580 sil Gly/A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID125014Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 2.5 mg/kg.1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Folate antagonists. 21. Synthesis and antimalarial properties of 2,4-diamino-6-(benzylamino)pyrido[3,2-d]pyrimidines.
AID1190840Antiplasmodial activity against Plasmodium falciparum NF54 by SYBR Green-based method2015Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
Synthesis and biological evaluation of adamantane-based aminophenols as a novel class of antiplasmodial agents.
AID1752549Antimalarial activity against chloroquine-sensitive plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition measured after 72 hrs by SYBR green dye based fluorescence analysis2021Bioorganic & medicinal chemistry, 09-15, Volume: 46Preparation, biological & cheminformatics-based assessment of N
AID1305454Therapeutic ratio of IC50 for HEK293 cells to IC50 for Plasmodium falciparum 3D72016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Selective anti-malarial minor groove binders.
AID748916Antiplasmodial activity against Plasmodium falciparum VS/1 expressing DHFR quadruple mutation by [3H]-hypoxanthine incorporation assay2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID518312Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum clinical isolate harboring S108N, N51I mutation in DHFR assessed as decrease in parasitaemia2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID373645Ratio of IC50 for pyrimethamine-resistant form-1 Plasmodium falciparum N51I, C59R, S108N, I164L, D187A mutant to IC50 for Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID57135Cytotoxicity by selective inhibition against human dihydrofolate reductase (DHFR).2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID56459Inhibition of recombinant Dihydrofolate reductase from Trypanosoma cruzi.1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Design, synthesis, and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolate reductase.
AID373630Inhibition of WR99210-resistant form-A Plasmodium falciparum DHFR-TS I51N, C59R, N108S, L164I, D54N mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID519620Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-TOU infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID641000Inhibition of Plasmodium falciparum DHFR assessed as oxidation of NADPH to NADP+ after 15 mins spectrophotometric assay2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent.
AID1058957Inhibition of mouse Mate1 transfected in HEK293 cells assessed as uptake of [14C]-TEA preincubated for 15 mins by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
The synthesis and biodistribution of [(11)C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo.
AID91142Effect of compound on percent survival of human fibroblast cells in culture was determined at 5 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID510929Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone3 bearing P-type ATPase4 D1247Y mutations after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID233571The ratio of SD90 of the quinine hydrochloride, to the SD90 of the test substance for the Dose of 0.28 mg/kg1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID1367782Inhibition of Plasmodium falciparum DHFR using DHF as substrate preincubated for 15 mins followed DHF addition measured after 15 mins by spectrophotometric method2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely.
AID124707Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after subcutaneous administration dose of 640 mg/kg; 1 survived after 60 days of post infection1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediamines.
AID235842Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum TM4/8.2 infected KB cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID576704Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR F57L, S58R, T61M, S117T mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID1228554Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum W2 assessed as inhibition of parasite growth2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.
AID1653498Antimicrobial activity against Mycobacterium smegmatis ATCC 6072019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID774659Antimalarial activity against late (4 to 5) gametocytic stage of Plasmodium falciparum at 120 uM after 72 hrs by image-based HTS assay relative to control2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID1196724Solubility of the compound in phosphate buffered saline at pH 7.4 by UV spectrophotometry2015European journal of medicinal chemistry, Mar-06, Volume: 92Antileishmanial activity of quinazoline derivatives: synthesis, docking screens, molecular dynamic simulations and electrochemical studies.
AID1723483Antimalarial activity against Plasmodium falciparum isolate GB0026 assessed as reduction in parasitemia at 1 to 10 times EC50 measured after 24 hrs relative to control2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Development of Potent
AID459260Antimicrobial activity against Toxoplasma gondii infected in HEL cells assessed as inhibition of parasite growth by [3H]uracil incorporation assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified cross-validated r(2)-guided region selection (q(2)-GRS) routine and its initial application.
AID1145673Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 to IC50 for sensitive Streptococcus faecium ATCC 80431977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1143987Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 160 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1485242Antiviral activity against vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1145676Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 to IC50 for sensitive Lactobacillus casei ATCC 74691977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID640997Inhibition of Plasmodium falciparum DHFR assessed as oxidation of NADPH to NADP+ at 10 uM after 15 mins spectrophotometric assay2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent.
AID1368007Inhibition of bovine liver DHFR using FH2 as substrate preincubated for 2 mins followed by substrate addition2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Ionic liquid mediated stereoselective synthesis of alanine linked hybrid quinazoline-4(3H)-one derivatives perturbing the malarial reductase activity in folate pathway.
AID1145678Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID671162Inhibition of Toxoplasma gondii DHFR2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
AID1623972Efflux ratio of apparent permeability in MDCK-MDR1 cells at 2 uM after 15 mins by LC/MS/MS analysis2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID232422Ratio of inhibition of Human DHFR to Inhibition of the C59R+S108N mutant of dihydrofolate reductase (DHFR)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID58262Inhibition of the C59R+S108N mutant of dihydrofolate reductase (DHFR) relative to Pyr.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID478209Antimicrobial activity against Toxoplasma gondii infected in human CRL1634 cells assessed as intracellular parasite survival at 5 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID1485255Cytotoxicity against African green monkey Vero cells assessed as alterations in cell morphology measured after 5 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID233452Selectivity ratio of IC50 (rat liver)/IC50 (Toxoplasma gondii1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID1688326Antimalarial activity against Plasmodium falciparum 3D7 asexual forms incubated for 72 hrs by luminescence method2020European journal of medicinal chemistry, Feb-15, Volume: 188Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
AID700787Inhibition of human 5HT2c receptor expressed in CHO-K1 cells assessed as inhibition of 5HT-induced calcium influx measured up to 30 secs by aequorin luminescence assay2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.
AID1077197Resistance index, ratio of IC50 for asexual erythrocytic stage of chloroquine-resistant Plasmodium falciparum Dd2 to IC50 for asexual erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF542014European journal of medicinal chemistry, Apr-09, Volume: 76Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID1774076Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID119306Number of mice cured at a subcutaneous dose of 320 mg/kg.1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID58254Inhibition of the S108N mutant of dihydrofolate reductase (DHFR)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID1779232Antimalarial activity against Plasmodium falciparum 3D7 assessed as reduction in parasite growth measured after 72 hrs by Monash assay based fluorescence analysis2021European journal of medicinal chemistry, Oct-05, Volume: 221Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID210627Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 10 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID1833136Anti-bradyzoite activity against Toxoplasma gondii ESG reporter strain infected in NHDF cells assessed as induced cyst formation at 2 uM measured after 5 days under alkaline condition by TEM analysis2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID565414Antimalarial activity against Plasmodium falciparum Pf3D70087/N9 infected in immunodeficient HM-IL2Rgamma null mouse after 7 days2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID668287Antitoxoplasmic activity against Toxoplasma gondii PRU tachyzoites infected in human HFF cells assessed as beta-galactosidase activity after 72 hrs by colorimetric assay2012European journal of medicinal chemistry, Aug, Volume: 54Discovery of a new antileishmanial hit in 8-nitroquinoline series.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1441254Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as mouse survival at 10 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID373626Inhibition of pyrimethamine-resistant form-1 Plasmodium falciparum N51I, C59R, S108N, I164L, D187A mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID1143938Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 20 mg/kg, sc administered 72 hrs after infection relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID91139Effect of compound on percent survival of human fibroblast cells in culture was determined at 0 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID1367780Inhibition of Plasmodium falciparum DHFR at 10 uM using DHF as substrate preincubated for 15 mins followed DHF addition measured after 15 mins by spectrophotometric method2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID356810Activation of on beta Hex A beta C137Y/C137Y mutant in enriched lysosomal fraction of fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity per mg of protein at 3 mg/ml by relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID57975Inhibitory activity against dihydrofolate reductase in rat.1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID119305Number of mice cured at a subcutaneous dose of 160 mg/kg.1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID394668Antiplasmodial activity against Plasmodium falciparum2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Genetic analysis of the dihydrofolate reductase-thymidylate synthase gene from geographically diverse isolates of Plasmodium malariae.
AID356812Pharmacological chaperone effect on beta Hex A alpha G269S/IV6 + 1G>A mutant in fibroblasts from Tay-Sachs disease patient assessed as increase in HEX A activity relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1227105Toxicity against ATSD patient fibroblasts assessed as reduction in cell viability up to 400 uM by almar blue assay2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID1135021Antimalarial activity against Plasmodium falciparum Vietnam Oak Knoll in po once daily dosed Owl monkey assessed as curative dose compound treated for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1774079Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1505094Antiplasmodial activity against drug-sensitive blood stage Plasmodium falciparum 3D7 by SYBR green 1 staining based fluorescence assay2018Journal of natural products, 01-26, Volume: 81, Issue:1
Isolation, Derivative Synthesis, and Structure-Activity Relationships of Antiparasitic Bromopyrrole Alkaloids from the Marine Sponge Tedania brasiliensis.
AID1611294Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay2019Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24
6-Hydrophobic aromatic substituent pyrimethamine analogues as potential antimalarials for pyrimethamine-resistant Plasmodium falciparum.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1457211Antimalarial activity against Plasmodium falciparum Dd2 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting 2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1145685Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction in growth in presence of 0.001 ug/ml folinic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID373633Inhibition of WR99210-resistant form-A Plasmodium falciparum DHFR-TS I51N, C59R, N108S, L164I, D54N mutant expressed in Escherichia coli BL21(DE3)2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID268784Inhibition of Pneumocystis carinii DHFR2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Analysis of complexes of inhibitors with Cryptosporidium hominis DHFR leads to a new trimethoprim derivative.
AID671160Inhibition of human DHFR2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
AID519617Antimicrobial activity against Toxoplasma gondii isolate GRE-1995-MAE infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1533256Antiplasmodial activity against Plasmodium falciparum K1CB1 harboring DHFR NRNI haplotype C59R/S108N double mutant2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
AID158541In vitro anti-plasmodial activity against Plasmodium falciparum dihydrofolate reductase CN51I/C59R/S108N/I164L (V1/S) mutant2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID748917Antiplasmodial activity against wild type Plasmodium falciparum TM4 by [3H]-hypoxanthine incorporation assay2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID232860Safety ratio is cytotoxicity to KB cells/IC50 K1.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID322135Antimalarial activity against Plasmodium falciparum W2 as reduced [3H]hypoxanthine uptake after 72 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID1143940Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 5 mg/kg, sc administered 72 hrs after infection relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID700788Selectivity ratio of IC50 for plasmodium falciparum 3D7A to IC50 for human 5HT2c receptor2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.
AID1833120Anti-tachyzoite activity against RFP-expressing Toxoplasma gondii RH Type 1 infected in NHDF cells assessed as plaque formation at 4 uM incubated for 96 hrs followed by removal of medium containing compounds and subsequent addition of fresh medium without2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID1457214Antimalarial activity against Plasmodium falciparum D6 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting m2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID518561Binding affinity to wild type Plasmodium falciparum DHFR by competitive binding assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID1135040Toxicity in Owl monkey administered as po qd for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1485247Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444879Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 blood stream form by Alamar blue assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness and the leishmaniases.
AID1450025Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 measured after 72 hrs by DAPI staining based high throughput screening assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Antiplasmodial β-triketones from the flowers of the Australian tree Angophora woodsiana.
AID722364Partition coefficient, log D of the compound using n-octanol/PBS buffer system at pH 7.4 by HPLC method2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Synthesis, characterization and antimalarial activity of quinoline-pyrimidine hybrids.
AID607064Antimalarial activity against Plasmodium falciparum Mad202011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Antimalarial pyrido[1,2-a]benzimidazoles.
AID1182789Antiplasmodial activity against Plasmodium falciparum 7G8 harboring mutations conferring drug-resistance by SYBR-green based assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID1723470Antimalarial activity against chloroquine-sensitive synchronized ring stage of Plasmodium falciparum 3D7 incubated for 48 to 52 hrs by SYBR green 1 dye based assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Development of Potent
AID1639288Selectivity index, ratio of IC50 for HEK293 cells to IC50 for drug-sensitive Plasmodium falciparum 3D7 ring stage forms2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID1667071Antiproliferative activity in human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTS assay2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID560256Antimalarial activity against Plasmodium falciparum Kenyan isolates expressing DHFR Ser108Asn and Cys59Arg or Ser108Asn and Asn51Ile double mutant by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.
AID1228555Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum V1/S assessed as inhibition of parasite growth2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.
AID361330Effect on acid phosphatase in fibroblasts with Hex A alpha-G269S/ins1278TACT mutation isolated from Tay-Sachs disease patient2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1227116Induction of lysosomal transport of HexA alpha G269S mutant in ATSD patient fibroblasts at 11 ug/ml incubated for 5 days by Western blotting method2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID1457220Antimalarial activity against intraerythrocytic stage of Plasmodium falciparum assessed as parasite reduction ratio at 10 times IC50 preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting method2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1134958Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as change in mean survival time at 20 mg/kg, sc single dose after 72 hrs of infection1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1355873Cytotoxicity against human HEK293 cells at 40 uM after 72 hrs by resazurin dye based fluorescence assay2018Journal of natural products, 07-27, Volume: 81, Issue:7
Antiplasmodial β-Triketone-Flavanone Hybrids from the Flowers of the Australian Tree Corymbia torelliana.
AID159446Antimalarial activity as survivor numbers at day 60 against drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 160 mg/kg subcutaneous dose after 72 hr1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides.
AID444882Ratio of ED50 for Trypanosoma brucei brucei Lister 427 to Ki for Leishmania major DHFR2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness and the leishmaniases.
AID1833148Anti-bradyzoite activity against Toxoplasma gondii ESG reporter stain infected in NHDF cells assessed as viable cells recovery causing host cell lysis at 2 uM measured after 15 days by optical microscopic analysis2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID1625412Antiplasmodial activity against chloroquine/antifolate-sensitive Plasmodium falciparum TM4 infected in human RBC incubated for 18 to 20 hrs by microdilution radioisotope method2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Antimalarial Oxoprotoberberine Alkaloids from the Leaves of Miliusa cuneata.
AID1462732Antimalarial activity against Plasmodium falciparum2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.
AID57972Inhibitory activity against rat liver Dihydrofolate reductase1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID58251Binding affinity towards mutant dihydrofolate reductase (N51I+C59R+S108N+I164L DHFR) of Plasmodium falciparum2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID210619Inhibition of Toxoplasma gondii cell growth1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID747613Inhibition of Pneumocystis jirovecii recombinant DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID576697Antimalarial activity against Plasmodium falciparum D6 infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID65357Inhibition of growth of methotrexate-sensitive (MB1417) strain of Escherichia coli cells.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Quantitative structure-activity relationship of antifolate inhibition of bacteria cell cultures resistant and sensitive to methotrexate.
AID1437504Selectivity index, ratio of IC50 for HEK293 cells to IC50 for chloroquine-sensitive Plasmodium falciparum 3D7 infected in human RBC
AID235846Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum V1/S infected Vero cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID245149Minimum inhibitory concentration against schizont maturation in Plasmodium falciparum NF-542005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Antimalarial activity and synthesis of new trisubstituted pyrimidines.
AID1533249Inhibition of human DHFR2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
AID1457209Antimalarial activity against Plasmodium falciparum TM90C2A infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation count2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID55826Inhibition of dihydrofolate reductase DHFR in Pneumocystis carinii.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase.
AID683369Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in red blood cells up to 19 uM after 72 hrs by parasitic LDH assay2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
Novel 4-aminoquinoline-pyrimidine based hybrids with improved in vitro and in vivo antimalarial activity.
AID124692Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after subcutaneous administration dose of 320 mg/kg; 3 toxic deaths after 2-5 days of injection1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediamines.
AID1441253Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as time duration for parasite cure at 10 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysi2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID356808Activation of on beta Hex A beta C137Y/C137Y mutant in postnuclear supernatant of fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity per mg of protein at 3 mg/ml by relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1623996Antiparasitic activity against Toxoplasma gondii RH in naive mouse receiving brain/lung tissue homogenate of 18 mg/kg, po bid for 7 days dosed CD1 mouse assessed as infection cure rate measured after 15 days post homogenate injection relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID1436318Antimalarial activity against intraerythrocytic stage of Plasmodium falciparum 3D7A assessed as log (viable parasites +1) at 10 times IC50 after 24 hrs by [3H]-hypoxanthine incorporation assay (Rvb = 5 No_unit)2017European journal of medicinal chemistry, Jan-27, Volume: 126Novel inhibitors of Plasmodium falciparum based on 2,5-disubstituted furans.
AID55851Binding affinity was reported with purified recombinant Pneumocystis carinii Dihydrofolate reductase1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID1059660Antibacterial activity against tachyzoite stage of Toxoplasma gondii PHdeltaHX infected in human TerT cells measured after 4 days
AID1077195Selectivity index, ratio of IC50 for CHO cells to IC50 for asexual erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF542014European journal of medicinal chemistry, Apr-09, Volume: 76Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID341469Inhibition of Escherichia coli dihydrofolate reductase2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID372374Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-6 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis.
AID55836Inhibitory activity against dihydrofolate reductase in Pneumocystis carinii at 37 centigrade.1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID1439481Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability up to 10 uM after 48 hrs by neutral red assay2017European journal of medicinal chemistry, Mar-31, Volume: 129Synthesis, antimalarial activity, heme binding and docking studies of N-substituted 4-aminoquinoline-pyrimidine molecular hybrids.
AID341472Selectivity for sToxoplasma gondii dihydrofolate reductase over human dihydrofolate reductase2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID1462733Inhibition of bovine liver DHFR2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID668289Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Discovery of a new antileishmanial hit in 8-nitroquinoline series.
AID1623971Apparent permeability from apical to basolateral side in MDCK-MDR1 cells at 2 uM after 15 mins by LC/MS/MS analysis2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID57601Ratio of Kd to Ki of compound for wild type Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID116380Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 80 mg/kg subcutaneous dose; no data1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID1143942Antimalarial activity against Plasmodium berghei infected in mouse assessed as increase in mean survival days of host at 1.25 mg/kg, sc administered 72 hrs after infection relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1639284Antiplasmodial activity against drug-resistant Plasmodium falciparum Dd2 ring stage forms assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID91143Effect of compound on percent survival of human fibroblast cells in culture was determined at 50 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID356805Pharmacological chaperone effect on beta Hex A beta-P504S/delta16kb mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity at 3 ug/ml by immunoselection assay relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID356785Pharmacological chaperone effect on beta Hex A beta-C137Y/C137Y mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity at 3 ug/ml by immunoselection assay relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID58119Thermodynamic dissociation constant of compound for mutant S108 Plasmodium falciparum dihydrofolate reductase; ND=no data1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID1228553Antimalarial activity against Plasmodium falciparum 3D7A infected in red blood cells assessed as inhibition of parasite growth after 24 hrs by [3H]hypoxanthine incorporation assay2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.
AID1058954Unbound plasma concentration in ddY mouse at 5 mg/kg2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
The synthesis and biodistribution of [(11)C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo.
AID1143999Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 40 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID576698Antimalarial activity against Plasmodium falciparum TM91c235 harboring DHFR F57L, S58R, T61M, S117T mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID510928Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone2 bearing P-type ATPase4 T418N and P990R mutations after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID1505096Antiplasmodial activity against chloroquine/cycloguanil/pyrimethamine-resistant blood stage Plasmodium falciparum K1 by SYBR green 1 staining based fluorescence assay2018Journal of natural products, 01-26, Volume: 81, Issue:1
Isolation, Derivative Synthesis, and Structure-Activity Relationships of Antiparasitic Bromopyrrole Alkaloids from the Marine Sponge Tedania brasiliensis.
AID747614Inhibition of human recombinant DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID1441245Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as mouse survival at 5 mg/kg, sc administered QD for 4 days starting at 2 hrs post infection by Giemsa-staining based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1667070Antiproliferative activity in human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTS assay2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID235840Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum Csl-2 infected Vero cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID1538873Antimalarial activity against Plasmodium falciparum FCR3 infected in human erythrocytes by Giemsa staining analysis2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Green synthesis, biological evaluation, molecular docking studies and 3D-QSAR analysis of novel phenylalanine linked quinazoline-4(3H)-one-sulphonamide hybrid entities distorting the malarial reductase activity in folate pathway.
AID1355868Antiplasmodial activity against drug-sensitive Plasmodium falciparum 3D7 ring stage infected in human erythrocytes after 72 hrs by DAPI staining based method2018Journal of natural products, 07-27, Volume: 81, Issue:7
Antiplasmodial β-Triketone-Flavanone Hybrids from the Flowers of the Australian Tree Corymbia torelliana.
AID56318Inhibitory activity against Toxoplasma gondii dihydrofolate reductase1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID58285Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with single S108T mutation2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.
AID1611284Selectivity ratio of Ki for Plasmodium falciparum dihydrofolate reductase N51I/C59R/S108N/I164L quadruple mutant expressed in Escherichia coli BL21(DE3)pLysS to Ki for wild type Plasmodium falciparum TM4/8.2 dihydrofolate reductase expressed in Escherichi2019Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24
6-Hydrophobic aromatic substituent pyrimethamine analogues as potential antimalarials for pyrimethamine-resistant Plasmodium falciparum.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1534798Anti-plasmodial activity against chloroquine resistant Plasmodium falciparum RKL9 infected in human erythrocytes after 24 hrs by Giemsa staining-based method2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis, in silico experiments and biological evaluation of 1,3,4-trisubstituted pyrazole derivatives as antimalarial agents.
AID1779233Antimalarial activity against synchronous ring stage of Plasmodium falciparum 3D7 assessed as parasite growth inhibition incubated for 72 hrs by Griffith assay based fluorescence analysis2021European journal of medicinal chemistry, Oct-05, Volume: 221Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID373627Inhibition of WR99210-resistant form-3 Plasmodium falciparum N51I, C59R, N108T, I164L mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID683344Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
Novel 4-aminoquinoline-pyrimidine based hybrids with improved in vitro and in vivo antimalarial activity.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1611289Selectivity ratio of Ki for human dihydrofolate reductase to Ki for Plasmodium falciparum dihydrofolate reductase N51I/C59R/S108N/I164L quadruple mutant2019Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24
6-Hydrophobic aromatic substituent pyrimethamine analogues as potential antimalarials for pyrimethamine-resistant Plasmodium falciparum.
AID700786Antiplasmodial activity against Plasmodium falciparum Dd2 assessed as inhibition of [3H]hypoxanthine incorporation incubated for 24 hrs prior to [3H]hypoxanthine addition measured after 24 hrs by beta scintillation counting2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.
AID158556In vitro inhibition of Plasmodium falciparum HB3 (S108N) culture1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria.
AID116248Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at dosage of 320 mg/kg after subcutaneous administration; no data1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID772516Antimalarial activity against mature gametocytic stage of Plasmodium falciparum assessed as inhibition of mature gamete exflagellation at 10 uM incubated for 24 hrs prior to exflagellation induction at 21 degC measured after 20 mins by microscopic analysi2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID356801Pharmacological chaperone effect on beta Hex A beta-R505Q/IVS11 + 5G>A mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity at 3 ug/ml by immunoselection assay relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID519619Antimicrobial activity against Toxoplasma gondii isolate GRE-1998-TRA infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID685501HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells2012Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID559547Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum V1S expressing DHFR quadruple mutant with point mutations at codons 108, 51, 59 and 164 gene by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.
AID116238Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after 20 mg/kg subcutaneous dose1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID124556Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after subcutaneous dose of 10 mg/kg1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediamines.
AID158542In vitro anti-plasmodial activity against Plasmodium falciparum dihydrofolate reductase N51I/C59R/S108N (W2)2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID57074Inhibition of dihydrofolate reductase in Candida albicans (in vitro).1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines.
AID1071119Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 100 ug/ml after 7 days by microplate Alamar blue assay relative to control2014European journal of medicinal chemistry, Mar-03, Volume: 74Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.
AID518564Selectivity ratio of Ki for human recombinant DHFR to Ki for wild type Plasmodium falciparum DHFR2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID543835Antimalarial activity against chloroquine-sensitive Plasmodium berghei ATCC 50175 infected in ICR mouse assessed as parasitemia at 1.2 mg/kg/day, po pretreated for 4 days before infection and measured after 72 hrs (Rvb = 4.6+/-0.21 %)2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Antimalarial activity of a new stilbene glycoside from Parthenocissus tricuspidata in mice.
AID733054Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines acting as antimycobacterial agents.
AID373628Inhibition of WR99210-resistant form-1 Plasmodium falciparum I51N, C59R, N108S, I164L mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID576708Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S58R, T61M and S117N mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID1475979Antiparasitic activity against parasite infected CBA/J mouse brain derived Toxoplasma gondii ME49 harboring delta hx::FLUC mutant derived infected in HFF assessed as reduction in plaque formation at 3 uM exposed for continuous 10 to 14 days2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii.
AID596016Antiparasitic activity against green fluorescent protein expressing hwgprt deficient Toxoplasma gondii RH infected in HFF assessed as reduction of ycf24/UPRT genes copy number ratio at 1 uM treated for 48 hrs immediately after infection followed by reinoc2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Chemistry and biology of macrolide antiparasitic agents.
AID1196722Antiparasitic activity against promastigote form of Leishmania mexicana MHOM/BZ/61/M379 at 100 uM after 24 hrs by haemocytometer2015European journal of medicinal chemistry, Mar-06, Volume: 92Antileishmanial activity of quinazoline derivatives: synthesis, docking screens, molecular dynamic simulations and electrochemical studies.
AID1485235Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID57269Thermodynamic dissociation constant of compound for wild type Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID116373Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 640 mg/kg subcutaneous dose1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID56179Inhibitory concentration against Toxoplasma gondii dihydrofolate reductase1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase.
AID268783Inhibition of Plasmodium falciparum DHFR2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Analysis of complexes of inhibitors with Cryptosporidium hominis DHFR leads to a new trimethoprim derivative.
AID1227114Inhibition of human placental HexB using MUGS substrate incubated for 1 to 2 hrs at pH 7.0 by spectrofluorometry2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID549613Antimalarial activity against multidrug-resistant Plasmodium falciparum TM91C235 assessed as inhibition of [3H]hypoxanthine uptake in presence of 1 mM folinic acid2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
In vitro efficacy of 7-benzylamino-1-isoquinolinamines against Plasmodium falciparum related to the efficacy of chalcones.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID356817Pharmacological chaperone effect on beta Hex A beta G353R/IVS12-26G>A mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID373636Inhibition of WR99210-resistant form-1 Plasmodium falciparum I51N, C59R, N108S, I164L mutant expressed in Escherichia coli BL21(DE3)2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID356787Pharmacological chaperone effect on beta Hex A beta-T150P/P417L mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity at 3 ug/ml by immunoselection assay relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID373644Ratio of IC50 for WR99210-resistant form-3 Plasmodium falciparum N51I, C59R, N108T, I164L mutant to IC50 for Plasmodium falciparum DHFR QM template N51I, C59R, S108N, I164L mutant2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID232867Safety ratio is cytotoxicity to vero cells/IC50 K1.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID1616619Antiplasmodial activity against Plasmodium falciparum 3D7A erythrocytic stage assessed as reduction in [3H]hypoxanthine incorporation preincubated for 24 hrs followed by [3H]hypoxanthine addition and measured after 24 hrs by microbeta scintillation counti2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Development of Chemical Entities Endowed with Potent Fast-Killing Properties against
AID1143953Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as daily dose required to suppression of 90% parasite infection administered with diet for 6 days1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1441252Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as parasite growth inhibition at 10 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID55705Inhibition of Dihydrofolate reductase of Pneumocystis carinii1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID529905Antiplasmodial activity against Plasmodium falciparum harboring K1 allele group of msp1, 3D7 allele group of msp2 gene and 94 bp of 7A11, 196bp of C4M79 and 336bp of C4M69 locus measured on day 23 by [3H]hypoxanthine incorporation assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.
AID1812457Antiplasmodial activity against synchronized ring stage Plasmodium falciparum 3D7 assessed as parasite reduction over one cycle upto 48 hrs at 10 times IC50 concentration2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID344040Toxicity against human foreskin fibroblasts at 50 uM after 48 hrs by MTT method2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID519612Antimicrobial activity against Toxoplasma gondii isolate RMS-1995-ABE harboring DHPS Ex5, A587V mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID234733Selectivity ratio of IC50 value against rat liver DHFR to that of Pneumocystis carinii DHFR1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID1182790Antiplasmodial activity against Plasmodium falciparum W2 harboring mutations conferring drug-resistance by SYBR-green based assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID57405Inhibitor constant of compound for mutant T46A Escherichia coli dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID210630Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 50 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID1485249Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1504883Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 72 hrs by DAPI staining based confocal microplate imaging method2017Journal of natural products, 12-22, Volume: 80, Issue:12
Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID58283Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with quadruple (N51I + C59R + S108N + I164L) mutations2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.
AID233653Selectivity ratio of IC50(rat liver)/IC50(Toxoplasma gondii)2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase.
AID1174526Cytotoxicity against African green monkey Vero cells after 72 hrs by neutral red assay2015European journal of medicinal chemistry, Jan-07, Volume: 894-Aminoquinoline-pyrimidine hybrids: synthesis, antimalarial activity, heme binding and docking studies.
AID1441246Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as parasite growth inhibition at 10 mg/kg, sc administered QD for 4 days starting at 96 hrs post infection by Giemsa-staining based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID1145684Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth in presence of 0.001 ug/ml folic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID601644Plasma protein binding in human by albumin chromatographic method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
AID1623975Selectivity ratio of EC50 for human MCF7 cells to EC50 for parasiticidal activity against bacterial beta-galactosidase expressing Toxoplasma gondii I RH 2F clone infected in HFF cells2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID1441248Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as mouse survival at 10 mg/kg, sc administered QD for 4 days starting at 96 hrs post infection by Giemsa-staining based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID122508Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 5 mg/kg.1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Folate antagonists. 21. Synthesis and antimalarial properties of 2,4-diamino-6-(benzylamino)pyrido[3,2-d]pyrimidines.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID519618Antimicrobial activity against Toxoplasma gondii isolate PSP-2005-MUP infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID607060Antimalarial activity against Plasmodium falciparum HB32011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Antimalarial pyrido[1,2-a]benzimidazoles.
AID1723475Antimalarial activity against Plasmodium falciparum isolate GB0006 assessed as reduction in parasitemia at 1 to 10 times EC50 supplemented with fresh medium containing compounds every 24 hrs for 72 hrs relative to control2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Development of Potent
AID235851Selectivity ratio is the ratio between the IC50 values of rat liver and Toxoplasma gondii1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID1574647Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1688347Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd22020European journal of medicinal chemistry, Feb-15, Volume: 188Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
AID58286Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with triple (C59R + S108N + I164L) mutations2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.
AID1623968Selectivity ratio of IC50 for human DHFR to IC50 for Toxoplasma gondii DHFR-TS2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID124835Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after subcutaneous administration dose of 80 mg/kg; 3 survived after 60 days of postinfection1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediamines.
AID1145687Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth in presence of p-aminobenzoic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1533244Inhibition of Plasmodium falciparum TM4/8.2 wild type DHFR NCSI haplotype2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
AID320500Antimalarial activity against Plasmodium falciparum NF54 after 36-40 hrs2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Design, synthesis and antimalarial activity of benzene and isoquinoline sulfonamide derivatives.
AID1611282Competitive inhibition of Plasmodium falciparum dihydrofolate reductase N51I/C59R/S108N/I164L quadruple mutant expressed in Escherichia coli BL21(DE3)pLysS using dihydrofolate as substrate in presence of NADPH by UV-vis spectrophotometry analysis2019Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24
6-Hydrophobic aromatic substituent pyrimethamine analogues as potential antimalarials for pyrimethamine-resistant Plasmodium falciparum.
AID1723477Antimalarial activity against Plasmodium falciparum isolate GB0021 assessed as reduction in parasitemia at 1 to 10 times EC50 supplemented with fresh medium containing compounds every 24 hrs for 72 hrs relative to control2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Development of Potent
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID356814Activation of on beta Hex A beta R505Q/IVS11 + 5G>A mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID722367Aqueous solubility in pH 5.5 PBS buffer at 37 degC incubated for 24 hrs by HPLC method2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Synthesis, characterization and antimalarial activity of quinoline-pyrimidine hybrids.
AID1261838Cytotoxicity against HFF assessed as cell proliferation after 96 hrs by alamar blue reduction assay2015European journal of medicinal chemistry, Nov-13, Volume: 105Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1.
AID248631Inhibitory concentration against cycloguanil sensitive Plasmodium falciparum FJB-D4 2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
1-Aryl-4,6-diamino-1,2-dihydrotriazine as antimalarial agent: a new synthetic route.
AID158852Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes by semiautomated micro dilution2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
AID158852Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes by semiautomated micro dilution2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
AID1624002Antiparasitic activity against Toxoplasma gondii RH infected in CD1 mouse assessed as improvement in mouse survival administered orally once daily or twice daily starting on day 1 post infection through day 7 and measured after 30 days relative to control2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID235838Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum Csl-2 infected BC cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID247058Effective dose against chloroquine-resistant, pyrimethamine-resistant, mefloquine-sensitive Plasmodium falciparum K12005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
AID683345Cytotoxicity against pig LLC-PK11 cells after 48 hrs by neutral red assay2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
Novel 4-aminoquinoline-pyrimidine based hybrids with improved in vitro and in vivo antimalarial activity.
AID124705Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 5 mg/kg subcutaneous dose1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediamines.
AID1227100Inhibition of human placental HexB using MUGS substrate incubated for 1 to 2 hrs at pH 4.5 by spectrofluorometry2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID1485251Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1504885Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay2017Journal of natural products, 12-22, Volume: 80, Issue:12
Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID210629Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 5 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID554324Antileishmanial activity against Leishmania major MHOM/SU/73/5-ASKH assessed as growth at 50 ug/ml by Alamar blue assay2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.
AID1457208Antimalarial activity against Plasmodium falciparum HB3 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting 2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID356799Pharmacological chaperone effect on beta Hex A beta-R505Q/IVS11 + 5G>A mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity at 3 ug/ml by immunoselection assay relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID249024Inhibitory concentration sensitive Plasmodium falciparum FJB-D9 2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
1-Aryl-4,6-diamino-1,2-dihydrotriazine as antimalarial agent: a new synthetic route.
AID1441258Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as parasite growth inhibition at 90 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID235839Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum Csl-2 infected KB cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID518565Selectivity ratio of Ki for recombinant Plasmodium falciparum V1/S DHFR S108N, N51I, C59R, I164L mutant to Ki for wild type Plasmodium falciparum DHFR2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID247087Effective dose against chloroquine-resistant, pyrimethamine-resistant, mefloquine-sensitive Plasmodium falciparum W2; Not determined2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
AID58120Thermodynamic dissociation constant of compound for Plasmodium falciparum dihydrofolate reductase; ND=no data1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID158864Antimalarial activity against Plasmodium falciparum 3D7 in erythrocytes2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1155472Antiplasmodial activity against Plasmodium falciparum SB1 after 72 hrs by SYBR I method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
AID210626Effect of compound on percent survival of wild type (RH) strain of Toxoplasma gondii grown in human fibroblast cells at 0 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID616033Cytotoxicity against human HFF cells after 72 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.
AID518313Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum clinical isolate harboring S108N, C59R mutation in DHFR assessed as decrease in parasitaemia2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID159452Antimalarial activity as survivor numbers at day 60 against drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 20 mg/kg subcutaneous dose after 72 hr1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides.
AID519616Antimicrobial activity against Toxoplasma gondii isolate RMS-2005-HAG infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1587114Plasmodicidal activity against Plasmodium falciparum 3D7A infected in CFDA-SE-labelled erythrocytes assessed as parasite killing at 10 times EC50 treated for 24 to 48 hrs following media refreshment for every 24 hrs by FACS analysis2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Synthesis, Profiling, and in Vivo Evaluation of Cyclopeptides Containing
AID233450Selectivity ratio of IC50 (rat liver)/IC50 (Pneumocystis carinii)1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID373639Inhibition of pyrimethamine-resistant form-1 Plasmodium falciparum N51I, C59R, S108N, I164L, D187A mutant expressed in Escherichia coli BL21(DE3)2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID116237Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at dosage of 160 mg/kg after subcutaneous administration; no data1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID1611290Antimalarial activity against Plasmodium falciparum TM4/8.2 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation pretreated for 24 hrs followed by [3H]-hypoxanthine addition measured after 18 hrs by liquid scintillation 2019Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24
6-Hydrophobic aromatic substituent pyrimethamine analogues as potential antimalarials for pyrimethamine-resistant Plasmodium falciparum.
AID576703Antimalarial activity against Plasmodium falciparum D6 harboring Plasmodium vivax DHFR S58R, T61M and S117N mutant infected in RBCs assessed as inhibition of [3H]hypoxanthine incorporation after 72 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID747612Selectivity ratio of IC50 for human recombinant DHFR to IC50 for Pneumocystis jirovecii recombinant DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID1667085Inhibition of STAT3 in human MDA-MB-231 cells assessed as change in Bcl-2 expression at 50 o 100 uM after 24 hrs by western blot analysis2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID125024Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 320 mg/kg; 2 cured and 3 toxic death1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Folate antagonists. 21. Synthesis and antimalarial properties of 2,4-diamino-6-(benzylamino)pyrido[3,2-d]pyrimidines.
AID1713723Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
A facile stereoselective synthesis of dispiro-indeno pyrrolidine/pyrrolothiazole-thiochroman hybrids and evaluation of their antimycobacterial, anticancer and AchE inhibitory activities.
AID1441243Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as parasite growth inhibition at 5 mg/kg, sc administered QD for 4 days starting at 2 hrs post infection by Giemsa-staining based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID1155471Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR I method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
AID189629The capillary permeability of radioligand was measured in Rat brain1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability.
AID58252Inhibition constant against wild-type PfDHFR (Plasmodium falciparum dihydrofolate reductase)2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.
AID519623Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-DJO infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1135019Toxicity in chloroquine-sensitive, pyrimethamine-resistant Plasmodium falciparum Malayan Camp CH/Q infected in Aotus monkey compound treated for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID322128In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs by SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID373638Inhibition of WR99210-resistant form-3 Plasmodium falciparum N51I, C59R, N108T, I164L mutant expressed in Escherichia coli BL21(DE3)2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID211988Binding affinity was evaluated as inhibition of recombinant wild type (WT) Plasmodium falciparum DHFR-TS.1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria.
AID1441257Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as mouse survival at 30 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID1327822Selectivity ratio of IC50 for human DHFR to IC50 for Toxoplasma gondii DHFR2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Discovery of Potent and Selective Leads against
AID90977Percentage growth inhibition of Toxoplasma gondii at concentration of 2 ug/mL using an human myelomonocytic cell line THP-12000Bioorganic & medicinal chemistry letters, May-01, Volume: 10, Issue:9
Quinonic derivatives active against a virulent strain of Toxoplasma gondii. Synthesis of 2-methylfuro[2,3-g]- and [3,2-g]isoquinolinetriones.
AID159582Antimalarial activity as change in MST for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 40 mg/kg subcutaneous dose over 72 hr1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides.
AID138101Dose needed to increase the survival of treated animals(mouse), to twice the number of days2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials.
AID343763Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival at 10 uM after 18 hrs by [5,6-13H]uracil incorporation assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID1329802Inhibition of trophozoite stage of Plasmodium falciparum DHFR assessed as reduction in NADPH depletion at 50 uM incubated for 30 mins followed by NADPH addition measured for 30 mins at 15 secs interval by UV/Vis spectrophotometric analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and evaluation of naphthyl bearing 1,2,3-triazole analogs as antiplasmodial agents, cytotoxicity and docking studies.
AID1853163Antimalarial activity against chloroquine sensitive Plasmodium falciparum 3D7 infected in human RBC assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green dye based fluorescence assay2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Preparation, biological evaluation and QSAR analysis of urea substituted 2,4-diamino-pyrimidine anti-malarials.
AID1504882Growth inhibition of chloroquine-resistant Plasmodium falciparum Dd2 at 40 uM after 72 hrs by DAPI staining based confocal microplate imaging method relative to control2017Journal of natural products, 12-22, Volume: 80, Issue:12
Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID1723481Antimalarial activity against Plasmodium falciparum isolate GB0020 assessed as reduction in parasitemia at 1 to 10 times EC50 measured after 24 hrs relative to control2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Development of Potent
AID607062Antimalarial activity against Plasmodium falciparum FC272011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Antimalarial pyrido[1,2-a]benzimidazoles.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1589588Inhibition of Leishmania major pteridine reductase 1 using di-hydrobiopterine as substrate in presence of NADPH2019Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8
Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.
AID248632Inhibitory concentration against cycloguanil sensitive Plasmodium falciparum FJB-D9 2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
1-Aryl-4,6-diamino-1,2-dihydrotriazine as antimalarial agent: a new synthetic route.
AID427683Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Synthesis and in vitro antiplasmodial evaluation of 4-anilino-2-trichloromethylquinazolines.
AID58255Inhibition of the wild-type dihydrofolate reductase (DHFR)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID747609Selectivity ratio of IC50 for rat liver DHFR to IC50 for Mycobacterium avium DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID1485244Cytotoxicity against dog MDCK cells assessed as alterations in normal cell morphology measured after 5 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1145674Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1723482Antimalarial activity against Plasmodium falciparum isolate GB002 assessed as reduction in parasitemia at 1 to 10 times EC50 measured after 24 hrs relative to control2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Development of Potent
AID1227109Toxicity against ATSD patient fibroblasts assessed as reduction in beta-galactosidase activity at >400 uM2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID1274586Cytotoxicity against HEK293 cells assessed as cell viability at 40 uM after 72 hrs by resazurin-based plate reader analysis2015Journal of natural products, Dec-24, Volume: 78, Issue:12
Rotenoids, Flavonoids, and Chalcones from the Root Bark of Millettia usaramensis.
AID373648Inhibition of WR99210-resistant form-2 Plasmodium falciparum N51I, C59R, N108S, I164L mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID1192798Antimalarial activity against drug-sensitive Plasmodium falciparum NF54 by SYBR green-based assay2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Synthesis and in vitro evaluation of novel 8-aminoquinoline-pyrazolopyrimidine hybrids as potent antimalarial agents.
AID1227102Inhibition of human placental HexA using pNPGlcNAc substrate2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID722366Solubility in octanol at pH 5.52013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Synthesis, characterization and antimalarial activity of quinoline-pyrimidine hybrids.
AID1182794Resistance index, ratio of IC50 for Plasmodium falciparum 7G8 to IC50 for Plasmodium falciparum NF542014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID576706Ratio of IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax DHFR F57L and S117N mutant to IC50 for Plasmodium falciparum D6 harboring Plasmodium vivax wild type DHFR2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID95488Cytotoxicity against human epidermoid carcinoma KB cell.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID1723478Antimalarial activity against Plasmodium falciparum isolate GB0048 assessed as reduction in parasitemia at 1 to 10 times EC50 supplemented with fresh medium containing compounds every 24 hrs for 72 hrs relative to control2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Development of Potent
AID1202552Cytotoxicity against African green monkey Vero cells after 24 hrs by MTT assay2015European journal of medicinal chemistry, , Volume: 96Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents.
AID122509Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 640 mg/kg; 1 cured and 2 toxic death1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Folate antagonists. 21. Synthesis and antimalarial properties of 2,4-diamino-6-(benzylamino)pyrido[3,2-d]pyrimidines.
AID1533242Selectivity ratio of Ki for human DHFR to Ki for Plasmodium falciparum V1/S DHFR IRNL haplotype N51I/C59R/S108N/I164L quadruple mutant2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
AID427686Antitoxoplasmic activity against Toxoplasma gondii tachyzoites infected in HFF assessed as beta-galactosidase activity after 96 hrs by colorimetric microtiter assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Synthesis and in vitro antiplasmodial evaluation of 4-anilino-2-trichloromethylquinazolines.
AID373625Inhibition of pyrimethamine-resistant form-2 Plasmodium falciparum N51I, C59R, S108N, I164L, K96N mutant expressed in Escherichia coli BL21(DE3) by Michaelis-Menten based competitive inhibition assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID722361Solubility in octanol at pH 7.42013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Synthesis, characterization and antimalarial activity of quinoline-pyrimidine hybrids.
AID1441256Antimalarial activity against Plasmodium yoelii YM infected in BALB/c mouse assessed as time duration for parasite cure at 30 mg/kg, sc administered BID for 4 days starting at 96 hrs post infection, 8 hrs apart by Giemsa-staining based microscopic analysi2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.
AID772515Antimalarial activity against gametocytic stage of Plasmodium berghei infected in blood assessed as inhibition of ookinete formation at 10 uM after 24 hrs by Giemsa staining-based microscopic analysis relative to control2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID1648008Selectivity ratio of IC50 for HEK293 cells to IC50 for antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd22020Journal of natural products, 02-28, Volume: 83, Issue:2
A Meroisoprenoid, Heptenolides, and
AID478202Antimicrobial activity against wild-type Toxoplasma gondii RH infected in human CRL1634 cells assessed as intracellular parasite survival at 10 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID1148781Toxicity in mouse infected with Plasmodium berghei KBG13 assessed as animal death at 2 times minimum curative dose1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Antimalarial activity of some novel derivatives of 2,4-diamino-5(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID247034Effective dose against chloroquine-sensitive, pyrimethamine-sensitive, mefloquine-sensitive Plasmodium falciparum 3D72005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID248853In vitro antimalarial activity for DHFR wild-type, chloroquine and pyrimethamine-sensitive Plasmodium falciparum D62005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
In vitro metabolism of phenoxypropoxybiguanide analogues in human liver microsomes to potent antimalarial dihydrotriazines.
AID668908Antimicrobial activity against tachyzoites of Toxoplasma gondii expressing PRU-beta-Gal gene infected in HFF after 72 hrs by colorimetric microtiter assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
4-Thiophenoxy-2-trichloromethyquinazolines display in vitro selective antiplasmodial activity against the human malaria parasite Plasmodium falciparum.
AID119310Number of mice cured at a dose of 80 mg/kg sc1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID1174524Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 assessed as inhibition of parasite growth up to 19 uM after 72 hrs by parasite LDH release assay2015European journal of medicinal chemistry, Jan-07, Volume: 894-Aminoquinoline-pyrimidine hybrids: synthesis, antimalarial activity, heme binding and docking studies.
AID58284Inhibition constant against PfDHFR (Plasmodium falciparum dihydrofolate reductase) with single A16V mutation2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.
AID1135023Antimalarial activity against Plasmodium vivax New Guinea Chesson in po once daily dosed Owl monkey assessed as curative dose compound treated for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID231127Ratio of the inhibitory concentration against [3H]-uracil incorporation into nuclear DNA and T. gondii(Tg) DHFR; IC50 ([3H]-uracil incorporation) / IC50(Tg)1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
AID722357Dissociation constant, pKa of the compound at pH 7.42013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Synthesis, characterization and antimalarial activity of quinoline-pyrimidine hybrids.
AID356818Pharmacological chaperone effect on beta Hex A beta-T150P/P417L mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID231314Ratio of binding affinity for mutant (N51I+C59R+S108N+I164L) to that of wild type dihydrofolate reductase2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID232870Safety ratio as cytotoxicity in vero cells relative to IC50 TM42002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID554322Antileishmanial activity against Leishmania mexicana MHOM/BZ/84/BEL46 assessed as growth at 50 ug/ml by Alamar blue assay2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.
AID1833119Anti-tachyzoite activity against RFP-expressing Toxoplasma gondii RH Type 1 infected in NHDF cells assessed as plaque formation at 2 uM incubated for 96 hrs followed by removal of medium containing compounds and subsequent addition of fresh medium without2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID1648005Cytotoxicity against HEK293 cells2020Journal of natural products, 02-28, Volume: 83, Issue:2
A Meroisoprenoid, Heptenolides, and
AID124864Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 1.25 mg/kg.1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Folate antagonists. 21. Synthesis and antimalarial properties of 2,4-diamino-6-(benzylamino)pyrido[3,2-d]pyrimidines.
AID58122Inhibitor constant of compound for Plasmodium falciparum dihydrofolate reductase1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Probing the molecular basis of resistance to pyrimethamine by site-directed mutagenesis.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID722362Antimalarial activity against chloroquine-susceptible Plasmodium falciparum D10 asexual erythrocyte forms after 48 hrs by parasite LDH assay2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Synthesis, characterization and antimalarial activity of quinoline-pyrimidine hybrids.
AID341462Inhibition of human dihydrofolate reductase2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID1143945Antimalarial activity against Plasmodium berghei infected in mouse assessed as disease cure from parasite infection at 160 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID1439480Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in red blood cells up to 10 uM after 72 hrs by Malstat reagent based LDH assay2017European journal of medicinal chemistry, Mar-31, Volume: 129Synthesis, antimalarial activity, heme binding and docking studies of N-substituted 4-aminoquinoline-pyrimidine molecular hybrids.
AID1639290Selectivity ratio of IC50 for Plasmodium falciparum Dd2 ring stage forms to IC50 for Plasmodium falciparum 3D7 ring stage forms2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID55698Compound was tested for inhibition activity against pneumocystis carinii (Pneumocystis carinii) Dihydrofolate reductase1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID216031In vitro cytotoxicity against Plasmodium falciparum infected vero cell line.2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID1227103Chaperoning efficacy at HexA alpha G269S mutant in ATSD patient fibroblasts assessed as maximum increase in enzyme activity using MUGS substrate incubated for 1 to 2 hrs by spectrofluorometry relative to control2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID279387Growth inhibition of Plasmodium falciparum HB3 ring stage in infected erythrocytes after 72 hrs in DAPI fluorimetry2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
AID57588Inhibition constant against binding of Escherichia coli dihydrofolate reductase1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules.
AID1426079Agonist activity at human TAAR1 expressed in HEK293 cells assessed as cAMP accumulation at 10 uM after 20 mins by BRET assay relative to beta-PEA2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID356776Activation of beta Hex A alpha G269S/c.1278insTACT mutant isolated from Tay-Sachs disease patient assessed as increase in HEX A activity relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID436208Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in type B+ human erythrocytes assessed as reduction of hemozoin formation at IC50 after 48 hrs relative to control2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Antimalarial pharmacodynamics of chalcone derivatives in combination with artemisinin against Plasmodium falciparum in vitro.
AID23734Micelle/water partition coefficient (Pmic) of the compound was determined1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Thermodynamic aspects of hydrophobicity and the blood-brain barrier permeability studied with a gel filtration chromatography.
AID91140Effect of compound on percent survival of human fibroblast cells in culture was determined at 10 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID158865Antimalarial activity against Plasmodium falciparum Dd2 in erythrocytes2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.
AID1723485Antimalarial activity against Plasmodium falciparum isolate GB002 assessed as reduction in parasitemia at 10 times EC50 measured after 72 hrs2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Development of Potent
AID245369In vitro minimum inhibitory concentration against Plasmodium falciparum NF54 over 40 hours2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis of substituted indole derivatives as a new class of antimalarial agents.
AID1774078Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID543852Antimalarial activity against chloroquine-sensitive Plasmodium berghei ATCC 50175 infected in ICR mouse assessed as chemosuppression of parasitemia at 1.2 mg/kg/day, po administered 24 hrs post-treatment measured after 4 days2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Antimalarial activity of a new stilbene glycoside from Parthenocissus tricuspidata in mice.
AID57813In vitro inhibitory concentration against rat liver dihydrofolate reductase1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase.
AID1145686Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth in presence of 0.001 ug/ml folinic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID602118NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID58128Binding affinity towards mutant dihydrofolate reductase (C59R+S108N+I164L DHFR) of Plasmodium falciparum2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID41219Cytotoxicity against human breast cancer cells.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID356811Pharmacological chaperone effect on beta Hex A alpha G269S/c.1278ins TACT mutant in fibroblasts from Tay-Sachs disease patient assessed as increase in HEX A activity relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1475978Antiparasitic activity against parasite infected CBA/J mouse brain derived Toxoplasma gondii ME49 harboring delta hx::FLUC mutant derived infected in HFF assessed as reduction in plaque formation at 3 uM pre-incubated for 4 hrs followed by compound washou2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii.
AID1667083Inhibition of STAT3 in human MDA-MB-231 cells assessed as upregulation of Bcl-xLexpression after 24 hrs by western blot analysis2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID159577Antimalarial activity as survivor numbers at day 60 for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 320 mg/kg subcutaneous dose over 72 hr1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides.
AID1439477Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for chloroquine-sensitive Plasmodium falciparum D6 infected in red blood cells2017European journal of medicinal chemistry, Mar-31, Volume: 129Synthesis, antimalarial activity, heme binding and docking studies of N-substituted 4-aminoquinoline-pyrimidine molecular hybrids.
AID219249Binding affinity towards wild-type dihydrofolate reductase of Plasmodium falciparum.2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID1071117Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 25 ug/ml after 7 days by microplate Alamar blue assay relative to control2014European journal of medicinal chemistry, Mar-03, Volume: 74Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.
AID56807In vitro inhibition of human dihydrofolate reductase1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines.
AID1071102Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by broth microdilution assay2014European journal of medicinal chemistry, Mar-03, Volume: 74Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.
AID159579Antimalarial activity as toxic deaths 2-5 days post infection for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 320 mg/kg subcutaneous dose over 72 hr1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides.
AID671161Inhibition of Escherichia coli DHFR2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
AID554326Cytotoxicity against human MRC5 cells after 72 hrs by Alamar blue assay2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.
AID1227108Chaperoning efficacy at HexA alpha G269S mutant in ATSD patient fibroblasts assessed as drug level causing maximum increase in enzyme activity using MUGS substrate incubated for 1 to 2 hrs by spectrofluorometry relative to control2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID91141Effect of compound on percent survival of human fibroblast cells in culture was determined at 25 uM2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID229964IC50 ratio against Plasmodium falciparum K1CB1/TM42002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID1227101Inhibition of beta-N-acetylhexosaminidase (unknown origin)2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID356793Pharmacological chaperone effect on beta Hex A beta-G353R/IVS12-26G>A mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX S activity at 3 ug/ml by immunoselection assay relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1274592Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 assessed as inhibition of parasite growth at 40 uM after 72 hrs by DAPI staining-based confocal microscopic analysis2015Journal of natural products, Dec-24, Volume: 78, Issue:12
Rotenoids, Flavonoids, and Chalcones from the Root Bark of Millettia usaramensis.
AID373640Inhibition of pyrimethamine-resistant form-2 Plasmodium falciparum N51I, C59R, S108N, I164L, K96N mutant expressed in Escherichia coli BL21(DE3)2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID519614Antimicrobial activity against Toxoplasma gondii isolate TRS-2004-REV infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1439510Antimalarial activity against Plasmodium falciparum2017European journal of medicinal chemistry, Mar-31, Volume: 129Novel 2,3-disubstituted quinazoline-4(3H)-one molecules derived from amino acid linked sulphonamide as a potent malarial antifolates for DHFR inhibition.
AID1833125Induction of stage conversion in Toxoplasma gondii ESG reporter strain at 1 uM2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID233406Ratio for IC50 of mammalian DHFR to IC50 of Pneumocystis carinii DHFR1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID1135018Antimalarial activity against chloroquine-resistant, pyrimethamine-sensitive Plasmodium falciparum Vietnam Oak Knoll in Aotus monkey assessed as dose required to >50% cures compound treated for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1329801Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis and evaluation of naphthyl bearing 1,2,3-triazole analogs as antiplasmodial agents, cytotoxicity and docking studies.
AID685500HARVARD: Cytotoxicity in HepG2 cell line2012Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID234735Selectivity ratio of IC50 value against rat liver DHFR and Toxoplasma gondii DHFR1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID56349The ability to inhibit Toxoplasma gondii Dihydrofolate reductase was tested1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
AID1367785In vivo antimalarial activity against Plasmodium berghei ANKA infected in BALB/c mouse assessed as reduction in parasitemia at 20 mg/kg, po administered daily for 4 days by Giemsa staining-based method2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely.
AID54410Binding affinity towards cytochrome P450 2C92004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.
AID1533255Antiplasmodial activity against Plasmodium falciparum TM4/8.2 harboring wild type DHFR NCSI haplotype2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
AID1327821Inhibition of recombinant human DHFR expressed in Escherichia coli preincubated for 15 mins followed by addition of DHF as substrate and NADPH measured after 60 mins by resazurin/diaphorase coupled assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Discovery of Potent and Selective Leads against
AID356815Activation of on beta Hex A beta R505Q/delta-16kb mutant in fibroblasts from Sandhoff disease patient assessed as increase in HEX A activity relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1833115Anti-tachyzoite activity against RFP-expressing Toxoplasma gondii RH Type 1 infected in NHDF cells assessed as destruction of host cells at 1 uM incubated for 96 hrs followed by removal of medium containing compounds and subsequent addition of fresh mediu2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID231312Ratio of binding affinity for mutant (C59R+S108N+I164L) to that of wild type dihydrofolate reductase2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID1368010Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Ionic liquid mediated stereoselective synthesis of alanine linked hybrid quinazoline-4(3H)-one derivatives perturbing the malarial reductase activity in folate pathway.
AID1457205Antimalarial activity against Plasmodium falciparum NF54 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1348963Growth inhibition of GFP-fused Toxoplasma gondii RH infected in HFF at 1 uM after 3 days by fluorescence microscopic method relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143A minimalistic approach to develop new anti-apicomplexa polyamines analogs.
AID1367777Inhibition of Plasmodium falciparum FP2 at 10 uM using Z-Leu-Arg-AMC as substrate preincubated for 30 min followed by substrate addition measured after 30 mins by spectrofluorimetric method2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely.
AID1534817Anti-plasmodial activity against Plasmodium berghei ANKA infected in mouse assessed as increase in mean survival time at 0.048 mmol/kg/day, po administered as single dose at 24 hrs time interval from day 1 to day 3 and measured 96 hrs post infection2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis, in silico experiments and biological evaluation of 1,3,4-trisubstituted pyrazole derivatives as antimalarial agents.
AID373641Inhibition of pyrimethamine-resistant form-3 Plasmodium falciparum N51I, C59R, S108N, I164L, I150V, N182I, N201D mutant expressed in Escherichia coli BL21(DE3)2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
AID1611296Selectivity ratio of IC50 for African green monkey Vero cells to IC50 for Plasmodium falciparum V1/S infected in human erythrocytes2019Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24
6-Hydrophobic aromatic substituent pyrimethamine analogues as potential antimalarials for pyrimethamine-resistant Plasmodium falciparum.
AID1415881Cytotoxicity against human HepG2 cells after 3 days by CellTiter blue assay2017MedChemComm, May-01, Volume: 8, Issue:5
Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-
AID601638Antimalarial activity against Plasmodium falciparum 3D7 infected in human A positive erythrocytes by [3H]hypoxanthine uptake assay in presence of serum in medium2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
AID1457206Antimalarial activity against Plasmodium falciparum K1 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting m2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID238767Inhibition constant against Plasmodium falciparum dihydrofolate reductase2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
AID1723486Antimalarial activity against Plasmodium falciparum isolate GB0026 assessed as reduction in parasitemia at 10 times EC50 measured after 72 hrs2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Development of Potent
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1611291Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum V1/S expressing Dihydrofolate reductase N51I/C59R/S108N/I164L mutant infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation pretreated for 18 hrs 2019Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24
6-Hydrophobic aromatic substituent pyrimethamine analogues as potential antimalarials for pyrimethamine-resistant Plasmodium falciparum.
AID1415878Antiplasmodial activity against Plasmodium falciparum 3D7 after 3 days by SYBR green1 dye based assay2017MedChemComm, May-01, Volume: 8, Issue:5
Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-
AID1355303Plasmodicidal activity against Plasmodium falciparum 3D7A infected in erythrocytes assessed as parasite survival at 10 times IC50 pre-incubated for 24 hrs followed by compound washout and measured after 24 hrs by 1H-hypoxanthine incorporation assay (Rvb =2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Discovery of Marinoquinolines as Potent and Fast-Acting Plasmodium falciparum Inhibitors with in Vivo Activity.
AID1667178Antimalarial activity against erythrocytic stage of Plasmodium falciparum 3D7 incubated for 50 hrs2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Synthesis and efficacy of pyrvinium-inspired analogs against tuberculosis and malaria pathogens.
AID1616629Antiplasmodial activity against asexual form of Plasmodium falciparum NF54 assessed as reduction in male gametocytes activation preincubated for 48 hrs followed by gametocytes activation and measured after 24 hrs by fluorescence based automated inverted m2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Development of Chemical Entities Endowed with Potent Fast-Killing Properties against
AID119308Number of mice cured at a dose of 40 mg/kg sc1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylamino)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinediamines.
AID1071118Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 at 50 ug/ml after 7 days by microplate Alamar blue assay relative to control2014European journal of medicinal chemistry, Mar-03, Volume: 74Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.
AID1182792Antiplasmodial activity against Plasmodium falciparum Dd2 harboring mutations conferring drug-resistance by SYBR-green based assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID1367779Inhibition of Plasmodium falciparum DHFR2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely.
AID1145680Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1833131Anti-bradyzoite activity against Toxoplasma gondii ESG reporter strain infected in NHDF cells assessed as increase in BAG-positive vacuole number at 2 uM pretreated with PYR for 3 days followed by compound treatment and further incubated for 4 days2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID122524Mean survival time against trophozoite induced Plasmodium berghei in mice minus control was evaluated at a dose 80 mg/kg; 3 cured at 60 days postinjection.1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Folate antagonists. 21. Synthesis and antimalarial properties of 2,4-diamino-6-(benzylamino)pyrido[3,2-d]pyrimidines.
AID1059657Selectivity ratio of IC50 for DHFR (unknown origin) to IC50 for Toxoplasma gondii DHFR
AID158540In vitro anti-plasmodial activity against Plasmodium falciparum dihydrofolate reductase C59R+S108N/I164L (Csl-2) mutant2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID1485245Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID322130In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1144009Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 10 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID361326Inhibition of beta-hexosaminidase A at pH 4.3 assessed as residual enzyme activity2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1143981Antimalarial activity against sporozoite-induced Plasmodium gallinaceum infected in white leghorn chicken assessed as disease cure from parasite infection at 320 mg/kg, sc administered 72 hrs after infection1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
AID235841Relative antiplasmodial activity to cytotoxicity in Plasmodium falciparum TM4/8.2 infected BC cells2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID158849Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Structure-activity relationships of novel anti-malarial agents. Part 2: cinnamic acid derivatives.
AID478201Antimicrobial activity against wild-type Toxoplasma gondii RH infected in human CRL1634 cells assessed as intracellular parasite survival at 5 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID55702In vitro inhibitory concentration against Pneumocystis carinii dihydrofolate reductase1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase.
AID65359Inhibition of growth of methotrexate-resistant (MB1428) strain of Escherichia coli cells.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Quantitative structure-activity relationship of antifolate inhibition of bacteria cell cultures resistant and sensitive to methotrexate.
AID708606Antiparasitic activity against Leishmania major promastigotes assessed as parasite growth at 50 ug/mL2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Structure-based selectivity optimization of piperidine-pteridine derivatives as potent Leishmania pteridine reductase inhibitors.
AID1201532Inhibition of Plasmodium falciparum DHFR after 48 hrs2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
AID478210Antimicrobial activity against Toxoplasma gondii infected in human CRL1634 cells assessed as intracellular parasite survival at 10 uM after 18 hrs by [5,6-13H]uracil-based scintillation counting2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID356781Activation of beta Hex A alphaG269S mutant isolated from Tay-Sachs disease patient assessed as increase in 4-methylumbelliferyl-7-(6-sulfo-2-acetamido-2-deoxy)-beta-D-glucopyranoside hydrolysis at 3 ug/ml relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1485237Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1533259Antiplasmodial activity against Plasmodium falciparum V1/S harboring DHFR IRNL haplotype N51I/C59R/S108N/I164L quadruple mutant2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
AID1437497Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human RBC after 72 hrs by DAPI staining based confocal microscopic method
AID232759Selectivity index measured as the ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR.1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase.
AID343762Antitoxoplasma activity against wild type Toxoplasma gondii RH assessed as survival at 5 uM after 18 hrs by [5,6-13H]uracil incorporation assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID1227118Induction of lysosomal transport of HexA alpha G269S mutant in ATSD patient fibroblasts at 11 ug/ml by immunofluorescence staining method2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID708404Antiparasitic activity against Leishmania mexicana promastigotes assessed as parasite growth at 50 ug/mL2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Structure-based selectivity optimization of piperidine-pteridine derivatives as potent Leishmania pteridine reductase inhibitors.
AID1134962Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as change in mean survival time at 1.25 mg/kg, sc single dose after 72 hrs of infection1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID356780Activation of beta Hex A alphaG269S mutant isolated from Tay-Sachs disease patient assessed as increase in activator-[3H]GM2 complex hydrolysis at 3 ug/ml relative to control2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID683346Cytotoxicity against human HepG2 cells after 48 hrs by neutral red assay2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
Novel 4-aminoquinoline-pyrimidine based hybrids with improved in vitro and in vivo antimalarial activity.
AID708411Toxicity against human MRC5 cells assessed as growth inhibition2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Structure-based selectivity optimization of piperidine-pteridine derivatives as potent Leishmania pteridine reductase inhibitors.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1485221Inhibition of human DHFR using dihydrofolate as substrate after 180 secs by spectrophotometric analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1504889Selectivity index, ratio of IC50 for HEK293 cells to IC50 for chloroquine-sensitive Plasmodium falciparum 3D72017Journal of natural products, 12-22, Volume: 80, Issue:12
Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID1439476Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in red blood cells after 72 hrs by Malstat reagent based LDH assay2017European journal of medicinal chemistry, Mar-31, Volume: 129Synthesis, antimalarial activity, heme binding and docking studies of N-substituted 4-aminoquinoline-pyrimidine molecular hybrids.
AID372372Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis.
AID1538872Inhibition of bovine liver DHFR using FH2 as substrate incubated for 2 mins followed by substrate addition2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Green synthesis, biological evaluation, molecular docking studies and 3D-QSAR analysis of novel phenylalanine linked quinazoline-4(3H)-one-sulphonamide hybrid entities distorting the malarial reductase activity in folate pathway.
AID124709Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after subcutaneous administration dose of 640 mg/kg; 2 toxic deaths after 2-5 days of injection1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediamines.
AID478213Cytotoxicity against human CRL1634 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID344039Toxicity against human foreskin fibroblasts at 25 uM after 48 hrs by MTT method2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1533260Cytotoxicity against African green monkey Vero cells by SRB assay2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
AID436211Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in type B+ human erythrocytes assessed as inhibition of sorbitol-induced hemolysis at 10 nM after 15 min by spectrophotometry2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Antimalarial pharmacodynamics of chalcone derivatives in combination with artemisinin against Plasmodium falciparum in vitro.
AID245657Minimum inhibitory concentration against schizont maturation of Plasmodium falciparum NF54 ring stage after 40 h2005Bioorganic & medicinal chemistry letters, Apr-01, Volume: 15, Issue:7
Antimalarial activity of 2,4,6-trisubstituted pyrimidines.
AID1155423Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 after 72 hrs by SYBR I method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
AID158189In vitro antiplasmodial activity (IC50) against Plasmodium falciparum wtTM4/8.22002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID1367781Inhibition of Plasmodium falciparum FP2 using Z-Leu-Arg-AMC as substrate preincubated for 30 min followed by substrate addition measured after 30 mins by spectrofluorimetric method2017Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24
Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely.
AID58267Inhibition of the S108N mutant of dihydrofolate reductase (DHFR) relative to Pyr.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID1774075Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID427682Cytotoxicity against human K562 cells after 72 hrs by flow cytometry2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Synthesis and in vitro antiplasmodial evaluation of 4-anilino-2-trichloromethylquinazolines.
AID1077199Antiplasmodial activity against asexual erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF54 assessed as parasite growth inhibition after 48 hrs by lactate dehydrogenase assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID1546294Antiparasitic activity against Toxoplasma gondii RH transfected with fluorescent transgene dTom2020Bioorganic & medicinal chemistry letters, 01-01, Volume: 30, Issue:1
A new chemotype with promise against Trypanosoma cruzi.
AID1201517Antitoxoplasmic activity against tachyzoite stage of Toxoplasma gondii PRU transfected with beta galactosidase infected in HFF assessed as parasite growth inhibition after 96 hrs by colorimetric microtiter assay2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
AID576710Ratio of IC50 for Plasmodium falciparum TM91c235 harboring DHFR F57L, S58R, T61M, S117T mutant to IC50 for Plasmodium falciparum D62010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system.
AID1227113Inhibition of HexA alpha G269S mutant in ATSD patient fibroblasts using MUGS substrate incubated for 1 to 2 hrs at pH 4.5 by spectrofluorometry2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID1771305Antiplasmodial activity against Plasmodium falciparum 3D7 infected in human erythrocyte assessed as intraerythrocytic growth inhibition incubated for 72 hrs by DAPI-staining based imaging analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials.
AID683712Antimalarial activity against liver stages of Plasmodium cynomolgi infected in human HepG2 cells assessed as growth inhibition of hepatic parasite after 3 days2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Targeting the liver stage of malaria parasites: a yet unmet goal.
AID1227119Induction of HexA alpha G269S mutant activity in ATSD patient fibroblasts assessed as hydrolysis of fluorescent analogue of GM2 ganglioside at 11 ug/ml incubated for 10 days by TLC method2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
AID57645In vitro inhibitory concentration against rat liver dihydrofolate reductase1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Structural studies on bioactive compounds. 8. Synthesis, crystal structure, and biological properties of a new series of 2,4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant tumor c
AID442355Antitoxoplasmic activity against Toxoplasma gondii PRU-betaGal tachyzoite after 96 hrs by colorimetric microtiter assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Original quinazoline derivatives displaying antiplasmodial properties.
AID158543In vitro anti-plasmodial activity against Plasmodium falciparum dihydrofolate reductase wild type (TM4/8.2)2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
AID1533258Antiplasmodial activity against Plasmodium falciparum CSL-2 harboring DHFR NRNL haplotype C59R/S108N/I164L triple mutant2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance.
AID235849Selectivity ratio is the ratio between the IC50 values of rat liver and Pneumocystis carinii1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID58253Inhibition of the C59R+S108N mutant of dihydrofolate reductase (DHFR)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum.
AID1812456Antiplasmodial activity against synchronized ring stage Plasmodium falciparum 3D7 assessed as parasite reduction rate in lag phase by measuring time required to achieve maximum speed of action at 10 times IC50 concentration2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID1534796Anti-plasmodial activity against Plasmodium berghei ANKA infected in mouse assessed as suppression in blood parasitemia level at 0.048 mmol/kg/day, po administered as single dose at 24 hrs time interval from day 1 to day 3 and measured 96 hrs post infecti2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis, in silico experiments and biological evaluation of 1,3,4-trisubstituted pyrazole derivatives as antimalarial agents.
AID1667077Inhibition of HDAC1 in human MDA-MB-231 cells assessed as accumulation of acetylated H4 at 50 to 100 uM by western blot analysis2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID361329Inhibition of beta-hexosaminidase A at pH 6.5 by competitive binding assay2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
AID1667079Inhibition of STAT3 in human MDA-MB-231 cells assessed as upregulation of p-p38 expression after 24 hrs by western blot analysis2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
AID1426077Agonist activity at mouse TAAR1 expressed in HEK293 cells assessed as cAMP accumulation at 10 uM after 20 mins by BRET assay relative to beta-PEA2017European journal of medicinal chemistry, Feb-15, Volume: 127Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID1254216Antiplasmodial activity against Plasmodium falciparum 3D7 infected in po dosed non-myelodepleted NOD-SCID IL2Rgammanull mouse engrafted with human erythrocytes assessed as reduction of parasitemia level administered qd for 4 days2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347140qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347135qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2014Structure (London, England : 1993), Jan-07, Volume: 22, Issue:1
Mycobacterium tuberculosis dihydrofolate reductase reveals two conformational states and a possible low affinity mechanism to antifolate drugs.
AID1345176Human Multidrug and toxin extrusion (SLC47 family of multidrug and toxin extrusion transporters)2010The Journal of pharmacology and experimental therapeutics, Apr, Volume: 333, Issue:1
Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,713)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901758 (37.30)18.7374
1990's744 (15.79)18.2507
2000's1051 (22.30)29.6817
2010's905 (19.20)24.3611
2020's255 (5.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 68.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index68.69 (24.57)
Research Supply Index8.67 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index124.25 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (68.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials738 (14.50%)5.53%
Reviews310 (6.09%)6.00%
Case Studies444 (8.73%)4.05%
Observational12 (0.24%)0.25%
Other3,584 (70.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (165)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Early Phase I Window of Opportunity Biomarker and Safety Trial to Test Pyrimethamine as an Inhibitor of NRF2 in HPV-negative, Locally Advanced Head and Neck Squamous Cell Carcinoma [NCT05678348]Early Phase 120 participants (Anticipated)Interventional2023-08-03Recruiting
Pharmacokinetics of Sulfadoxine-pyrimethamine Plus Amodiaquine When Used for Malaria Intermittent Preventive Treatment in Children [NCT01328990]Phase 1/Phase 2150 participants (Actual)Interventional2011-04-30Completed
Multicenter, Randomized Clinical Trial to Compare the Efficacy and Tolerance of Prenatal Therapy With Pyrimethamine + Sulfadiazine vs Spiramycine to Reduce Vertical Transmission of Toxoplasma Gondii Following Primary Infection in Pregnancy [NCT01189448]Phase 3149 participants (Actual)Interventional2010-11-30Completed
Proposed Investigator-Initiated Clinical Trial of Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease) [NCT01102686]Phase 1/Phase 220 participants (Anticipated)Interventional2009-08-31Completed
Intermittent Preventive Treatment With Azithromycin-containing Regimens for the Prevention of Malarial Infections and Anaemia and the Control of Sexually Transmitted Infections in Pregnant Women in Papua New Guinea [NCT01136850]Phase 32,793 participants (Actual)Interventional2009-11-30Completed
Efficacy and Safety of Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Centers in Nangarhar, Kunar, Thakhar and Faryab Provinces of Afghanistan [NCT01115439]100 participants (Actual)Observational2010-03-31Completed
A Comparative Study of Azithromycin and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant HIV Positive Patients [NCT02527005]Phase 1140 participants (Actual)Interventional2015-09-30Completed
Safety and Tolerability of Bi-monthly Intermittent Preventive Treatment With Mefloquine-Artesunate or Sulfadoxine-Pyrimethamine Plus Amodiaquine for Prevention of Malaria and Related Complications in Patients With Sickle Cell Anaemia. [NCT01319448]Phase 1/Phase 2270 participants (Actual)Interventional2011-09-30Completed
Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Dose Escalation Trial to Determine Safety and Development of Protective Efficacy After Exposure to Only Pre-erythrocytic Stages of Plasmodium Falciparum [NCT03083847]Phase 155 participants (Actual)Interventional2017-06-05Completed
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants [NCT02793622]Phase 3782 participants (Actual)Interventional2016-09-30Completed
A Four-arm Trial Comparing Artemether-lumefantrine With or Without Single-dose Primaquine and Sulphadoxine-pyrimethamine/Amodiaquine With or Without Single-dose Tafenoquine to Reduce P. Falciparum Transmission in Mali [NCT05081089]Phase 280 participants (Actual)Interventional2021-10-12Completed
A Comparative Study of Mefloquine and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant Human Immunodeficiency Virus Positive Patients [NCT02524444]Phase 1142 participants (Actual)Interventional2015-09-30Completed
Effects of Metronidazole Plus Intermittent Preventive Treatment of Malaria in Pregnancy on Birth Outcomes: a Randomised Controlled Trial in Zambia [NCT04189744]Phase 35,436 participants (Actual)Interventional2019-12-15Completed
A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children [NCT02211729]Phase 322,090 participants (Actual)Interventional2014-05-31Completed
Clinical Trial to Evaluate Efficacy and Safety of Sulfadoxine/Pyrimethamine-Amodiaquine and Dihydroartemsinin-Piperaquine Plus Ivermectin Administered Monthly as Intermittent Preventive Treatment in School-aged Children in Burkina Faso [NCT05946642]Phase 313,000 participants (Anticipated)Interventional2023-07-15Recruiting
MULTIple Doses of IPTi Proposal: a Lifesaving High Yield Intervention [NCT05085340]45,000 participants (Anticipated)Observational2022-02-14Recruiting
Pseudo-randomised, Double-blinded Placebo-controlled Trial of Chloroquine or Sulphadoxine-pyrimethamine Alone or in Combination With Primaquine or Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Pakistan [NCT00959517]Phase 2588 participants (Actual)Interventional2001-07-31Completed
Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda [NCT04336189]Phase 32,757 participants (Anticipated)Interventional2020-12-28Recruiting
Safety and Feasibility of a Malaria Transmission Model in Semi-immune Kenyan Adults Using Plasmodium Falciparum Sporozoites [NCT04280692]Phase 1/Phase 244 participants (Actual)Interventional2022-08-22Active, not recruiting
Lungwena Antenatal Intervention Study. A Single-centre Intervention Trial in Rural Malawi, Testing Maternal and Infant Health Effects of Presumptive Intermittent Treatment of Pregnant Women With Sulfadoxine-pyrimethamine and Azithromycin [NCT00131235]Phase 31,320 participants (Actual)Interventional2003-12-31Active, not recruiting
Randomized Controlled Trial of Azithromycin (AZ) and Sulphadoxine-pyrimethamine (SP) for Prophylaxis Against Malaria in Pregnancy (IPT) [NCT03944317]168 participants (Anticipated)Interventional2019-06-01Not yet recruiting
Egg to Ameliorate Environmental Enteric Dysfunction and Improve Growth in Children With Moderate Acute Malnutrition [NCT06002438]400 participants (Anticipated)Interventional2023-10-09Recruiting
LRAs United as a Novel Anti-HIV Strategy (LUNA): a Randomized Controlled Trial. [NCT03525730]Phase 1/Phase 228 participants (Actual)Interventional2018-04-18Completed
Assessment of the Efficacy of Sulphadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda [NCT01184911]Phase 40 participants (Actual)Interventional2010-10-31Withdrawn(stopped due to Research plan changed; no longer conducting clinical trial.)
A Single Centre, Open-label, Parallel-group, Single Oral Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pyrimethamine in Healthy Japanese and Caucasian Male Subjects [NCT03258762]Phase 114 participants (Actual)Interventional2017-09-25Completed
A Randomized Controlled Trial of Monthly Dihydroartemisinin-piperaquine Versus Monthly Sulfadoxine-pyrimethamine Versus Daily Trimethoprim-sulfamethoxazole Versus No Therapy for the Prevention of Malaria [NCT00948896]Phase 3600 participants (Actual)Interventional2010-06-30Completed
Effectiveness of Seasonal Malaria Chemoprevention in Koulikoro, Mali [NCT04149106]Phase 34,556 participants (Anticipated)Interventional2019-07-01Active, not recruiting
'Controlled Human Malaria Infection Study to Assess Gametocytaemia and Mosquito Transmissibility in Participants Challenged With Plasmodium Falciparum by Sporozoite Challenge to Establish a Model for the Evaluation of Transmission-blocking Interventions' [NCT02836002]Phase 1/Phase 229 participants (Actual)Interventional2016-06-30Completed
Evaluation of the Safety and Effectiveness of EPI-linked Malaria Intermittent Chemotherapy and Iron Supplementation [NCT00857077]2,485 participants (Actual)Interventional2000-09-30Completed
Clinical Trial to Evaluate Intermittent Screening and Treatment and Intermittent Preventive Treatment of Malaria in Asymptomatic Schoolchildren to Decrease P. Falciparum Infection and Transmission: Phase 2 Comparing Drug Regimens [NCT05980156]Phase 4646 participants (Actual)Interventional2023-02-13Completed
Randomized Control Trial of the Use of Supplementary Food and Measures to Control Inflammation in Malnourished Pregnant Women to Improve Birth Outcomes [NCT03079388]1,489 participants (Actual)Interventional2017-02-27Completed
Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falciparum I [NCT03952650]Phase 1/Phase 2252 participants (Actual)Interventional2019-05-23Completed
Evaluation of the Safety and Efficacy of Mefloquine as Intermittent Preventive Treatment of Malaria in Pregnancy [NCT00811421]5,820 participants (Actual)Interventional2009-09-30Completed
An Open-Label, Single Sequence, Crossover Study to Investigate the Effects of OCT1 Inhibition Utilizing Pyrimethamine on Pharmacokinetics of BMS-986165 in Healthy Male Volunteers. [NCT04086719]Phase 116 participants (Actual)Interventional2019-09-12Completed
Impact Evaluation of Intermittent Preventive Treatment of Malaria in Infants Plus (IPTi+) in Cameroon: The Plus Project [NCT05889052]2,080 participants (Anticipated)Observational2023-07-19Recruiting
Intermittent Preventive Treatment in Pregnancy With Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine to Prevent Malaria Infection and Reduce Adverse Pregnancy Outcomes in Papua New Guinea - a Randomised Controlled Trial [NCT05426434]Phase 31,172 participants (Anticipated)Interventional2022-08-31Recruiting
Randomized Clinical Trial of the Efficacy and Safety of Dihydroartimisinine+Papiraquine (Artekin) Compared With First Line Drugs for Treatment of Vivax and Uncomplicated Falciparum Malaria in Afghanistan [NCT00682578]Phase 31,086 participants (Actual)Interventional2007-07-31Completed
IPT in Schoolchildren: Comparison of the Efficacy, Safety, and Tolerability of Antimalarial Regimens in Uganda [NCT00852371]Phase 3760 participants (Actual)Interventional2008-02-29Completed
Impact Evaluation of Intermittent Preventive Treatment of Malaria in Infants Plus (IPTi+) in Côte d'Ivoire: The Plus Project [NCT05856357]1,568 participants (Anticipated)Observational2023-08-11Recruiting
Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine Versus Weekly Chloroquine Prophylaxis During Pregnancy in Solomon Islands: a Randomized Controlled Trial [NCT00964691]Phase 42,504 participants (Anticipated)Interventional2009-08-31Terminated(stopped due to Low prevalence of malaria, high prevalence of reported allergy to sulphur drugs, high proportion of women not meeting the inclusion criterea.)
Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso: the Malaria Component [NCT00680732]Phase 41,370 participants (Actual)Interventional2003-06-30Completed
A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant Papua New Guinean Women [NCT02575755]Phase 4150 participants (Anticipated)Interventional2012-10-31Recruiting
The Role of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria And Its Effects in Pregnancy [NCT00711906]Phase 3352 participants (Actual)Interventional2009-02-28Terminated(stopped due to Malaria prev. fell in the study area, so we cannot evaluate the primary endpoint)
A Phase 3, Open Label, Randomized, Comparative Study To Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa [NCT01103063]Phase 32,891 participants (Actual)Interventional2010-10-31Terminated(stopped due to See termination reason in detailed description.)
Therapeutic Efficacy Study of Pyrimethamine / Sulfdoxine (Fansidar®) for the Treatment of Uncomplicated Falciparum Malaria in the Peruvian Amazon [NCT00951106]0 participants Interventional1998-01-31Completed
Validation of the Use of Istope-Based Molecular Techniques for Malaria Control [NCT00646126]Phase 30 participants Interventional2005-08-31Completed
[NCT00766662]0 participants Interventional2006-10-31Completed
Open-label, Randomized Clinical Trial in Kenya to Determine the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Vs. Praziquantel in the Treatment of S. Mansoni in Children [NCT01054651]Phase 3212 participants (Actual)Interventional2009-10-31Completed
Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients [NCT00000643]Phase 2150 participants InterventionalCompleted
Pyrimethamine Pharmacokinetics in HIV Positive Patients Seropositive for Toxoplasma Gondii [NCT00000973]Phase 126 participants InterventionalCompleted
A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection [NCT00000666]600 participants InterventionalCompleted
Short Course of Quinine Plus a Single Dose of Sulphadoxine-Pyrimethamine for Plasmodium Falciparum Malaria [NCT00167739]Phase 450 participants Interventional2003-04-30Completed
Intermittent Treatment With Sulfadoxine-Pyrimethamine for Malaria Control in Children: A Randomised, Double Blind, and Placebo-Controlled Clinical Trial [NCT00168948]Phase 41,200 participants Interventional2003-03-31Active, not recruiting
Efficacy of Sulphadoxine-pyrimethamine and Amodiaquine Alone or in Combination as Intermittent Preventive Treatment in Pregnancy in the Kassena-Nankana District of Ghana: a Randomized Controlled Trial [NCT00146783]Phase 2/Phase 33,642 participants (Actual)Interventional2004-06-30Completed
Community Effectiveness of Intermittent Preventive Treatment Delivered Through the Expanded Programme of Immunisation for Malaria and Anaemia Control in Tanzanian Infants [NCT00152204]Phase 313,000 participants (Anticipated)Interventional2005-03-31Active, not recruiting
To Evaluate the Efficacy of Chloroquine and SP for Acute Uncomplicated P. Falciparum and the Efficacy of Chloroquine for Acute Uncomplicated P. Vivax in the Timika Region of Papua, Indonesia. [NCT00157859]150 participants Interventional2004-04-30Completed
An Open-label Three Arm Trial of the Efficacy and Safety of Chlorproguanil / Dapsone (Lapdap) Compared With Chloroquine and Sulfadoxine / Pyrimethamine for the Treatment of Vivax Malaria in Pakistan and Afghanistan [NCT00158561]Phase 3750 participants Interventional2004-02-29Completed
An Open Study for a 2-year Period to Confirm the Safety and Immunogenicity of the Candidate Malaria Vaccine RTS,S/AS02A in Mozambican Children Aged 1 to 4 Years at the Time of First Vaccine Dose. [NCT00323622]Phase 21,737 participants (Actual)Interventional2005-04-30Completed
Chloroquine and Sulfadoxine-Pyrimethamine Efficacy for the Treatment of Uncomplicated Falciparum Malaria in Blantyre, Malawi [NCT00125489]Phase 4210 participants Interventional2005-05-31Completed
Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infant: a Randomized, Double-blind, and Placebo-controlled Clinical Trial [NCT00206739]Phase 41,070 participants (Actual)Interventional2003-01-31Completed
A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Pyrimethamine and Metformin IR After Oral Administration in Healthy Male Volunteers [NCT01973933]Phase 120 participants (Actual)Interventional2013-06-30Completed
A Dose-Escalation, Phase I/II Study of Oral Azithromycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS [NCT00000966]Phase 145 participants InterventionalCompleted
A Dose-Escalated, Double-Blind, Placebo-Controlled, Randomized Phase I Clinical Trial of Pyrimethamine in Patients Affected With Chronic GM2 Gangliosidosis (Tay-Sachs or Sandhoff Variants) [NCT00679744]Phase 10 participants (Actual)Interventional2008-05-31Withdrawn(stopped due to Due to lack of funding)
Evaluation of the Public Health Impact and Cost Effectiveness of Seasonal Intermittent Preventive Treatment in Children in Senegal [NCT00712374]Phase 4100,000 participants (Anticipated)Interventional2008-09-30Enrolling by invitation
Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in HIV-Seropositive and HIV-Seronegative Pregnant Women in Zambia [NCT00270530]Phase 4454 participants Interventional2002-11-30Completed
New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa. [NCT00730366]Phase 32,766 participants (Actual)Interventional2004-03-31Completed
Acceptability and Feasibility of IPTp With Dihydroartemisinin-piperaquine With or Without Azithromycin to Prevent Malaria, Sexually Transmitted and Reproductive Tract Infections in HIV-uninfected Pregnant Women (IMPROVE) in Kenya. [NCT04160026]Phase 41,600 participants (Actual)Interventional2019-11-11Completed
Efficacy, Safety, and Pharmacokinetics of Sulphadoxine-pyrimethamine-amodiaquine (SP-AQ), SP-AQ Plus Primaquine, Dihydroartemisinin-piperaquine (DP), DP Plus Methylene Blue for Preventing Transmission of P. Falciparum Gametocytes in Mali [NCT02831023]Phase 280 participants (Actual)Interventional2016-07-31Completed
Efficacy of Intermittent Sulfadoxine-Pyrimethamine and Sulfadoxine-Pyrimethamine + Artesunate Treatment in the Prevention of Malaria in Pregnancy in an Area With Chloroquine-Resistant Plasmodium Falciparum [NCT00164255]Phase 41,614 participants (Actual)Interventional2003-01-31Completed
A Longitudinal Study Assessing the Infectious Status and Immunity of Mothers and Their Children in Lambaréné, Including Intermittent Treatment of Children With Sulfadoxine-pyrimethamine for Malaria Control and Its Impact on Long-term Health [NCT00167843]Phase 41,189 participants Interventional2002-12-31Completed
Open Label Drug Study (With Single and Parallel Group Components) to Evaluate Combination Antimalarial Therapy for Efficacy, Gametocyte Carriage and Molecular Markers Associated With SP Resistance in Uncomplicated Plasmodium Falciparum Infections [NCT00203736]240 participants Interventional2003-01-31Completed
Open-Label, Randomised, Parallel Group in Vivo Drug Study to Evaluate Combination Anti-Malarial Therapy (CAT), Artesunate and Sulfadoxine-Pyrimethamine Versus Sulfadoxine-Pyrimethamine Alone, in Terms of Therapeutic Efficacy, Prevalence of Gametocyte Carr [NCT00203814]280 participants Interventional2004-01-31Completed
Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Zambia [NCT06166498]Phase 3600 participants (Anticipated)Interventional2024-02-15Not yet recruiting
Drug Options for Intermittent Preventive Treatment for Malaria in Infants in an Area With High Resistance to Sulfadoxine/Pyrimethamine: an Evaluation of Short and Long-acting Antimalarial Drugs [NCT00158574]Phase 2/Phase 32,419 participants (Actual)Interventional2005-01-31Completed
Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women [NCT00209781]1,028 participants Interventional2003-08-31Active, not recruiting
Evaluation of a Malaria Transmission Target Strategy Based on the Periodic Treatment With Sulfadoxine-Pyrimethamine vs. Early Case Management [NCT00623155]262 participants (Actual)Interventional2002-07-31Completed
The Prevention of Anaemia and Malaria in Infants in an Area of Intense and Perennial Malaria Transmission [NCT00497471]832 participants (Actual)Interventional1995-02-28Terminated(stopped due to Follow-up end in 1999)
Randomized Trial of Effectiveness and Acceptability of Three Alternative Regimens for Malaria Seasonal Intermittent Preventive Treatment in Senegal [NCT00529620]Phase 31,833 participants (Actual)Interventional2007-09-30Completed
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania [NCT02909712]Phase 2201 participants (Actual)Interventional2016-09-30Completed
Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse [NCT00002064]0 participants InterventionalCompleted
[NCT00372294]Phase 30 participants Interventional2005-07-31Active, not recruiting
Pilot (Phase I-II) Study of Pyrimethamine (Daraprim) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS) [NCT00065390]Phase 18 participants Interventional2003-07-31Completed
Presumptive Treatment With Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prophylaxis in Children With Sickle Cell Anemia [NCT00399074]Phase 3220 participants (Anticipated)Interventional2006-10-31Completed
Preventing Anemia in Children (6months-30months) in a Malaria Endemic Rural Area in Ghana - A Randomized Double Blind Study [NCT00301054]872 participants Interventional2005-06-30Completed
Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children: Evaluation of Safety, Tolerability, and Efficacy [NCT00123552]Phase 3601 participants (Actual)Interventional2004-11-30Completed
An Open-label in Vivo Drug Study to Evaluate Artesunate Plus Sulfadoxine-pyrimethamine (ASSP) Pharmacokinetics, Therapeutic Efficacy, Gametocyte Carriage and Birth Outcomes in Pregnant Women With Uncomplicated Falciparum Malaria [NCT00331708]3 participants (Actual)Interventional2006-04-30Terminated(stopped due to Lack of suitable participants)
Intermittent Preventive Treatment With Sulfadoxine/Pyrimethamine During Pregnancy Among HIV-Positive and HIV-Negative Women: 2-Dose Versus Monthly - Malawi [NCT00126906]700 participants Interventional2002-10-31Completed
Characterization of Novel Molecular Tools for the Epidemiological Surveillance of Antimalarial Drug Resistance in Mali [NCT00127998]1,011 participants Interventional2005-07-31Completed
The Effectiveness, Cost and Cost Effectiveness of Intermittent Preventive Treatment or Screening and Treatment of Malaria in Pregnancy Among Women Using Long Lasting Insecticide Treated Bed Net: a Randomised Controlled Trial. [NCT00432367]Phase 33,333 participants (Actual)Interventional2007-02-28Completed
A Randomised Double Blind Clinical Trial of Amodiaquine (AQ) and Sulphadoxine-pyrimethamine (SP) Used Singly and in Combination (AQ+SP) Compared With Chloroquine (CQ) in the Treatment of Falciparum Malaria Infection in Pregnancy [NCT00131703]Phase 3900 participants Interventional2003-03-31Completed
A Double-blind, Randomised, Placebo-controlled Trial to Measure the Potential of Intermittent Treatment With Artesunate Plus Sulphadoxine/Pyrimethamine (SP) to Reduce the Malaria Burden in Sub-Saharan Africa [NCT00132561]Phase 2/Phase 31,200 participants Interventional2002-06-30Completed
The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children With Recrudescent Malaria in Guinea-Bissau [NCT00137553]Phase 460 participants Interventional2001-05-31Completed
Efficacy of Sulfadoxine-Pyrimethamine in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children in Lambaréné [NCT00453856]Phase 4139 participants (Anticipated)Interventional2007-03-31Terminated(stopped due to The study was terminated because of Early Treatment Failure in child.The justification for this decision are concerns about safety of children.)
Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine Versus Amodiaquine-Artesunate Coformulation in Uncomplicated Plasmodium Falciparum Malaria : an Open Randomized Study [NCT00460369]240 participants (Actual)Interventional2007-04-30Completed
A Study Of Impact Of Intermittent Preventive Treatment In Children With Amodiaquine Plus Artesunate Versus Sulphadoxine-Pyrimethamine On Hemoglobin Levels And Malaria Morbidity In Hohoe District Of Ghana [NCT00119132]Phase 2/Phase 32,602 participants (Actual)Interventional2005-06-30Completed
A Randomised, Placebo Controlled Trial of Intermittent Preventative Treatment With Sulfadoxine-pyrimethamine in Gambian Multigravidae. [NCT00120809]Phase 33,000 participants Interventional2002-07-31Completed
A Randomised Non-Inferiority Trial of Sulfadoxine-Pyrimethamine Plus Artesunate Compared to Chloroquine for the Treatment of Vivax Malaria in Eastern Afghanistan. [NCT00486694]Phase 2190 participants (Actual)Interventional2004-03-31Completed
Anti-malarial Drug Resistance in Cameroon: Therapeutic Efficacy and Biological Markers of Resistance [NCT00146718]Phase 2/Phase 3755 participants Interventional2003-08-31Completed
Assessing and Monitoring the Efficacy of Sulfadoxine/ Pyrimethamine (SP) and the Combination of SP Plus Artesunate for Uncomplicated Malaria Infections Among Children [NCT00140361]Phase 4390 participants (Actual)Interventional2000-01-31Completed
Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance [NCT00140517]700 participants Interventional2002-10-31Completed
A Randomised Trial of the Efficacy and Safety of Four Drug Regimens When Used for Intermittent Preventive Treatment of Malaria in Senegalese Children [NCT00132548]Phase 32,200 participants Interventional2004-06-30Completed
Evaluating the Effectiveness and Cost-effectiveness of Integrating Mass Drug Administration for Helminth Control With Seasonal Malaria Chemoprevention in Ghanaian Children [NCT06182176]1,200 participants (Anticipated)Interventional2024-05-27Not yet recruiting
Effectiveness of Seasonal Malaria Chemoprevention in Nampula Province, Mozambique: Evaluated Using a Type Two Hybrid Implementation Science Observational Study [NCT05186363]Phase 43,156 participants (Actual)Interventional2022-01-08Active, not recruiting
Open Label Study to Evaluate Combination Anti-malarial Therapy,in Terms of Efficacy, Prevalence of Gametocyte Carriage and Molecular Markers Associated With Sulfadoxine Pyrimethamine Resistance in Uncomplicated Plasmodium Falciparum [NCT00203801]700 participants Interventional2002-01-31Completed
Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate (SP+AS) Versus SP+AS Plus Primaquine for Clearance of Low Density P. Falciparum Infection in Eastern Sudan [NCT00330902]Phase 3104 participants (Actual)Interventional2004-01-31Completed
Assessment of the Public Health Benefit of Artemisinine Based Combination Therapies for Uncomplicated Malaria Treatment in Mali [NCT00452907]Phase 4780 participants (Actual)Interventional2005-07-31Completed
Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine [NCT00509015]6,000 participants (Anticipated)Interventional2008-02-29Completed
Efficacy and Safety of Pediatric Immunization-linked Preventive Intermittent Treatment With Antimalarials in Decreasing Anemia and Malaria Morbidity in Rural Western Kenya [NCT00111163]1,516 participants Interventional2004-03-31Completed
A New Approach to Deliver Malaria Preventions to Pregnant Women at a Community Level in Uganda [NCT00118027]2,150 participants Interventional2003-05-31Completed
Randomized Trial of the Effectiveness of Amodiaquine-Artesunate, Amodiaquine-Sulfadoxine-Pyrimethamine, and Chloroquine-Sulfadoxine-Pyrimethamine, for Treatment of Uncomplicated Malaria in Gambian Children [NCT00118807]Phase 31,800 participants Interventional2003-08-31Completed
Pilot Study of Pyrimethamine and Sulfadoxine (Fansidar) for the Treatment of Individuals With the Autoimmune Lymphoproliferative Syndrome (ALPS) [NCT00013689]Phase 18 participants Interventional2001-03-31Completed
A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS [NCT00000674]30 participants InterventionalCompleted
Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis [NCT00000794]Phase 2100 participants InterventionalCompleted
The Efficacy and Cost-effectiveness of Malaria Prevention in Pregnancy in an Area of Low and Unstable Transmission in Kabale, Uganda: Use of Intermittent Preventive Treatment and Insecticide-treated Nets. [NCT00142207]Phase 34,775 participants (Actual)Interventional2004-01-31Completed
The in-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Individuals-a 28 Day Efficacy Trial Involving HIV+ and HIV- Adults. [NCT00144352]Phase 4540 participants Interventional2002-09-30Completed
The Effect of Folic Acid Supplementation on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya [NCT00130065]Phase 4600 participants Interventional2003-11-30Completed
IPTp With Dihydroartemisinin-piperaquine and Azithromycin for Malaria, Sexually Transmitted and Reproductive Tract Infections in Pregnancy in High Sulphadoxine-pyrimethamine Resistance Areas in Kenya, Malawi and Tanzania [NCT03208179]Phase 34,680 participants (Actual)Interventional2018-03-29Completed
The Impact of Intermittent Malaria Treatment Administered Through the EPI Scheme on Malaria Morbidity in Mozambican Children [NCT00209794]Phase 1/Phase 21,498 participants Interventional2002-09-30Active, not recruiting
A Phase II/III, Randomized, Comparative Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in India [NCT00074841]Phase 2/Phase 3230 participants (Actual)Interventional2003-09-30Completed
Chemoprophylaxis With Sulfadoxine-pyrimethamine to Prevent Recurrence of Severe Anaemia in Gambian Children Aged 3 Months to 9 Years [NCT00131716]Phase 31,200 participants (Actual)Interventional2003-05-31Completed
Influence of HIV Infection on the Effectiveness of Malaria Prevention During Pregnancy, With Emphasis on the Effect of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda [NCT00132535]2,548 participants Interventional2003-08-31Completed
An Open Randomised Trial of the Efficacy of Sulfadoxine-Pyrimethamine (SP), Amodiaquine + SP (AQ-SP), AQ + Artesunate (AQ-Art), Chlorproguanil-Dapsone + Art (CD-Art), and Lumefantrine-Artemether (LA) for Uncomplicated Malaria in Malawi [NCT00164710]Phase 4365 participants Interventional2005-04-30Completed
A Phase 2/3, Randomized, Comparative, Double Blind Trial Of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia [NCT00084240]Phase 2/Phase 332 participants (Actual)Interventional2004-03-31Terminated(stopped due to See Detailed Description)
Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi [NCT06083688]Phase 41,000 participants (Anticipated)Interventional2024-10-31Not yet recruiting
Efficacy of Chloroquine + Sulfadoxine Pyrimethamine Versus Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines [NCT00229775]560 participants (Actual)Interventional2003-07-31Completed
Age of Exposure and Immunity to Malaria in Infants [NCT00231452]349 participants (Actual)Interventional2005-09-30Completed
Community Acceptability and Cost-effectiveness of Two Drug Distribution Methods for Home Based Management of Fevr in Kayunga District, Uganda [NCT00259142]1,314 participants (Anticipated)Interventional2005-11-30Terminated(stopped due to Study never started)
SP Resistance Markers and Falciparum Malaria Transmission [NCT00299247]Phase 30 participants (Actual)InterventionalWithdrawn
Intermittent Preventive Treatment During Pregnancy in Benin: a Randomized, Open, and Equivalent Trial Comparing Sulfadoxine-Pyrimethamine With Mefloquine [NCT00274235]Phase 31,600 participants (Anticipated)Interventional2005-07-31Completed
Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants [NCT00285662]1,100 participants (Anticipated)Interventional2006-06-30Completed
A Pilot Randomized Controlled Trial of Azithromycin or Artesunate Added to Sulphadoxine Pyrimethamine as Therapy for Malaria in Pregnancy [NCT00287300]141 participants Interventional2003-09-30Completed
Effect of Antimalarial Treatment on Gametocyte Carriage in Asymptomatic P. Falciparum: A Randomized Controlled Trial [NCT00289250]Phase 3360 participants Interventional2001-05-31Completed
Comparative Evaluation of the Safety and the Efficacy of Artemether + Lumefantrine (Coartem™) vs. Sulfadoxine + Pyrimethamine (SP) in Both HIV+ and HIV- Adults With Uncomplicated P. Falciparum Malaria in Zambia [NCT00304980]3,000 participants Interventional2003-03-31Terminated
Effect of Add-on Anti-Toxoplasmosis Treatment on Parameters Defining Toxoplasma Gondii Infection and on Psychopathology in Patients With Schizophrenia or Major Depression Serologically Positive for Toxoplasma Gondii - Phase 3 Study [NCT00300404]Phase 340 participants Interventional2002-01-31Completed
An Evaluation of Sulfadoxine-pyrimethamine Resistance and Effectiveness of IPTp in Nigeria [NCT01636895]Phase 4600 participants (Anticipated)Interventional2011-01-31Recruiting
An Individually Randomised Trial of Seasonal Malaria Chemoprevention Versus a Long-acting Artemisinin Combination Therapy for the Prevention of Malaria and Anaemia in Children Living in an Area of Extended Seasonal Transmission in Ghana. [NCT01651416]Phase 42,400 participants (Actual)Interventional2012-07-31Completed
Efficacy and Safety of Artesunate+Sulphadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Center Asadabad in Kunar Province of Afghanistan [NCT01707199]83 participants (Actual)Interventional2012-10-31Completed
A Randomized, Controlled Clinical Trial of Chloroquine as Chemoprophylaxis Versus Intermittent Preventive Therapy to Prevent Malaria in Pregnancy in Malawi [NCT01443130]Phase 3900 participants (Actual)Interventional2012-02-29Completed
Comparative Study of Efficacy of Two Antifolates Prophylactic Strategies Against Malaria in HIV Positive Pregnant Women (MACOMBA Study) [NCT01746199]Phase 3193 participants (Actual)Interventional2013-12-31Completed
Comparison of Two Strategies for the Delivery of Intermittent Preventive Treatment in Children (IPTc) in an Area of Seasonal Malaria Transmission [NCT00376155]Phase 414,000 participants (Actual)Interventional2006-05-31Completed
Controlled Human Malaria Infection Study to Assess Gametocytemia and Mosquito Transmissibility in Participants Challenged With Plasmodium Falciparum by Sporozoite or Blood Stage Challenge to Establish a Model for the Evaluation of Transmission-blocking In [NCT03454048]24 participants (Actual)Interventional2018-05-07Completed
Phase I/II Study of SOD1 Inhibition by Pyrimethamine in Familial ALS [NCT01083667]Phase 1/Phase 232 participants (Actual)Interventional2009-11-30Completed
An Open-label in Vivo Drug Study to Evaluate the Pharmacokinetics, Therapeutic Efficacy, Gametocyte Carriage and Birth Outcomes Following Sulfadoxine-pyrimethamine Intermittent Presumptive Treatment (SP IPT) in Pregnant Women [NCT00380146]31 participants (Actual)Interventional2006-09-30Completed
A Phase 1 Study of Pyrimethamine, a STAT3 Inhibitor, for the Treatment of Intermediate/ High-risk Myelodysplastic Syndromes (MDS) That Has Relapsed or is Refractory to Azanucleosides [NCT03057990]Phase 10 participants (Actual)Interventional2019-09-11Withdrawn(stopped due to Study never opened; closed on 06/29/2021 due to no enrllment)
Monitoring of Markers of Sulfadoxine-pyrimethamine (SP) Resistance in the Implementation Countries of TIPTOP Project [NCT03998839]7,200 participants (Actual)Observational2018-03-05Completed
Comparison of IST Using Ultra-sensitive Malaria Rapid Diagnostic Test and Pyronaridine - Artesunate - PYRAMAX®) to Standard IPT Sulfadoxine-pyrimethamine to Prevent Malaria in Pregnant Women Living in Endemic Areas [NCT04783051]Phase 3250 participants (Actual)Interventional2021-05-06Completed
Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Uncomplicated Malaria and in 2-10 Month Old Asymptomatic Infants. [NCT00361114]Phase 3112 participants (Actual)Interventional2006-07-31Terminated(stopped due to SP arms were stopped due to high levels of treatment failure.CD not available.)
Randomized, Single Oral Dose, Open-label, Single-period, Parallel Group, Bioequivalence Study to Compare Sulfadoxine/Pyrimethamine Two Dispersible Tablets (250 mg Sulfadoxine / 12.5 mg Pyrimethamine) Versus G-COSPE® One Tablet (500 mg Sulfadoxine / 25 mg [NCT05497063]Phase 170 participants (Anticipated)Interventional2022-12-31Not yet recruiting
Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial [NCT01722539]Phase 3616 participants (Actual)Interventional2012-11-30Completed
Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Kolokani Circle, Koulikoro Region, Mali, August-November 2016: Interventional Matched-pair Clustered Cohort [NCT03035305]36,717 participants (Actual)Interventional2016-08-31Completed
Feasibility and Effectiveness of Delivering Mass Drug Administration for Helminths Through the Seasonal Malaria Chemoprevention (SMC) Platform in a West African Paediatric Population [NCT05354258]600 participants (Anticipated)Interventional2022-06-16Active, not recruiting
A Prospective Randomized Open-Label Study on the Efficacy and Safety of Intermittent Preventive Treatment in Pregnancy (IPTp) With Dihydroartemisinin-Piperaquine (DP) Versus IPTp With Sulfadoxine-Pyrimethamine (SP) in Malawi [NCT03009526]Phase 3602 participants (Actual)Interventional2017-01-17Completed
A Controlled Comparative Trial of Trimethoprim - Sulfamethoxazole Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT) [NCT00000727]Phase 3322 participants InterventionalCompleted
Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 1) [NCT02163447]Phase 3300 participants (Actual)Interventional2014-06-23Completed
A Phase I/II Study of Pyrimethamine, a STAT3 Inhibitor, for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [NCT01066663]Phase 1/Phase 220 participants (Actual)Interventional2010-03-31Completed
Phase IV Randomized Study of Pyrimethamine, Sulfadiazine, and Leucovorin Calcium for Congenital Toxoplasmosis [NCT00004317]Phase 4600 participants (Anticipated)Interventional2000-07-31Recruiting
Pyrimethamine Plus Sulfadiazine Versus Trimethoprim Plus Sulfamethoxazole for Treatment of Toxoplasmic Encephalitis in AIDS Patients: A Randomized Controlled Trial. [NCT00367081]Phase 430 participants Interventional2003-05-31Completed
Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in Different Zones of Drug Resistance in Rwanda [NCT00372632]Phase 41,717 participants (Actual)Interventional2005-12-31Completed
Randomized Controlled Trial of the Impact of Offering a Nutrition and Health Intervention to Children Recovered From Moderate Acute Malnutrition [NCT02351687]1,499 participants (Actual)Interventional2014-04-30Completed
Improving Cognition and Gestational Duration With Targeted Nutrition [NCT05949190]1,600 participants (Anticipated)Interventional2023-08-18Recruiting
Monthly Versus Two Doses of Ante-Natal Intermittent Preventive Treatment With Sulphadoxine-Pyrimethamine in University College Hospital [NCT03599596]Phase 1136 participants (Anticipated)Interventional2018-09-01Not yet recruiting
Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual Blood Stag [NCT02511054]Phase 157 participants (Actual)Interventional2015-07-21Completed
Seasonal Malaria Chemoprevention in Burkina Faso : Chemoprevention Efficacy Study [NCT05478954]Phase 4800 participants (Actual)Interventional2022-07-15Active, not recruiting
Effectiveness, Feasibility and Acceptability of Seasonal Malaria Chemoprevention in Aweil South County in Northern Bahr Eel Ghazal, South Sudan: A Type 2 Hybrid Effectiveness-implementation Study Using a Convergent Mixed-methods Approach [NCT05471544]Phase 33,575 participants (Anticipated)Interventional2022-07-18Active, not recruiting
A Hybrid Effectiveness-implementation Study to Assess the Effectiveness and Chemoprevention Efficacy of Implementing Seasonal Malaria Chemoprevention in Five Districts in Karamoja Region, Uganda [NCT05323721]Phase 46,805 participants (Actual)Interventional2022-06-01Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00323622 (10) [back to overview]Anti-hepatitis B (HBs) Antibody Concentrations.
NCT00323622 (10) [back to overview]Anti-circumsporozoite Protein (CS) Antibody Concentrations.
NCT00323622 (10) [back to overview]Number of Subjects With Serious Adverse Events (SAEs)
NCT00323622 (10) [back to overview]Time to First or Only Episode of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI) of Secondary Case Definition 3
NCT00323622 (10) [back to overview]Time to First or Only Episode of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI) of Secondary Case Definition 2
NCT00323622 (10) [back to overview]Time to First or Only Episode of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI) of Secondary Case Definition 1
NCT00323622 (10) [back to overview]Time to First or Only Clinical Episode of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI) of Primary Case Definition
NCT00323622 (10) [back to overview]Number of Subjects With Anemia.
NCT00323622 (10) [back to overview]Number of Subjects Prevalent for Plasmodium Falciparum (P. Falciparum) Parasitemia
NCT00323622 (10) [back to overview]Number of Primary Case Definition Clinical Episodes of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI)
NCT00948896 (4) [back to overview]Incident Malaria Cases Per Person Year at Risk in HIV-exposed Participants
NCT00948896 (4) [back to overview]Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants
NCT00948896 (4) [back to overview]Rebound Incidence of Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk
NCT00948896 (4) [back to overview]Incidence of Any Adverse Events Defined as Severity Grade 3-4 That Are Possibly, Probably, or Definitely Related to Study Drugs
NCT01066663 (3) [back to overview]Median Progression Free Survival (PFS)
NCT01066663 (3) [back to overview]Incidence of Grade 3 or Higher Treatment-Related Toxicity
NCT01066663 (3) [back to overview]Phase I: Maximum Tolerated Dose (MTD)
NCT01083667 (2) [back to overview]Appel ALS Score
NCT01083667 (2) [back to overview]Mean Change in SOD1 CSF
NCT01103063 (30) [back to overview]Percentage of Participants With Pre-eclampsia From Week 20 to Delivery
NCT01103063 (30) [back to overview]Percentage of Participants With Severe Maternal Anemia (Hemoglobin [Hb] <8 g/dL) at 36-38 Weeks of Gestation
NCT01103063 (30) [back to overview]Percentage of Participants With Sexually Transmitted Infections From First Dose to 36-38 Weeks of Gestation
NCT01103063 (30) [back to overview]Percentage of Participants With Sub-optimal Pregnancy Outcome in Efficacy Analyzable Per Protocol (PP) Population
NCT01103063 (30) [back to overview]Percentage of Participants With Sub-optimal Pregnancy Outcome Including Neonatal Death and Congenital Malformation
NCT01103063 (30) [back to overview]Percentage of Participants With Treponema Pallidum Infection at 36-38 Weeks of Gestation
NCT01103063 (30) [back to overview]Percentage of Participants With Trichomonas Vaginalis Infection at 36-38 Weeks of Gestation
NCT01103063 (30) [back to overview]Percentage of Perinatal or Neonatal Deaths
NCT01103063 (30) [back to overview]Percentage Participants With Sub-optimal Pregnancy Outcome in Intent-to-Treat (IIT) Population
NCT01103063 (30) [back to overview]Sexually Transmitted Infection (STI) Episodes Per Participant
NCT01103063 (30) [back to overview]Nasopharyngeal Swabs Positive for Macrolide Resistant Streptococcus Pneumoniae
NCT01103063 (30) [back to overview]Nasopharyngeal Swabs Positive for Penicillin Resistant Streptococcus Pneumoniae
NCT01103063 (30) [back to overview]Birth Weight of Live Borne Neonate
NCT01103063 (30) [back to overview]Change From Baseline to 36-38 Weeks of Gestation in Hb Concentration.
NCT01103063 (30) [back to overview]Number of Episodes of Symptomatic Malaria Per Participant From First Intermittent Preventive Treatment of Falciparum Dose to Delivery
NCT01103063 (30) [back to overview]Percentage of Neonates With Congenital Abnormalities at Birth
NCT01103063 (30) [back to overview]Percentage of Neonates With LBW (<2500 g) in Efficacy Analyzable PP Population
NCT01103063 (30) [back to overview]Percentage of Neonates With LBW (<2500 g) in ITT Population
NCT01103063 (30) [back to overview]Percentage of Neonates With Ophthalmia Neonatorum at Birth Period
NCT01103063 (30) [back to overview]Percentage of Participants Requiring Additional Treatment for Symptomatic Malaria From First Dose to Delivery
NCT01103063 (30) [back to overview]Percentage of Participants With Bacterial Infections Including Pneumonia and Other Lower Respiratory Tract Infections From First Dose to Delivery
NCT01103063 (30) [back to overview]Percentage of Participants With Bacterial Vaginosis Infection at 36-38 Weeks of Gestation.
NCT01103063 (30) [back to overview]Percentage of Participants With Chlamydia Trachomatis Infection at 36-38 Weeks of Gestation
NCT01103063 (30) [back to overview]Percentage of Participants With Cord Blood Parasitemia at Delivery
NCT01103063 (30) [back to overview]Percentage of Participants With Maternal Anemia (Hb <11 g/dL) at 36-38 Weeks of Gestation
NCT01103063 (30) [back to overview]Percentage of Participants With Neisseria Gonorrhoeae Infection at 36-38 Weeks of Gestation
NCT01103063 (30) [back to overview]Percentage of Participants With Peripheral Parasitemia at 36-38 Weeks of Gestation
NCT01103063 (30) [back to overview]Percentage of Participants With Peripheral Parasitemia at Delivery
NCT01103063 (30) [back to overview]Percentage of Participants With Placental Malaria at Delivery Based on Histology
NCT01103063 (30) [back to overview]Percentage of Participants With Placental Parasitemia at Delivery
NCT01443130 (14) [back to overview]Incidence of Maternal Anemia (Hemoglobin < 10 Grams/Deciliter)
NCT01443130 (14) [back to overview]Infant Mortality Rate to 14 Weeks of Age
NCT01443130 (14) [back to overview]Incidence of Stillbirth
NCT01443130 (14) [back to overview]Incidence of Malaria Infection, All Species.
NCT01443130 (14) [back to overview]Incidence of Preterm Delivery
NCT01443130 (14) [back to overview]Incidence of Placental Malaria Infection Based on Histology
NCT01443130 (14) [back to overview]Incidence of Placental Malaria by Placental Impression Smear
NCT01443130 (14) [back to overview]Incidence of Miscarriage
NCT01443130 (14) [back to overview]Incidence of Maternal Severe Anemia (Hemoglobin < 7gm/dl)
NCT01443130 (14) [back to overview]Incidence of Low Birth Weight (LBW) (Birthweight < 2500 Grams)
NCT01443130 (14) [back to overview]Incidence of Intrauterine Growth Restriction (IUGR)
NCT01443130 (14) [back to overview]Incidence of Infection in the Fetal Circulation
NCT01443130 (14) [back to overview]Incidence of Clinical Malaria, All Species
NCT01443130 (14) [back to overview]Incidence of Active Placental Malaria Infection
NCT02163447 (14) [back to overview]Incidence of Malaria in Infants
NCT02163447 (14) [back to overview]Incidence of Malaria in Infants
NCT02163447 (14) [back to overview]Incidence of Hospital Admissions in Infants
NCT02163447 (14) [back to overview]Incidence of Complicated Malaria in Infants
NCT02163447 (14) [back to overview]Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (<2500g), Still Birth, Pre-term Delivery
NCT02163447 (14) [back to overview]Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery
NCT02163447 (14) [back to overview]Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP
NCT02163447 (14) [back to overview]Prevalence of Placental Malaria
NCT02163447 (14) [back to overview]Prevalence of Parasitemia in Infants
NCT02163447 (14) [back to overview]Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy
NCT02163447 (14) [back to overview]Prevalence of Gametocytemia in Pregnant Women
NCT02163447 (14) [back to overview]Prevalence of Gametocytemia in Infants
NCT02163447 (14) [back to overview]Prevalence of Anemia in Pregnant Women
NCT02163447 (14) [back to overview]Incidence of Malaria in Pregnant Women
NCT02793622 (14) [back to overview]Prevalence of Placental Parasitemia
NCT02793622 (14) [back to overview]Prevalence of Maternal Malaria
NCT02793622 (14) [back to overview]Prevalence of Placental Malaria by Histology
NCT02793622 (14) [back to overview]Prevalence of Anemia in Infants
NCT02793622 (14) [back to overview]Incidence of Complicated Malaria in Infants
NCT02793622 (14) [back to overview]Incidence of Hospital Admissions in Infants
NCT02793622 (14) [back to overview]Incidence of Malaria in Infants
NCT02793622 (14) [back to overview]Infant Mortality Rate
NCT02793622 (14) [back to overview]Mean Gestational Age in Weeks at Birth
NCT02793622 (14) [back to overview]Number of Participants Who Deliver With a Composite Adverse Birth Outcome
NCT02793622 (14) [back to overview]Number of Participants With Adverse Events
NCT02793622 (14) [back to overview]Prevalence of Anemia in Pregnant Women
NCT02793622 (14) [back to overview]Prevalence of Asymptomatic Parasitemia in Infants
NCT02793622 (14) [back to overview]Prevalence of Asymptomatic Parasitemia in Pregnant Women
NCT03083847 (4) [back to overview]Number of Participants With Local and Systemic Adverse Events (AEs)
NCT03083847 (4) [back to overview]Number of Participants With P.Falciparum Blood Stage Infection
NCT03083847 (4) [back to overview]Number of Participants With Serious Adverse Events (SAEs)
NCT03083847 (4) [back to overview]Number of Participants Requiring Treatment With Additional Anti-malarial Medication
NCT03258762 (36) [back to overview]Apparent Clearance Following Oral Dosing (CL/F) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]Apparent Volume of Distribution Following Oral Dosing (Vd/F) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
NCT03258762 (36) [back to overview]Number of Participants With Abnormal Urinalysis Parameter
NCT03258762 (36) [back to overview]Change From Baseline of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, and QT Interval Corrected for Heart Rate by Fredericia's Formula (QTcF) Interval
NCT03258762 (36) [back to overview]Change From Baseline of ECG Parameter: ECG Mean Heart Rate
NCT03258762 (36) [back to overview]Change From Baseline of Clinical Chemistry Parameters: Protein
NCT03258762 (36) [back to overview]Urine Potential of Hydrogen (pH) at Indicated Time Points
NCT03258762 (36) [back to overview]Area Under the Concentration-time Curve From Time 0 to 24 (AUC[0-24]) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]Change From Baseline of Clinical Chemistry Parameters: Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)
NCT03258762 (36) [back to overview]Change From Baseline in Temperature
NCT03258762 (36) [back to overview]Change From Baseline in Pulse Rate
NCT03258762 (36) [back to overview]Specific Gravity at Indicated Time Points
NCT03258762 (36) [back to overview]Change From Baseline of Clinical Chemistry Parameters: Glucose, Sodium, Calcium, Potassium, and Urea.
NCT03258762 (36) [back to overview]Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet and Leukocytes
NCT03258762 (36) [back to overview]Change From Baseline in Hematology Parameter: Reticulocytes
NCT03258762 (36) [back to overview]Change From Baseline in Hematology Parameter: Mean Corpuscular Volume
NCT03258762 (36) [back to overview]Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin
NCT03258762 (36) [back to overview]Change From Baseline in Hematology Parameter: Hemoglobin
NCT03258762 (36) [back to overview]Change From Baseline in Hematology Parameter: Erythrocytes
NCT03258762 (36) [back to overview]Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
NCT03258762 (36) [back to overview]AUC (0-24) of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]Vd/F of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]Change From Baseline of Clinical Chemistry Parameters: Direct Bilirubin, Bilirubin, Creatinine.
NCT03258762 (36) [back to overview]Tmax of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]Time to Maximum Observed Concentration (Tmax) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]Terminal Half-life (t1/2) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]T1/2 of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]Maximum Observed Concentration (Cmax) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]Change From Baseline in Hematology Parameter: Hematocrit
NCT03258762 (36) [back to overview]Cmax of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]CL/F of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]AUC (0-t) of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]AUC (0-inf) of Pyrimethamine in Healthy Caucasian Male Participants
NCT03258762 (36) [back to overview]Area Under the Concentration-time Curve From Time 0 to t (AUC[0-t]) of Pyrimethamine in Healthy Japanese Male Participants
NCT03258762 (36) [back to overview]Area Under the Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) of Pyrimethamine in Healthy Japanese Male Participants
NCT03454048 (8) [back to overview]Magnitude of Adverse Events in the CHMI-trans Model
NCT03454048 (8) [back to overview]Frequency of Adverse Events in the CHMI-trans Model
NCT03454048 (8) [back to overview]Gametocyte Prevalence
NCT03454048 (8) [back to overview]AUC Gametocytes
NCT03454048 (8) [back to overview]Gametocyte Commitment
NCT03454048 (8) [back to overview]Number of Participants Infectious for Mosquitoes Through DFA
NCT03454048 (8) [back to overview]Peak Density Gametocytes
NCT03454048 (8) [back to overview]Gametocyte Sex-ratio
NCT03952650 (3) [back to overview]Number of Participants With Local and Systemic Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT03952650 (3) [back to overview]Number of Participants With Local and Systemic Grade 3 Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT03952650 (3) [back to overview]Number of Participants With Positive Sensitive Blood Smear (sBS)

Anti-hepatitis B (HBs) Antibody Concentrations.

Concentrations are presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL). Anti-HBs antibody concentration levels were measured in blood samples from Cohort 2 only. (NCT00323622)
Timeframe: At Months 33 and 45 (Month 0 = administration of Dose 1 of RTS,S/AS02A or comparator vaccine in the NCT00197041 study).

,,,
InterventionmIU/mL (Geometric Mean)
Month 33 [N = 33, 116, 34, 115]Month 45 [N = 35, 115, 32, 113]
Cohort 2-Engerix-B ≥24M Group67.499.4
Cohort 2-Prevnar- Hiberix <24M Group20.326.6
Cohort 2-RTS,S/AS02A <24M Group4008.63323.8
Cohort 2-RTS,S/AS02A ≥24M Group1842.51557.0

[back to top]

Anti-circumsporozoite Protein (CS) Antibody Concentrations.

Concentrations for anti-CS antibodies are presented as Geometric Mean Concentrations (GMCs), expressed in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL). The cut-off of the assay was the seropositivity cut-off of 0.5 EL.U/mL. Subjects were pooled across age ranges for this outcome measure. (NCT00323622)
Timeframe: At Months 33 and 45 (Month 0 = administration of Dose 1 of RTS,S/AS02A or comparator vaccine in the NCT00197041 study).

,,,
InterventionEL.U/mL (Geometric Mean)
Month 33 [N = 490, 487, 149, 149]Month 45 [N = 452, 447, 150, 145]
Cohort 1-Engerix-B/Prevnar-Hiberix GroupNANA
Cohort 1-RTS,S/AS02A Group10.18.9
Cohort 2-Engerix-B/Prevnar-Hiberix Group0.60.4
Cohort 2-RTS,S/AS02A Group16.215.4

[back to top]

Number of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. (NCT00323622)
Timeframe: Throughout the entire study period: from Month 21 to Month 45 (Month 0 = administration of Dose 1 of RTS,S/AS02A or comparator vaccine in the NCT00197041 study).

InterventionSubjects (Number)
Cohort 1-RTS,S/AS02A <24M Group21
Cohort 1-RTS,S/AS02A ≥24M Group17
Cohort 2-RTS,S/AS02A <24M Group1
Cohort 2-RTS,S/AS02A ≥24M Group0
Cohort 1-Prevnar-Hiberix <24M Group24
Cohort 1-Engerix-B ≥24M Group29
Cohort 2-Prevnar- Hiberix <24M Group1
Cohort 2-Engerix-B ≥24M Group4

[back to top]

Time to First or Only Episode of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI) of Secondary Case Definition 3

PFMI was detected by passive case detection. Symptomatic PFMI of Secondary Case Definition (SCD) 3 was defined as the presence of P. falciparum asexual parasitaemia above 15000 per microliter (µL) on Giemsa stained thick blood films accompanied by fever (axillary temperature equal or above 37.5 degrees Celsius) in an unwell child brought for treatment to a healthcare facility. The time to first or only episode of symptomatic PFMI is expressed in terms of rate of first PFMI (RPFMI), that is, the number of PFMI events reported (n) over the period elapsed until the PFMI event occurred (i.e. events per Persons Year at Risk [PYAR]) for each group. Analysis for this outcome was performed on Cohort 1 subjects solely, with groups pooled across age ranges. (NCT00323622)
Timeframe: From Month 21 to Month 33 (M21-33), and from Month 33 to Month 45 (M33-45). Month 0 = administration of Dose 1 of RTS,S/AS02A or comparator vaccine in study NCT00197041

,
Interventionn/PYAR (Number)
RPFMI - SCD 3 - M21-33 (N=650;645)RPFMI - SCD 3 - M33-45 (N=638;629)
Cohort 1-Engerix-B/Prevnar-Hiberix Group0.3290.122
Cohort 1-RTS,S/AS02A Group0.2880.122

[back to top]

Time to First or Only Episode of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI) of Secondary Case Definition 2

PFMI was detected by passive case detection. Symptomatic PFMI of Secondary Case Definition (SCD) 2 was defined as the presence of P. falciparum asexual parasitaemia (any level if parasitemia) on Giemsa stained thick blood films in an unwell child brought for treatment with a history of fever (axillary temperature equal or above 37.5 degrees Celsius) within 24 hours or documented fever. The time to first or only episode of symptomatic PFMI is expressed in terms of rate of first PFMI (RPFMI), that is, the number of PFMI events reported (n) over the period elapsed until the PFMI event occurred (i.e. events per Persons Year at Risk [PYAR]) for each group. Analysis for this outcome was performed on Cohort 1 subjects, with groups pooled across age ranges. (NCT00323622)
Timeframe: From Month 21 to Month 33 (M21-33), and from Month 33 to Month 45 (M33-45). Month 0 = administration of Dose 1 of RTS,S/AS02A or comparator vaccine in study NCT00197041

,
Interventionn/PYAR (Number)
RPFMI - SCD 2 - M21-33 (N=650;645)RPFMI - SCD 2 - M33-45 (N=638;629)
Cohort 1-Engerix-B/Prevnar-Hiberix Group0.6300.270
Cohort 1-RTS,S/AS02A Group0.5400.260

[back to top]

Time to First or Only Episode of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI) of Secondary Case Definition 1

PFMI was detected by passive case detection. Symptomatic PFMI of Secondary Case Definition (SCD) 1 was defined as the presence of P. falciparum asexual parasitaemia (any level if parasitemia) on Giemsa stained thick blood films accompanied by fever (axillary temperature equal or above 37.5 degrees Celsius) in an unwell child brought for treatment. The time to first or only episode of symptomatic PFMI is expressed in terms of rate of first PFMI (RPFMI), that is, the number of PFMI events reported (n) over the period elapsed until the PFMI event occurred (i.e. events per Persons Year at Risk [PYAR]) for each group. Analysis for this outcome was solely performed on Cohort 1 subjects, with groups pooled across age ranges. (NCT00323622)
Timeframe: From Month 21 to Month 33 (M21-33), and from Month 33 to Month 45 (M33-45). Month 0 = administration of Dose 1 of RTS,S/AS02A or comparator vaccine in study NCT00197041

,
Interventionn/PYAR (Number)
RPFMI - SCD 1 - M21-33 (N=650;645)RPFMI - SCD 1 - M33-45 (N=638;629)
Cohort 1-Engerix-B/Prevnar-Hiberix Group0.4090.174
Cohort 1-RTS,S/AS02A Group0.3650.161

[back to top]

Time to First or Only Clinical Episode of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI) of Primary Case Definition

Malaria infection by Plasmodium falciparum was detected by passive case detection. A symptomatic PFMI episode of Primary Case Definition (PCD) was defined as the presence of P. falciparum asexual parasitaemia above 2500 per µL on Giemsa stained thick blood films accompanied by fever (axillary temperature equal or above 37.5 degrees Celsius at the time of presentation) occurring in an unwell child brought for treatment to a healthcare facility. The time to first or only episode of symptomatic PFMI is expressed in terms of rate of first PFMI (RPFMI), that is, the number of PFMI events reported (n) over the period elapsed until the PFMI event occurred (i.e. events per Persons Year at Risk [PYAR]) for each group. Analysis for this outcome was solely performed on Cohort 1 subjects, with groups pooled across age ranges. (NCT00323622)
Timeframe: From Month 21 to Month 33 (M21-33), and from Month 33 to Month 45 (M33-45). Month 0 = administration of Dose 1 of RTS,S/AS02A or comparator vaccine in study NCT00197041

,
Interventionn/PYAR (Number)
RPFMI - PCD - M21-33 (N=650;645)RPFMI - PCD - M33-45 (N=638;629)
Cohort 1-Engerix-B/Prevnar-Hiberix Group0.3750.149
Cohort 1-RTS,S/AS02A Group0.3300.140

[back to top]

Number of Subjects With Anemia.

"Anemia was indicated by a hematocrit level (HL) below (<) 25%. The numbers of subjects with HL below (<) and above or equal (≥) 25 %, and with missing HL results were tabulated. In the tabulation below, the number of subjects falling into the HL ≥25% category corresponds to the number of subjects with anemia as asked per outcome. Analysis for this outcome was performed on Cohort 1 subjects solely, with groups pooled across age ranges." (NCT00323622)
Timeframe: At Months 33 and 45 (Month 0 = administration of Dose 1 of RTS,S/AS02A or comparator vaccine in the NCT00197041 study).

,
InterventionSubjects (Number)
HL <25%, Month 33 (N = 650, 645)HL ≥25%, Month 33 (N = 650, 645])Missing Results, Month 33 (N = 650;645)HL <25%, Month 45 (N = 638, 629)HL ≥25%, Month 45 (N = 638, 629)Missing Results, Month 45 (N = 638;629)
Cohort 1-Engerix-B/Prevnar-Hiberix Group259350054386
Cohort 1-RTS,S/AS02A Group258464054098

[back to top]

Number of Subjects Prevalent for Plasmodium Falciparum (P. Falciparum) Parasitemia

Subjects prevalent for P. falciparum parasitemia were defined as subjects with the presence of P. falciparum asexual parasitemia above 0 per microliter (µL) on Giemsa stained thick blood films.Analysis for this outcome was performed on Cohort 1 subjects solely, with groups pooled across age ranges. (NCT00323622)
Timeframe: At Months 33 (M33) and 45 (M45) (Month 0 = administration of Dose 1 of RTS,S/AS02A or comparator vaccine in the NCT00197041 study).

,
InterventionSubjects (Number)
Subjects prevalent for parasitemia, M33[N=590,590]Subjects prevalent for parasitemia, M45[N=541,547]
Cohort 1-Engerix-B/Prevnar-Hiberix Group121101
Cohort 1-RTS,S/AS02A Group9366

[back to top]

Number of Primary Case Definition Clinical Episodes of Symptomatic Plasmodium Falciparum Malaria Infection (PFMI)

PFMI was detected by passive case detection. A symptomatic PFMI episode of Primary Case Definition (PCD) was defined as the presence of P. falciparum asexual parasitaemia above 2500 per µL on Giemsa stained thick blood films accompanied by fever (axillary temperature equal or above 37.5 degrees Celsius at the time of presentation) occurring in an unwell child brought for treatment to a healthcare facility. The number of PFMI episodes (EPFMI) per person-year (pyr) was tabulated, using as unit EPFMI episode per pyr. Analysis for this outcome was performed on Cohort 1 subjects solely, with groups pooled across age ranges. (NCT00323622)
Timeframe: From Month 21 to Month 33 (M21-33), and from Month 33 to Month 45 (M33-45). Month 0 = administration of Dose 1 of RTS,S/AS02A or comparator vaccine in study NCT00197041

,
InterventionEPFMI episode per pyr (Number)
EPFMI - PCD - M21-33 (N=650;645)EPFMI - PCD - M33-45 (N=638;629)
Cohort 1-Engerix-B/Prevnar-Hiberix Group291100
Cohort 1-RTS,S/AS02A Group25299

[back to top]

Incident Malaria Cases Per Person Year at Risk in HIV-exposed Participants

The primary outcome was the incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given. Treatments within 14 days of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 days after each treatment for malaria. (NCT00948896)
Timeframe: Randomization to 24 months of age

,,,
InterventionEpisodes per person year at risk (Number)
Randomization - 24 mo. of AgeRandomization -16 mo. of Age17-24 mo. of Age
HIV-exposed & Daily TS2.861.703.79
HIV-exposed & Monthly DP1.830.902.67
HIV-exposed & Monthly SP4.503.725.22
HIV-exposed & no Chemoprevention6.285.427.04

[back to top]

Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants

The incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given (6-24 mo of age). Treatments within 14d of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 d after each treatment for malaria. (NCT00948896)
Timeframe: 6 to 24 months of age

,,,
InterventionEpisode per person year at risk (Number)
6-24 mo. of Age6-11 mo. of Age12-24 mo. of Age
HIV-unexposed & Daily TS5.213.276.32
HIV-unexposed & Monthly DP3.021.493.88
HIV-unexposed & Monthly SP6.735.517.41
HIV-unexposed & no Chemoprevention6.956.417.24

[back to top]

Rebound Incidence of Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk

(NCT00948896)
Timeframe: 24 months to 36 months of age

,,,,,,,
InterventionIncidence per person year at risk (Number)
All incident episodes of malariaComplicated malariaAll-cause hospital admissions
HIV-exposed & Daily TS8.130.1160.186
HIV-exposed & Monthly DP6.780.0440.089
HIV-exposed & Monthly SP6.750.1470.318
HIV-exposed & no Chemoprevention9.080.1610.459
HIV-unexposed & Daily TS10.900.0460.091
HIV-unexposed & Monthly DP10.7700.023
HIV-unexposed & Monthly SP11.980.1320.452
HIV-unexposed & no Chemoprevention10.850.0460.046

[back to top] [back to top]

Median Progression Free Survival (PFS)

Progression-free survival based on the Kaplan-Meier method is defined as the duration of time from study entry to documented disease progression (PD) or death. Per RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions. (NCT01066663)
Timeframe: Disease were evaluated weekly in 1st 28 days, and every 2 weeks in 2nd cycle then monthly, and every 3-6 months during the follow-up.

Interventionmonths (Median)
DL1: Pyrimethamine 12.5 mg1.116
DL2: Pyrimethamine 25 mg3.677
DL3: Pyrimethamine 50 mg0.969

[back to top] [back to top]

Phase I: Maximum Tolerated Dose (MTD)

maximum tolerated dose and recommended Phase 2 dose pyrimethamine (NCT01066663)
Timeframe: Disease were evaluated weekly in 1st 28 days, and every 2 weeks in 2nd cycle then monthly. Median treatment duration is 1.07 months with range 0.23-9.99 months.

Interventionmg (Number)
Pyrimethamine Phase 1 (Dose-escalation)NA

[back to top]

Appel ALS Score

an objective and timed measurement of strength and function of subjects including muscle testing, respiratory function and fine motor function, all summed together for a total value, and is measured at baseline, visit 2, visit 6 and end of study. The scale ranges from 30 in a healthy person to to 164 in a maximally impaired person; an increase in score indicates progression and is expected in disease progression. (NCT01083667)
Timeframe: Week 0, 6, 18, and end of study

Interventionunits on a scale (Number)
Pyrimethamine18

[back to top]

Mean Change in SOD1 CSF

Reported change in mean SOD1 CSf from baseline to visit 6 (week 18) and end of study for all subjects who completed the measure (NCT01083667)
Timeframe: baseline, Visit 6 week 18, end of study

Interventionng/ml (Mean)
Pyrimethamine6.8

[back to top]

Percentage of Participants With Pre-eclampsia From Week 20 to Delivery

Pre-eclampsia was diagnosed as systolic blood pressure of at least 140 mmHg and/or diastolic blood pressure of at least 90 mmHg on two separate readings taken at least 4 hours apart and proteinuria at least 300 mg protein in a 24 hour urine collection. (NCT01103063)
Timeframe: From Week 20 to approximately 40 weeks of gestational age

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine0.63
Sulfadoxine + Pyrimethamine1.04

[back to top]

Percentage of Participants With Severe Maternal Anemia (Hemoglobin [Hb] <8 g/dL) at 36-38 Weeks of Gestation

Severe maternal anemia was defined as Hb <8 g/dL. (NCT01103063)
Timeframe: At 36-38 weeks of gestation.

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine1.80
Sulfadoxine + Pyrimethamine2.00

[back to top]

Percentage of Participants With Sexually Transmitted Infections From First Dose to 36-38 Weeks of Gestation

Sexual transmitted disease included Treponema pallidum, Neisseria gonorrhoeae, and Chlamydia trachomatis infections. This was diagnosed based on clinical presentation prior to Week 36-38 and/or lab test results between Week 36-38. (NCT01103063)
Timeframe: Upto 36-38 weeks of gestation

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine12.32
Sulfadoxine + Pyrimethamine16.47

[back to top]

Percentage of Participants With Sub-optimal Pregnancy Outcome in Efficacy Analyzable Per Protocol (PP) Population

Adverse pregnancy outcomes were defined as live-borne neonate (singleton) with LBW (<2,500g), premature births (<37 weeks as confirmed by the Ballard score), abortion (≤28 weeks), still birth (>28 weeks), lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age

InterventionPercentage of Participants (Number)
Azithromycin + Chloroquine10.38
Sulfadoxine + Pyrimethamine10.12

[back to top]

Percentage of Participants With Sub-optimal Pregnancy Outcome Including Neonatal Death and Congenital Malformation

Sub-optimal pregnancy outcome including neonatal deaths and congenital malformations, defined as any of the following: live-borne neonate (singleton) with low birth-weight (or LBW for short, defined as live birth weight <2,500g), premature birth (<37 weeks), abortion (≤28 weeks), still birth (>28 weeks), neonatal death, congenital malformation, lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age.

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine28.51
Sulfadoxine + Pyrimethamine26.51

[back to top]

Percentage of Participants With Treponema Pallidum Infection at 36-38 Weeks of Gestation

Participants positive for Treponema pallidum infection was diagnosed based on laboratory result at 36-38 weeks of gestation. Treponema Pallidum particle Agglutination Assay was used. (NCT01103063)
Timeframe: At 36-38 weeks of gestation

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine0.93
Sulfadoxine + Pyrimethamine2.01

[back to top]

Percentage of Participants With Trichomonas Vaginalis Infection at 36-38 Weeks of Gestation

Participants positive for Trichomonas vaginalis infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected for the laboratory test. (NCT01103063)
Timeframe: At 36-38 weeks of gestation

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine8.24
Sulfadoxine + Pyrimethamine10.67

[back to top]

Percentage of Perinatal or Neonatal Deaths

Percentage of perinatal or neonatal deaths were noted. (NCT01103063)
Timeframe: Day 28 after delivery.

InterventionPercentage of neonates (Number)
Azithromycin + Chloroquine2.19
Sulfadoxine + Pyrimethamine1.85

[back to top]

Percentage Participants With Sub-optimal Pregnancy Outcome in Intent-to-Treat (IIT) Population

Adverse pregnancy outcomes were defined as live-borne neonate (singleton) with low birth weight (LBW) (<2,500 g), premature births (<37 weeks as confirmed by the Ballard score), abortion (≤28 weeks), still birth (>28 weeks), lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine26.16
Sulfadoxine + Pyrimethamine23.67

[back to top]

Sexually Transmitted Infection (STI) Episodes Per Participant

Number of episodes of sexually transmitted infection episodes per participant were noted. The STI's including Treponema pallidum, Neisseria gonorrhoeae, Chlamydia trachomatis, from first dose to delivery (diagnosis was based on clinical presentation and lab results). (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age .

InterventionNumber of episodes (Least Squares Mean)
Azithromycin + Chloroquine0.14
Sulfadoxine + Pyrimethamine0.19

[back to top]

Nasopharyngeal Swabs Positive for Macrolide Resistant Streptococcus Pneumoniae

This outcome measure evaluated the Streptococcus pneumoniae sensitivity against macrolide antibiotics. (NCT01103063)
Timeframe: Visits 6 and 7

,
InterventionPercentage of participants (Number)
Visit 6 (N = 8 and 17 respectively)Visit 7 (N = 16 and 11 respectively)
Azithromycin + Chloroquine00
Sulfadoxine + Pyrimethamine11.760

[back to top]

Nasopharyngeal Swabs Positive for Penicillin Resistant Streptococcus Pneumoniae

This outcome measure evaluated the Streptococcus pneumoniae sensitivity against penicillin antibiotics. (NCT01103063)
Timeframe: Visits 6 and 7

,
InterventionPercentage of participants (Number)
Visit 6 (N = 8 and 17 respectively)Visit 7 (N = 16 and 11 respectively)
Azithromycin + Chloroquine00
Sulfadoxine + Pyrimethamine00

[back to top]

Birth Weight of Live Borne Neonate

Birth weight of live borne neonates were calculated in grams. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age.

Interventiongrams (Least Squares Mean)
Azithromycin + Chloroquine3148.3
Sulfadoxine + Pyrimethamine3146.2

[back to top]

Change From Baseline to 36-38 Weeks of Gestation in Hb Concentration.

Change from Baseline to 36-38 weeks of gestation in Hb concentration was noted. (NCT01103063)
Timeframe: Baseline, at 36-38 weeks of gestation.

Interventiong/dL (Least Squares Mean)
Azithromycin + Chloroquine0.13
Sulfadoxine + Pyrimethamine0.27

[back to top]

Number of Episodes of Symptomatic Malaria Per Participant From First Intermittent Preventive Treatment of Falciparum Dose to Delivery

This outcome measure determined if an episode of malaria started within the time period of first dose to delivery. Clinical episode of malaria was determined if the participant presented with clinical symptoms of malaria (fever >37.5°C, oral) and diagnosed (either by rapid diagnostic tests or microscopy) with malaria. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age

InterventionNumber of episodes (Least Squares Mean)
Azithromycin + Chloroquine0.06
Sulfadoxine + Pyrimethamine0.13

[back to top]

Percentage of Neonates With Congenital Abnormalities at Birth

Neonates with congenital abnormalities at birth were noted. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age.

InterventionPercentage of neonates (Number)
Azithromycin + Chloroquine2.19
Sulfadoxine + Pyrimethamine2.44

[back to top]

Percentage of Neonates With LBW (<2500 g) in Efficacy Analyzable PP Population

LBW was defined as live birth weight <2500 g (up to and including 2499 g). (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age

InterventionPercentage of neonates (Number)
Azithromycin + Chloroquine4.72
Sulfadoxine + Pyrimethamine5.21

[back to top]

Percentage of Neonates With LBW (<2500 g) in ITT Population

LBW was defined as live birth weight <2500 g (up to and including 2499 g). (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age

InterventionPercentage of neonates (Number)
Azithromycin + Chloroquine5.01
Sulfadoxine + Pyrimethamine5.72

[back to top]

Percentage of Neonates With Ophthalmia Neonatorum at Birth Period

Ophthalmia neonatorum was diagnosed at birth. The laboratory diagnosis was performed among neonates with purulent discharge. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age

InterventionPercentage of neonates (Number)
Azithromycin + Chloroquine0.35
Sulfadoxine + Pyrimethamine0.17

[back to top]

Percentage of Participants Requiring Additional Treatment for Symptomatic Malaria From First Dose to Delivery

This outcome measure evaluated the participants requiring additional treatments for malaria during the study period following the first dose (diagnosed based on clinical presentation and/or lab test results). (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine5.74
Sulfadoxine + Pyrimethamine10.52

[back to top]

Percentage of Participants With Bacterial Infections Including Pneumonia and Other Lower Respiratory Tract Infections From First Dose to Delivery

Participants positive for bacterial infections including other lower respiratory tract infections were measured anytime from first dose administration to delivery. (NCT01103063)
Timeframe: Up to approximately 40 weeks of gestational age

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine0.48
Sulfadoxine + Pyrimethamine1.25

[back to top]

Percentage of Participants With Bacterial Vaginosis Infection at 36-38 Weeks of Gestation.

Bacterial vaginosis was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected for the Gram staining. (NCT01103063)
Timeframe: At 36-38 weeks of gestation

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine8.58
Sulfadoxine + Pyrimethamine11.84

[back to top]

Percentage of Participants With Chlamydia Trachomatis Infection at 36-38 Weeks of Gestation

Participants positive for Chlamydia trachomatis infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected and PCR assay was used for analysis. (NCT01103063)
Timeframe: At 36-38 weeks of gestation

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine1.47
Sulfadoxine + Pyrimethamine0.63

[back to top]

Percentage of Participants With Cord Blood Parasitemia at Delivery

This outcome measure evaluated the percentage of participants positive for cord blood parasitemia at delivery. A participant was positive for parasitemia if the number of asexual parasites per μL was >0. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine0.49
Sulfadoxine + Pyrimethamine0.75

[back to top]

Percentage of Participants With Maternal Anemia (Hb <11 g/dL) at 36-38 Weeks of Gestation

Anemia was defined as Hb <11 g/dL. (NCT01103063)
Timeframe: At 36-38 weeks of gestation.

InterventionPercentage of Participants (Number)
Azithromycin + Chloroquine50.57
Sulfadoxine + Pyrimethamine49.11

[back to top]

Percentage of Participants With Neisseria Gonorrhoeae Infection at 36-38 Weeks of Gestation

Participants positive for Neisseria gonorrhoeae infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected and PCR assay was used for analysis. (NCT01103063)
Timeframe: At 36-38 weeks of gestation

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine0.40
Sulfadoxine + Pyrimethamine1.64

[back to top]

Percentage of Participants With Peripheral Parasitemia at 36-38 Weeks of Gestation

This outcome measure evaluated the percentage of participants positive for peripheral parasitemia at 36-38 weeks of gestation. A participant was positive for parasitemia if the number of asexual parasites per μL was >0. (NCT01103063)
Timeframe: At 36-38 weeks of gestation

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine2.71
Sulfadoxine + Pyrimethamine4.38

[back to top]

Percentage of Participants With Peripheral Parasitemia at Delivery

This outcome measure evaluated the percentage of participants positive for peripheral parasitemia at delivery. A participant was positive for parasitemia if the number of asexual parasites per μL was >0. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine6.05
Sulfadoxine + Pyrimethamine7.46

[back to top]

Percentage of Participants With Placental Malaria at Delivery Based on Histology

Participants positive for placental malaria at delivery were evaluated based on placental histology. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine4.81
Sulfadoxine + Pyrimethamine5.73

[back to top]

Percentage of Participants With Placental Parasitemia at Delivery

Participants with placental parasitemia at delivery were diagnosed using Placental blood smear at birth from participants who deliver at hospital. (NCT01103063)
Timeframe: Approximately 40 weeks of gestational age

InterventionPercentage of participants (Number)
Azithromycin + Chloroquine5.30
Sulfadoxine + Pyrimethamine5.67

[back to top]

Incidence of Maternal Anemia (Hemoglobin < 10 Grams/Deciliter)

Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of anemia among maternal participants during pregnancy . Anemia is defined as having a hemoglobin value less than 10 grams/deciliter (gm/dL). (NCT01443130)
Timeframe: From enrollment until delivery, approximately 12-36 weeks

Interventionpercentage of maternal participants (Number)
Maternal Chloroquine Prophylaxis18.3
Maternal Chloroquine IPT23.7
Maternal SP IPT22.0

[back to top]

Infant Mortality Rate to 14 Weeks of Age

Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants who died within 14 weeks of delivery. (NCT01443130)
Timeframe: For 14 weeks after delivery.

Interventionpercentage of infants (Number)
Infant Chloroquine Prophylaxis2.22
Infant Chloroquine IPT3.65
Infant SP IPT3.09

[back to top]

Incidence of Stillbirth

Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was stillbirth, defined as an infant born without any signs of life at 28 weeks or greater of gestation. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment

Interventionpercentage of deliveries (Number)
Maternal Chloroquine Prophylaxis1.10
Maternal Chloroquine IPT0.37
Maternal SP IPT1.90

[back to top]

Incidence of Malaria Infection, All Species.

Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of malaria infection episodes measured by positive parasitemia in maternal subjects. (NCT01443130)
Timeframe: Enrollment to delivery (approximately 12-36 weeks)

Interventionpercentage of participants (Number)
Maternal Chloroquine Prophylaxis0.67
Maternal Chloroquine IPT1.67
Maternal SP IPT3.00

[back to top]

Incidence of Preterm Delivery

Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was preterm delivery, defined as delivery less than 37 weeks of gestation. The outcome of the delivery was not considered, and could have been live birth, stillbirth, or miscarriage. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment

Interventionpercentage of deliveries (Number)
Maternal Chloroquine Prophylaxis8.46
Maternal Chloroquine IPT9.89
Maternal SP IPT6.84

[back to top]

Incidence of Placental Malaria Infection Based on Histology

The placenta was collected at the time of delivery for examination by histology to determine malaria infection. Malaria infection was concluded if histology identified parasites or malaria pigment in the placental tissue. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment

Interventionpercentage of pregnancies (Number)
Maternal Chloroquine Prophylaxis11.58
Maternal Chloroquine IPT15.42
Maternal SP IPT15.42

[back to top]

Incidence of Placental Malaria by Placental Impression Smear

Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of malaria infection in the placenta based on diagnosis by positive placental impression smear results. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment

Interventionpercentage of placentas (Number)
Maternal Chloroquine Prophylaxis0
Maternal Chloroquine IPT0
Maternal SP IPT0.40

[back to top]

Incidence of Miscarriage

Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was miscarriage, defined as an infant delivered without any signs of life at less than 28 weeks of gestation. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment

Interventionpercentage of pregnancies (Number)
Maternal Chloroquine Prophylaxis0.33
Maternal Chloroquine IPT0.67
Maternal SP IPT1.00

[back to top]

Incidence of Maternal Severe Anemia (Hemoglobin < 7gm/dl)

Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of severe anemia among maternal participants during pregnancy. Severe anemia is defined as having a hemoglobin value less than 7 gm/dl. (NCT01443130)
Timeframe: From enrollment until delivery, approximately 12-36 weeks

Interventionpercentage of maternal participants (Number)
Maternal Chloroquine Prophylaxis0.0
Maternal Chloroquine IPT0.3
Maternal SP IPT0.3

[back to top]

Incidence of Low Birth Weight (LBW) (Birthweight < 2500 Grams)

Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of infants whose birthweight was less than 2500 grams. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment

Interventionpercentage of infants (Number)
Infant Chloroquine Prophylaxis15.59
Infant Chloroquine IPT10.98
Infant SP IPT12.11

[back to top]

Incidence of Intrauterine Growth Restriction (IUGR)

Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants with IUGR at delivery. IUGR is defined as weight below the 10th percentile for gestational age based on the World Health Organization (WHO) fetal growth curve. This classification is supported by literature resulting from the INTERGROWTH-21st Project; José Villar. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment

Interventionpercentage of participants (Number)
Infant Chloroquine Prophylaxis16.54
Infant Chloroquine IPT18.01
Infant SP IPT20.80

[back to top]

Incidence of Infection in the Fetal Circulation

Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of positive for malaria cord blood smear and cord PCR results in maternal subjects based on the results of the thick smear and PCR from the cord blood sample. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment

Interventionpercentage of participants (Number)
Maternal Chloroquine Prophylaxis1.95
Maternal Chloroquine IPT2.78
Maternal SP IPT0.80

[back to top]

Incidence of Clinical Malaria, All Species

Maternal participants were followed to outcome of the pregnancy. Clinical malaria is defined as malaria infection at any parasite density with associated symptoms including at least one of the following: objective fever measured at the clinic, history of fever in the past 48 hours or other symptoms in the last 48 hours including: headache, myalgia, vomiting, or weakness. (NCT01443130)
Timeframe: Enrollment to delivery (approximately 12-36 weeks)

Interventionpercentage of participants (Number)
Maternal Chloroquine Prophylaxis0.67
Maternal Chloroquine IPT1.33
Maternal SP IPT3.00

[back to top]

Incidence of Active Placental Malaria Infection

Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of placental malaria infections in maternal subjects diagnosed by the presence of parasites and/or pigment on histological section or molecular evidence of infection (PCR). (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment

Interventionpercentage of participants (Number)
Maternal Chloroquine Prophylaxis3.09
Maternal Chloroquine IPT3.16
Maternal SP IPT4.74

[back to top]

Incidence of Malaria in Infants

Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age. (NCT02163447)
Timeframe: Time at risk will begin at birth and will end when study participants reaches 24 months of age or early study termination (if prior to 24 months of age)

InterventionEvents per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy0.26
3 Dose DP Pregnancy / 3 Monthly DP Infancy0.30
3 Dose DP Pregnancy / Monthly DP Infancy0.00
Monthly DP Pregnancy / 3 Monthly DP Infancy0.43
Monthly DP Pregnancy / Monthly DP Infancy0.03

[back to top]

Incidence of Malaria in Infants

Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age. (NCT02163447)
Timeframe: Time at risk will begin at 24 months of age and will end when study participants reaches 36 months of age or termination

InterventionEvents per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy0.87
3 Dose DP Pregnancy / 3 Monthly DP Infancy0.88
3 Dose DP Pregnancy / Monthly DP Infancy0.83
Monthly DP Pregnancy / 3 Monthly DP Infancy1.24
Monthly DP Pregnancy / Monthly DP Infancy0.64

[back to top]

Incidence of Hospital Admissions in Infants

Admission to a hospital for pediatric inpatient care for any reason (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination

InterventionEvents per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy0.043
3 Dose DP Pregnancy / 3 Monthly DP Infancy0.036
3 Dose DP Pregnancy / Monthly DP Infancy0.089
Monthly DP Pregnancy / 3 Monthly DP Infancy0.082
Monthly DP Pregnancy / Monthly DP Infancy0.043

[back to top]

Incidence of Complicated Malaria in Infants

Any treatment for malaria meeting criteria for severe malaria or danger signs (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination

InterventionEvents per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy0.022
3 Dose DP Pregnancy / 3 Monthly DP Infancy0.024
3 Dose DP Pregnancy / Monthly DP Infancy0.000
Monthly DP Pregnancy / 3 Monthly DP Infancy0.035
Monthly DP Pregnancy / Monthly DP Infancy0.000

[back to top]

Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (<2500g), Still Birth, Pre-term Delivery

Congenital malformations, spontaneous abortion, LBW (<2500g), still birth, pre-term delivery (NCT02163447)
Timeframe: Delivery

InterventionParticipants (Count of Participants)
Mothers - 3 Dose SP19
Mothers - 3 Dose DP19
Mothers - Monthly DP9

[back to top]

Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery

Prevalence of maternal parasitemia at delivery by microscopy and LAMP (NCT02163447)
Timeframe: At delivery

,,
Interventionparticipants (Number)
MicroscopyLAMP
Mothers - 3 Dose DP13
Mothers - 3 Dose SP525
Mothers - Monthly DP01

[back to top]

Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP

Prevalence of placental blood samples positive for parasites by microscopy or LAMP (NCT02163447)
Timeframe: Delivery

,,
InterventionParticipants (Count of Participants)
Micropscopic assessment of placental bloodLAMP assessment of placental blood
Mothers - 3 Dose DP33
Mothers - 3 Dose SP519
Mothers - Monthly DP02

[back to top]

Prevalence of Placental Malaria

Prevalence of placental malaria based on placental histopathology dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence and by histopathology as a categorical variable based on Rogerson et al criteria. (NCT02163447)
Timeframe: Delivery

InterventionParticipants (Count of Participants)
Mothers - 3 Dose SP49
Mothers - 3 Dose DP30
Mothers - Monthly DP26

[back to top]

Prevalence of Parasitemia in Infants

Proportion of routine monthly samples positive for parasites by LAMP. Proportion of routine samples (LAMP or blood smears) positive for asexual parasites. (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination

InterventionPositive blood smears (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy59
3 Dose DP Pregnancy / 3 Monthly DP Infancy25
3 Dose DP Pregnancy / Monthly DP Infancy7
Monthly DP Pregnancy / 3 Monthly DP Infancy52
Monthly DP Pregnancy / Monthly DP Infancy4

[back to top]

Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy

Detection of malaria parasites by LAMP during pregnancy (NCT02163447)
Timeframe: After first dose of study drug through delivery or early termination

InterventionPositive specimens (Number)
Mothers - 3 Dose SP206
Mothers - 3 Dose DP74
Mothers - Monthly DP26

[back to top]

Prevalence of Gametocytemia in Pregnant Women

Proportion of urgent blood smears positive for gametocytes (NCT02163447)
Timeframe: Gestational age between 12-20 weeks (at study entry) up to delivery

InterventionPositive blood smears (Number)
Mothers - 3 Dose SP4
Mothers - 3 Dose DP1
Mothers - Monthly DP3

[back to top]

Prevalence of Gametocytemia in Infants

Proportion of routine blood smears positive for gametocytes (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination

InterventionPositive blood smears (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy7
3 Dose DP Pregnancy / 3 Monthly DP Infancy1
3 Dose DP Pregnancy / Monthly DP Infancy0
Monthly DP Pregnancy / 3 Monthly DP Infancy4
Monthly DP Pregnancy / Monthly DP Infancy0

[back to top]

Prevalence of Anemia in Pregnant Women

Prevalence of routine hemoglobin measurements < 11 g/dL (NCT02163447)
Timeframe: After first dose of study drugs up to delivery or early termination

Interventionhemoglobin measurements taken every 12wk (Number)
Mothers - 3 Dose SP94
Mothers - 3 Dose DP72
Mothers - Monthly DP61

[back to top]

Incidence of Malaria in Pregnant Women

Incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. (NCT02163447)
Timeframe: Time at risk will begin after first dose of study drug and will end when study participants deliver or early study termination

Interventionevents per person years (Number)
Mothers - 3 Dose SP0.95
Mothers - 3 Dose DP0.31
Mothers - Monthly DP0

[back to top]

Prevalence of Placental Parasitemia

Proportion of placental blood samples positive for parasites by Loop-mediated isothermal amplification (LAMP) or microscopy (NCT02793622)
Timeframe: Delivery

,
InterventionParticipants (Count of Participants)
LAMPMicroscopy
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy71
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy7129

[back to top]

Prevalence of Maternal Malaria

Maternal blood positive for malaria parasites by microscopy. (NCT02793622)
Timeframe: Gestational age between 12-20 weeks (at study entry) up to delivery

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy28
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy1

[back to top]

Prevalence of Placental Malaria by Histology

Any evidence of placental infection (parasites or pigment). Number of participants with placental tissue positive for malaria parasites or pigment. (NCT02793622)
Timeframe: Delivery

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy197
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy94

[back to top]

Prevalence of Anemia in Infants

"Defined as the proportion with hemoglobin < 10 g/dL measure routinely at 12, 28, and 52 weeks of age. Number of cases per person year (PPY).~This is a prevalence measure but are repeated measures during infancy. In other words we measured this outcome up to 3 times for each participant during infancy (at 12, 28 and 52 weeks of age)." (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination

Interventionroutine hemoglobin measurement (Count of Units)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy222
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy216

[back to top]

Incidence of Complicated Malaria in Infants

Complicated malaria defined as an episode of malaria with danger signs (any of the following: less than 3 convulsions over 24 h, inability to sit or stand, vomiting everything, unable to breastfeed or drink) or the meeting standardized criteria for severe malaria. (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy44
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy24

[back to top]

Incidence of Hospital Admissions in Infants

Admission to the pediatric ward for any cause (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy19
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy8

[back to top]

Incidence of Malaria in Infants

episodes per person year (NCT02793622)
Timeframe: Time at risk will begin at birth and end when study participants reaches 12 months of age or early study termination

Interventionepisodes per person year (Number)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy1.98
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy1.71

[back to top]

Infant Mortality Rate

Any deaths occurring after birth (NCT02793622)
Timeframe: Birth up to 12 months of age

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy9
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy7

[back to top]

Mean Gestational Age in Weeks at Birth

Gestational age in weeks determined by ultrasound dating (gold standard) and by the metabolic profiling outcome from biological specimens including placental tissue and placental blood. (NCT02793622)
Timeframe: At the time of delivery

Interventionweeks (Mean)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy39.4
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy39.6

[back to top]

Number of Participants Who Deliver With a Composite Adverse Birth Outcome

Composite adverse birth outcome defined as any one of the following: 1) Low birth weight (< 2500 gm); 2) Preterm delivery (< 37 weeks gestational age); 3) Small for gestational age (< 10th percentile relative to an external growth reference) (NCT02793622)
Timeframe: Delivery

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy60
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy54

[back to top]

Number of Participants With Adverse Events

All grade 3 and 4 adverse events (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy54
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy43

[back to top]

Prevalence of Anemia in Pregnant Women

hemoglobin < 11 g/dL (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery

InterventionParticipants (Count of Participants)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy28
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy8

[back to top]

Prevalence of Asymptomatic Parasitemia in Infants

Proportion of routine monthly samples positive for parasites by microscopy and LAMP (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination

Interventionblood smears (Count of Units)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy344
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy357

[back to top]

Prevalence of Asymptomatic Parasitemia in Pregnant Women

Proportion of routine monthly samples positive for parasites by microscopy and LAMP (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery

Interventionblood smears (Count of Units)
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy519
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy9

[back to top]

Number of Participants With Local and Systemic Adverse Events (AEs)

Participants who had one or more episodes of related or/and unrelated adverse events (AEs). An AE is defined as any untoward medical occurrence temporarily associated with the subject's participation in research, whether or not considered related or not. Refer to adverse event table for specific AE. (NCT03083847)
Timeframe: 7 months

Interventionparticipants (Number)
Pilot (1a):1 Injection of 5x10^4 PfSPZ Challenge+Pyrimethamine2
Pilot (1b):1 Injection of 1x10^5 PfSPZ Challenge+Pyrimethamine2
Pilot (1d):1 Injection of 2x10^5 PfSPZ Challenge+Pyrimethamine3
Main (2a):3 Doses of 2x10^5 PfSPZ Challenge+Pyrimethamine+NF548
Main (2b):3 Doses of 2x10^5 PfSPZ Challenge+Pyrimethamine+7G89
Main (3):3 Doses of 2x10^5 PfSPZ Challenge+Chloroquine+7G810
Pilot (5a): 1 Injection of 1x10^5 PfSPZ Challenge+Chloroquine2
Pilot (5b): 1 Injection of 2x10^5 PfSPZ Challenge+Chloroquine4

[back to top]

Number of Participants With P.Falciparum Blood Stage Infection

Participants with P. falciparum blood stage infection defined as detection of P. falciparum parasites by qPCR (real time NIH qPCR and sensitive retrospective Laboratory of Malaria Immunology & Vaccinology (LMIV) qPCR) following Sanaria® PfSPZ Challenge (NF54) via direct venous injection (DVI). (NCT03083847)
Timeframe: 14 days post PfSPZ Challenge injection

InterventionParticipants (Number)
Pilot (1a):1 Injection of 5x10^4 PfSPZ Challenge+Pyrimethamine0
Pilot (1b): 1 Dose of 1x10^5 PfSPZ Challenge + Pyrimethamine0
Pilot (1d): 1 Dose of 2x10^5 PfSPZ Challenge + Pyrimethamine0
Main (2a): 3 Doses of 2x10^5 PfSPZ + Pyrimethamine + NF54 CHMI0
Main (2b): 3 Doses of 2x10^5 PfSPZ + Pyrimethamine + 7G8 CHMI0

[back to top]

Number of Participants With Serious Adverse Events (SAEs)

Participants who had one or more episodes of serious adverse events (SAEs). SAE is defined as a life-threatening reaction or event that results in death. (NCT03083847)
Timeframe: 7 months

Interventionparticipants (Number)
Pilot (1a):1 Injection of 5x10^4 PfSPZ Challenge+Pyrimethamine0
Pilot (1b):1 Injection of 1x10^5 PfSPZ Challenge+Pyrimethamine0
Pilot (1d):1 Injection of 2x10^5 PfSPZ Challenge+Pyrimethamine0
Main (2a):3 Doses of 2x10^5 PfSPZ Challenge+Pyrimethamine+NF540
Main (2b):3 Doses of 2x10^5 PfSPZ Challenge+Pyrimethamine+7G80
Main (3):3 Doses of 2x10^5 PfSPZ Challenge+Chloroquine+7G82
Pilot (5a): 1 Injection of 1x10^5 PfSPZ Challenge+Chloroquine0
Pilot (5b): 1 Injection of 2x10^5 PfSPZ Challenge+Chloroquine0

[back to top]

Number of Participants Requiring Treatment With Additional Anti-malarial Medication

Incidence of a clinical malaria diagnosis occurring after PfSPZ-Cvac challenge requiring treatment with atovaquone/proguanil (Malarone). (NCT03083847)
Timeframe: 12 days post PfSPZ Challenge injection

Interventionparticipants (Number)
Main (3): 3 Doses of 2x10^5 PfSPZ + Chloroquine + 7G8 CHMI0
Pilot (5a): 1 Injection of 1x10^5 PfSPZ Challenge+Chloroquine0
Pilot (5b): 1 Dose of 2x10^5 PfSPZ Challenge + Chloroquine0

[back to top]

Apparent Clearance Following Oral Dosing (CL/F) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionMilliliter per hour (Geometric Mean)
Healthy Japanese Participants773.2

[back to top]

Apparent Volume of Distribution Following Oral Dosing (Vd/F) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionMilliliter (Geometric Mean)
Healthy Japanese Participants135330.9

[back to top]

Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or events associated with liver injury and impaired liver function were categorized as SAE. All participants who take at least one dose of study treatment were included in Safety Population. (NCT03258762)
Timeframe: Up to Day 23

,
InterventionParticipants (Count of Participants)
Any AEsAny SAEs
Healthy Caucasian Participants60
Healthy Japanese Participants20

[back to top]

Number of Participants With Abnormal Urinalysis Parameter

The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of can be read as Trace, + and ++ indicating proportional concentrations in the urine sample. Only participants with abnormal findings for urinalysis at any visit has been presented. (NCT03258762)
Timeframe: Day -1, 24, 96, 168, 336 and follow up (504 hours)

,
InterventionParticipants (Count of Participants)
Ketones, 336 hours, ++Ketones, 336 hours, traceKetones, follow up (504 hours), +Occult blood, 336 hours, +Occult blood, follow up, traceProtein, Day -1, traceProtein, 24 hours, traceProtein, 96 hours, traceProtein, 168 hours, traceProtein, 336 hours, trace
Healthy Caucasian Participants0100113413
Healthy Japanese Participants2011002223

[back to top]

Change From Baseline of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, and QT Interval Corrected for Heart Rate by Fredericia's Formula (QTcF) Interval

A single 12-lead ECG was obtained at indicated time points using an ECG machine that automatically measures PR, QRS, QT, and QTcF intervals. Day 1 (Pre-dose) value was defined as Baseline for ECG parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Pre-dose on Day 1), 4, 12, 24, 48, and 504 hours

,
InterventionMillisecond (Mean)
PR Interval, 4 hours, n=7, 7PR Interval, 12 hours, n=7, 7PR Interval, 24 hours, n=7, 7PR Interval, 48 hours, n=7, 7PR Interval, 504 hours, n=7, 6QRS duration, 4 hours, n=7, 7QRS duration, 12 hours, n=7, 7QRS duration, 24 hours, n=7, 7QRS duration, 48 hours, n=7, 7QRS duration, 504 hours, n=7, 6QT interval, 4 hours, n=7, 7QT interval, 12 hours, n=7, 7QT interval, 24 hours, n=7, 7QT interval, 48 hours, n=7, 7QT interval, 504 hours, n=7, 6QTcF interval, 4 hours, n=7, 7QTcF interval, 12 hours, n=7, 7QTcF interval, 24 hours, n=7, 7QTcF interval, 48 hours, n=7, 7QTcF interval, 504 hours, n=7, 6
Healthy Caucasian Participants-4.6-5.9-0.10.32.2-2.1-0.6-2.00.4-0.8-20.4-21.7-7.3-14.7-9.2-6.6-5.7-0.1-2.9-2.2
Healthy Japanese Participants-5.3-8.7-3.1-17.0-7.3-1.6-0.30.33.1-0.3-4.0-17.94.32.314.7-4.9-7.7-0.911.66.7

[back to top]

Change From Baseline of ECG Parameter: ECG Mean Heart Rate

A single 12-lead ECG was obtained at indicated time points using an ECG machine that automatically calculates mean ECG heart rate. Day 1 (Pre-dose) value was defined as Baseline for ECG parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Pre-dose on Day 1), 4, 12, 24, 48, and 504 hours

,
InterventionBeats per minute (Mean)
4 hours, n=7, 712 hours, n=7, 724 hours, n=7, 748 hours, n=7, 7504 hours, n=7, 6
Healthy Caucasian Participants6.07.13.15.03.2
Healthy Japanese Participants-2.32.3-5.36.7-7.1

[back to top]

Change From Baseline of Clinical Chemistry Parameters: Protein

Blood samples were collected for the analysis of clinical chemistry parameter including protein at indicated time points. Day -1 value was defined as Baseline for clinical chemistry parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionGram per liter (Mean)
24 hours, n=7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n=7, 7Follow-up (504 hours), n=7, 6
Healthy Caucasian Participants-2.3-2.9-4.1-2.4-4.2
Healthy Japanese Participants-4.9-4.6-3.6-4.4-5.4

[back to top]

Urine Potential of Hydrogen (pH) at Indicated Time Points

Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). (NCT03258762)
Timeframe: Day -1, 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionpH (Mean)
Day -1, n=7, 724 hours, n=7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n=7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants6.865.796.076.076.006.08
Healthy Japanese Participants6.215.865.795.936.006.43

[back to top]

Area Under the Concentration-time Curve From Time 0 to 24 (AUC[0-24]) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours* nanogram per milliliter (Geometric Mean)
Healthy Japanese Participants8756.3

[back to top]

Change From Baseline of Clinical Chemistry Parameters: Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)

Blood samples were collected for the analysis of clinical chemistry parameters including alkaline phosphatase, ALT and AST at indicated time points. Day -1 value was defined as Baseline for clinical chemistry parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionInternational units per liter (Mean)
Alkaline Phosphatase, 24 hours, n=7, 7Alkaline Phosphatase, 96 hours, n=7, 7Alkaline Phosphatase, 168 hours, n=7, 7Alkaline Phosphatase, 336 hours, n=7, 7Alkaline Phosphatase, Follow-up (504 hours), n=7,6ALT, 24 hours, n=7, 7ALT, 96 hours, n=7, 7ALT, 168 hours, n=7, 7ALT, 336 hours, n=7, 7ALT, Follow up (504 hours), n=7, 6AST, 24 hours, n=7, 7AST, 96 hours, n=7, 7AST, 168 hours, n=7, 7AST, 336 hours, n=7, 7AST, Follow up (504 hours), n=7, 6
Healthy Caucasian Participants-3.3-3.1-4.1-2.9-9.3-3.3-5.1-4.4-3.9-5.3-1.9-4.3-3.0-2.4-1.5
Healthy Japanese Participants-9.0-6.7-7.0-11.0-9.6-3.0-2.10.70.90.4-3.4-3.7-2.00.30.0

[back to top]

Change From Baseline in Temperature

Temperature of participants were measured at indicated time points in semi-supine position after 5 minutes rest. Day 1 (Pre-dose) value was defined as Baseline for vital sign parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Pre-dose on Day 1), 4, 12, 24, 48, 72, 96, 120, 144, 168, 336 and 504 hours

,
InterventionCelsius (Mean)
4 hours, n=7, 712 hours, n=7, 724 hours, n=7, 748 hours, n=7, 772 hours, n=7, 796 hours, n=7, 7120 hours, n=7, 7144 hours, n=7, 7168 hours, n=7, 7336 hours, n=7, 7504 hours, n=7, 6
Healthy Caucasian Participants0.270.26-0.01-0.04-0.10-0.04-0.17-0.090.01-0.13-0.07
Healthy Japanese Participants-0.010.04-0.07-0.16-0.10-0.11-0.10-0.14-0.09-0.27-0.26

[back to top]

Change From Baseline in Pulse Rate

Pulse rate of participants were measured at indicated time points in semi-supine position after 5 minutes rest. Day 1 (Pre-dose) value was defined as Baseline for vital sign parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Pre-dose on Day 1), 4, 12, 24, 48, 72, 96, 120, 144, 168, 336 and 504 hours

,
InterventionBeats per minute (Mean)
4 hours, n=7, 712 hours, n=7, 724 hours, n=7, 748 hours, n=7, 772 hours, n=7, 796 hours, n=7, 7120 hours, n=7, 7144 hours, n=7, 7168 hours, n=7, 7336 hours, n=7, 7504 hours, n=7, 6
Healthy Caucasian Participants4.710.1-5.0-0.3-0.30.62.0-0.17.11.62.2
Healthy Japanese Participants3.65.03.43.44.91.41.10.14.41.0-2.1

[back to top]

Specific Gravity at Indicated Time Points

Urine samples were collected for analysis of specific gravity of urine. Urinary specific gravity is a measure of the concentration of solutes in the urine. It measures the ratio of urine density compared with water density and provides information on the kidney's ability to concentrate urine. (NCT03258762)
Timeframe: Day -1, 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionRatio (Mean)
Day -1, n=7, 724 hours, n=7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n=7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants1.01771.02561.02361.02071.02461.0222
Healthy Japanese Participants1.01271.02141.02111.02111.01931.0183

[back to top]

Change From Baseline of Clinical Chemistry Parameters: Glucose, Sodium, Calcium, Potassium, and Urea.

Blood samples were collected for the analysis of clinical chemistry parameters including glucose, sodium, calcium, potassium, and urea at indicated time points. Day -1 value was defined as Baseline for clinical chemistry parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionMillimoles per liter (Mean)
Glucose, 24 hours, n=7, 7Glucose, 96 hours, n=7, 7Glucose, 168 hours, n=7, 7Category title 4. : Glucose, 336 hours, n=7, 7Glucose, Follow-up (504 hours), n= 7, 6Calcium, 24 hours, n=7, 7Calcium, 96 hours, n=7, 7Calcium, 168 hours, n=7, 7Calcium, 336 hours, n=7, 7Calcium, Follow up (504 hours), n=7, 6Potassium, 24 hours, n=7, 7Potassium, 96 hours, n=7, 7Potassium, 168 hours, n=7, 7Potassium, 336 hours, n=7, 7Potassium, Follow up (504 hours), n=7, 6Sodium, 24 hours, n=7, 7Sodium, 96 hours, n=7, 7Sodium, 168 hours, n=7, 7Sodium, 336 hours, n=7, 7Sodium, Follow up (504 hours), n=7, 6Urea, 24 hours, n=7, 7Urea, 96 hours, n=7, 7Urea, 168 hours, n=7, 7Urea, 336 hours, n=7, 7Urea, Follow up,(504 hours) n=7, 6
Healthy Caucasian Participants-0.26-0.10-0.37-0.090.00-0.054-0.033-0.033-0.040-0.0420.00-0.11-0.21-0.21-0.220.01.01.7-0.3-0.51.01-0.03-0.261.061.27
Healthy Japanese Participants-0.33-0.43-0.60-0.43-0.24-0.116-0.006-0.006-0.083-0.100-0.030.000.01-0.100.09-0.3-0.6-1.30.3-0.10.330.260.41-0.160.99

[back to top]

Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet and Leukocytes

Blood samples were collected for the analysis of hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet and leukocytes at indicated time points. Day -1 value was defined as Baseline for hematology parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. Data was not available as all basophil values were below the detection limit. Hence, the change from baseline in basophil values were not calculated. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
Intervention10^9 cells per liter (Mean)
Eosinophils, 24 hours, n=4, 3Eosinophils, 96 hours, n=4, 3Eosinophils, 168 hours, n=4, 3Eosinophils, 336 hours, n=3, 3Eosinophils, Follow up (504 hours), n=4, 2Lymphocytes, 24 hours, n=7, 7Lymphocytes, 96 hours, n=7, 7Lymphocytes, 168 hours, n=7, 7Lymphocytes, 336 hours, n=7, 7Lymphocytes, Follow up (504 hours), n=7, 6Monocytes, 24 hours, n=7, 7Monocytes, 96 hours, n=7, 7Monocytes, 168 hours, n=7, 7Monocytes, 336 hours, n=7, 7Monocytes, Follow up (504 hours), n=7, 6Neutrophils, 24 hours, n=7, 7Neutrophils, 96 hours, n=7, 7Neutrophils, 168 hours, n=7, 7Neutrophils, 336 hours, n=7, 7Neutrophils, Follow up (504 hours), n=7, 6Platelet, 24 hours, n=7, 7Platelet, 96 hours, n=7, 7Platelet, 168 hours, n=7, 7Platelet, 336 hours, n=7, 7Platelet, Follow up (504 hours), n=7, 6Leukocytes, 24 hours, n=7, 7Leukocytes, 96 hours, n=7, 7Leukocytes, 168 hours, n=7, 7Leukocytes, 336 hours, n=7, 7Leukocytes, Follow up (504 hours), n=7, 6
Healthy Caucasian Participants0.070.000.000.00-0.050.360.300.260.090.000.04-0.010.000.00-0.03-0.54-0.79-0.69-0.96-0.97-11.6-6.3-13.3-27.3-24.3-0.09-0.46-0.36-0.77-0.97
Healthy Japanese Participants-0.03-0.030.000.00-0.05-0.27-0.11-0.10-0.50-0.41-0.11-0.040.01-0.09-0.06-0.63-0.76-0.61-0.93-1.09-18.3-15.1-20.0-22.4-22.9-1.00-0.89-0.67-1.50-1.59

[back to top]

Change From Baseline in Hematology Parameter: Reticulocytes

Blood samples were collected for the analysis of hematology parameter including reticulocytes at indicated time points. Day -1 value was defined as Baseline for hematology parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionProportion of reticulocytes in blood (Mean)
24 hours, n= 7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n= 7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants0.0003-0.00060.00090.00030.0017
Healthy Japanese Participants-0.00160.00170.0013-0.0011-0.0013

[back to top]

Change From Baseline in Hematology Parameter: Mean Corpuscular Volume

Blood samples were collected for the analysis of hematology parameter including mean corpuscular volume at indicated time points. Day -1 value was defined as Baseline for hematology parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionFemtoliter (Mean)
24 hours, n= 7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n= 7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants-0.7-1.4-1.1-1.9-1.7
Healthy Japanese Participants-0.60.1-0.30.40.4

[back to top]

Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin

Blood samples were collected for the analysis of hematology parameter including mean corpuscular hemoglobin at indicated time points. Day -1 value was defined as Baseline for hematology parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionPicogram (Mean)
24 hours, n= 7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n= 7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants0.00.0-0.1-0.3-0.2
Healthy Japanese Participants0.0-0.40.00.10.0

[back to top]

Change From Baseline in Hematology Parameter: Hemoglobin

Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated time points. Day -1 value was defined as Baseline for hematology parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionGram per liter (Mean)
24 hours, n= 7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n= 7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants3.00.0-1.7-3.6-6.0
Healthy Japanese Participants2.02.60.0-4.9-12.1

[back to top]

Change From Baseline in Hematology Parameter: Erythrocytes

Blood samples were collected for the analysis of hematology parameter including erythrocytes at indicated time points. Day -1 value was defined as Baseline for hematology parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
Intervention10^12 cells per liter (Mean)
24 hours, n= 7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n= 7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants0.1000.006-0.021-0.079-0.183
Healthy Japanese Participants0.0260.101-0.024-0.187-0.411

[back to top]

Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

Blood pressure of participants were measured at indicated time points in semi-supine position after 5 minutes rest. Day 1 (Pre-dose) value was defined as Baseline for vital sign parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Pre-dose on Day 1), 4, 12, 24, 48, 72, 96, 120, 144, 168, 336 and 504 hours

,
InterventionMillimeter of mercury (mmHg) (Mean)
DBP, 4 hours, n=7, 7DBP, 12 hours, n=7, 7DBP, 24 hours, n=7, 7DBP, 48 hours, n=7, 7DBP, 72 hours, n=7, 7DBP, 96 hours, n=7, 7DBP, 120 hours, n=7, 7DBP, 144 hours, n=7, 7DBP, 168 hours, n=7, 7DBP, 336 hours, n=7, 7DBP, 504 hours, n=7, 6SBP, 4 hours, n=7, 7SBP, 12 hours, n=7, 7SBP, 24 hours, n=7, 7SBP, 48 hours, n=7, 7SBP, 72 hours, n=7, 7SBP, 96 hours, n=7, 7SBP, 120 hours, n=7, 7SBP,144 hours, n=7, 7SBP, 168 hours, n=7, 7SBP, 336 hours, n=7, 7SBP, 504 hours, n=7, 6
Healthy Caucasian Participants-0.7-0.3-2.92.0-4.6-2.7-3.4-5.4-1.0-5.3-0.71.31.0-3.4-1.1-4.62.60.9-3.30.9-2.6-1.5
Healthy Japanese Participants-7.0-5.4-3.9-3.4-4.0-5.9-4.1-7.6-5.1-5.7-7.3-0.11.4-1.0-1.9-1.0-1.4-6.3-6.60.4-3.9-5.0

[back to top]

AUC (0-24) of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours* nanogram per milliliter (Geometric Mean)
Healthy Caucasian Participants6930.8

[back to top]

Vd/F of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionMilliliters (Geometric Mean)
Healthy Caucasian Participants157125.8

[back to top]

Change From Baseline of Clinical Chemistry Parameters: Direct Bilirubin, Bilirubin, Creatinine.

Blood samples were collected for the analysis of clinical chemistry parameters including direct bilirubin, bilirubin and creatinine at indicated time points. Day -1 value was defined as Baseline for clinical chemistry parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionMicromoles per liter (Mean)
Direct bilirubin, 24 hours, n=7, 7Direct bilirubin, 96 hours, n=7, 7Direct bilirubin, 168 hours, n=7, 7Direct bilirubin, 336 hours, n=7, 7Direct bilirubin, Follow-up (504 hours), n=7, 6Bilirubin, 24 hours, n=7, 7Bilirubin, 96 hours, n=7, 7Bilirubin, 168 hours, n=7, 7Bilirubin, 336 hours, n=7, 7Bilirubin, Follow up (504 hours), n=7, 6Creatinine, 24 hours, n=7, 7Creatinine, 96 hours, n=7, 7Creatinine, 168 hours, n=7, 7Creatinine, 336 hours, n=7, 7Creatinine, Follow up (504 hours), n=7, 6
Healthy Caucasian Participants0.60.70.90.90.33.12.41.0-0.3-1.726.630.124.614.99.5
Healthy Japanese Participants0.70.40.6-0.3-0.31.4-0.60.7-4.0-3.421.724.420.914.15.6

[back to top]

Tmax of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours (Median)
Healthy Caucasian Participants1.000

[back to top]

Time to Maximum Observed Concentration (Tmax) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours (Median)
Healthy Japanese Participants2.000

[back to top]

Terminal Half-life (t1/2) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours (Geometric Mean)
Healthy Japanese Participants122.75

[back to top]

T1/2 of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours (Mean)
Healthy Caucasian Participants99.46

[back to top]

Maximum Observed Concentration (Cmax) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The Pharmacokinetic (PK) parameters were calculated by non-compartmental analysis. PK Population is defined as all participants who administered at least one dose of study treatment and who have PK sample taken and analyzed. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionNanogram per milliliter (Geometric Mean)
Healthy Japanese Participants430.5

[back to top]

Change From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected for the analysis of hematology parameter including hematocrit at indicated time points. Day -1 value was defined as Baseline for hematology parameters. Change from Baseline was defined as difference between post-dose visit values minus Baseline value. (NCT03258762)
Timeframe: Baseline (Day -1), 24, 96, 168, 336 hours and follow up (504 hours)

,
InterventionProportion of red blood cells in blood (Mean)
24 hours, n= 7, 796 hours, n=7, 7168 hours, n=7, 7336 hours, n= 7, 7Follow up (504 hours), n=7, 6
Healthy Caucasian Participants0.007-0.006-0.006-0.016-0.025
Healthy Japanese Participants0.0010.009-0.004-0.014-0.036

[back to top]

Cmax of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionNanogram per milliliter (Geometric Mean)
Healthy Caucasian Participants371.1

[back to top]

CL/F of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionMilliliters per hour (Geometric Mean)
Healthy Caucasian Participants1114.4

[back to top]

AUC (0-t) of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours* nanogram per milliliter (Geometric Mean)
Healthy Caucasian Participants41582.0

[back to top]

AUC (0-inf) of Pyrimethamine in Healthy Caucasian Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours* nanogram per milliliter (Geometric Mean)
Healthy Caucasian Participants44869.1

[back to top]

Area Under the Concentration-time Curve From Time 0 to t (AUC[0-t]) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours* nanogram per milliliter (Geometric Mean)
Healthy Japanese Participants59013.1

[back to top]

Area Under the Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) of Pyrimethamine in Healthy Japanese Male Participants

Blood samples were collected at indicated time points. The PK parameters were calculated by non-compartmental analysis. (NCT03258762)
Timeframe: Pre-dose, 1, 2, 4, 6, 12 hours post-dose on Day 1, Day 2, Day 3, Day 4, Day 6, Day 8, Day 15 and Day 22

InterventionHours* nanogram per milliliter (Geometric Mean)
Healthy Japanese Participants64670.3

[back to top]

Magnitude of Adverse Events in the CHMI-trans Model

"symptoms will be ranked as (1) mild, (2) moderate, or (3) severe, depending on their intensity according to the following scale:~Mild (grade 1): awareness of symptoms that are easily tolerated and do not interfere with usual daily activity~Moderate (grade 2): discomfort that interferes with or limits usual daily activity~Severe (grade 3): disabling, with subsequent inability to perform usual daily activity, resulting in absence or required bed rest" (NCT03454048)
Timeframe: up to day 51 after challenge infection

,,,
InterventionAdverse events (Number)
Mild (grade I)Moderate (grade II)Severe (grade III)
Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP64229
Group 2 (Cohort A) LD-PIP/LD-PIP2/SP562217
Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP86174
Group 4 (Cohort B) LD-PIP/LD-PIP2/SP4183

[back to top]

Frequency of Adverse Events in the CHMI-trans Model

Frequency of adverse events in the CHMI-trans model. (NCT03454048)
Timeframe: up to day 51 after challenge infection

InterventionAdverse events (Number)
Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP95
Group 2 (Cohort A) LD-PIP/LD-PIP2/SP95
Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP107
Group 4 (Cohort B) LD-PIP/LD-PIP2/SP52

[back to top]

Gametocyte Prevalence

Number of individuals in each study arm that show prevalence of gametocytes as defined by quantitative reverse-transcriptase PCR (qRT-PCR) for CCp4 (female) and PfMGET (male) mRNA with a threshold of 5 gametocytes/mL for positivity. (NCT03454048)
Timeframe: up to day 51 after challenge infection

InterventionParticipants (Count of Participants)
Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP5
Group 2 (Cohort A) LD-PIP/LD-PIP2/SP6
Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP6
Group 4 (Cohort B) LD-PIP/LD-PIP2/SP6

[back to top]

AUC Gametocytes

The area under the curve of gametocyte density versus time. The median AUC was calculated for both cohorts. Since onset of gametocytaemia differs depending on method of infection a window of 15 days was used to calculate AUC, from the time-point where a minimum of 50% of participants within a cohort had detectable gametocytemia. (NCT03454048)
Timeframe: up to day 51 after challenge infection

Intervention(gametocytes*days)/mL (Median)
Cohort A99
Cohort B11043

[back to top]

Gametocyte Commitment

The gametocyte commitment rate is estimated by dividing the peak gametocyte by the peak of asexual parasites. (NCT03454048)
Timeframe: up to day 51 after challenge infection

Interventiongametocytes/asexual parasite (Median)
Cohort A0.0011
Cohort B0.0323

[back to top]

Number of Participants Infectious for Mosquitoes Through DFA

Prevalence of gametocyte infectiousness for Anopheles mosquitoes through Direct Feeding Assays (Direct Skin Feeding Assay, DFA). (NCT03454048)
Timeframe: up to day 51 after challenge infection

InterventionParticipants (Count of Participants)
Cohort A0
Cohort B9

[back to top]

Peak Density Gametocytes

Peak density of gametocytes by qRT-PCR. (NCT03454048)
Timeframe: up to day 51 after challenge infection

InterventionGametocytes/mL (Median)
Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP13.9
Group 2 (Cohort A) LD-PIP/LD-PIP2/SP21.4
Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP1442.2
Group 4 (Cohort B) LD-PIP/LD-PIP2/SP813.2

[back to top]

Gametocyte Sex-ratio

Proportion of male gametocytes (NCT03454048)
Timeframe: up to day 51 after challenge infection

InterventionProportion of male gametocytes (Median)
Cohort A0.20
Cohort B0.31

[back to top]

Number of Participants With Local and Systemic Adverse Events (AEs) and Serious Adverse Events (SAEs)

Count of participants with local and systemic adverse events (AEs) and serious adverse events (SAEs) occurring after PfSPZ-CVac immunization. This outcome measure applies to main phase arms 1b, 2b, 4a, and 4b. Arms 5b and 6b were not performed as patent parasitemia with the higher dose of PfSPZ was not observed in the pilot phase (Arms 1a, 2a). (NCT03952650)
Timeframe: For the main phase: from the day of inoculation to approximately 6 months post-3rd inoculation. For the booster phase: from the time of inoculation to approximately 6 months post-booster inoculation

InterventionParticipants (Count of Participants)
1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 5788
2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 5759
4a - Safety Comparator: Dosing Interval on Days: 1, 29, 5751
4b - Safety Comparator: Dosing Interval on Days: 1, 29, 5736

[back to top]

Number of Participants With Local and Systemic Grade 3 Adverse Events (AEs) and Serious Adverse Events (SAEs)

Count of participants with local and systemic grade 3 signs or symptoms lasting more than 48 hours despite adequate management and serious adverse events (SAEs) occurring after PfSPZ-CVac DVI. Only arm 3a was analyzed for this outcome measure, per the protocol objectives. (NCT03952650)
Timeframe: From day of inoculation to 14 days post-inoculation

InterventionParticipants (Count of Participants)
3a - Pilot/Safety: Dosing Interval on Days: 10

[back to top]

Number of Participants With Positive Sensitive Blood Smear (sBS)

Count of participants with positive sensitive blood smear (sBS) occurring after PfSPZ-CVac immunization starting on day 7 post DVI. Only pilot phase arms (Arms 1a, 2a) were analyzed for this outcome measure. Arms 5a and 6a were not performed, as no patent parasitemia was observed in either Arms 1a or 2a, per the protocol. (NCT03952650)
Timeframe: 7 -12 days post-inoculation

InterventionParticipants (Count of Participants)
1a - Pilot/Safety: Dosing Interval on Days: 10
2a - Pilot/Safety: Dosing Interval on Days: 10

[back to top]